Stabilized flavivirus vaccines

Abstract

Provided herein are stabilized flavivirus heterotetramers containing two variant flavivirus envelope proteins and two variant flavivirus membrane proteins. Nucleic acid vaccines encoding the variant flavivirus proteins are also provided. The disclosure also provides methods of eliciting an immune response and / or neutralizing antibodies to flavivirus in a human subject.

Description

[0001] Attorney Docket No. 45817-0191WO1 / MTX1505.20 STABILIZED FLAVIVIRUS VACCINES CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority of U. S. Provisional Application No. 63 / 730,715, filed on December 11, 2024, the content of which is incorporated by reference in its entirety7herein.

[0002] SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety'. Said XML copy, created on December 11. 2025, is named 45817-0191WOl_SL.xml and is 635,815 bytes in size.

[0004] BACKGROUND

[0005] Flavivirus is a genus of positive-strand RNA viruses in the family Flaviviridae. The genus includes the West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, Zika virus, Japanese encephalitis virus.

[0006] Powassan virus, St. Louis Encephalitis virus, Usutu virus, and Spondweni virus which may cause disease (e.g., encephalitis) in humans.

[0007] Dengue virus is a mosquito-bome flavivirus that causes dengue fever, a severe flu-like illness. There are four distinct, but closely related, serotypes of the virus that cause dengue (DENV-1, DENV-2, DENV-3, and DENV-4). Dengue virus is transmitted to humans through the bites of infected female mosquitoes, primarily the Aedes aegypti mosquito. This species prefers to bite humans and is most active during daylight hours. After virus incubation for about a week, an infected human may develop dengue fever. Dengue fever is characterized by high fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and mild bleeding (such as nose or gum bleed, or easy bruising). In severe cases, it can evolve into severe dengue or dengue hemorrhagic fever, which can cause bleeding, blood plasma leakage, and low- platelet count. The disease is endemic in more than 100 countries in the World Health Organization's (WHO) regions of Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. Attorney Docket No. 45817-0191WO1 / MTX1505.20 Two live attenuated tetravalent vaccines, Dengvaxia (CYD-TDV) and Qdenga (TAK-003), have been developed to protect against dengue fever. However, both come with specific usage guidelines and limitations. For instance, in the US, Dengvaxia is approved for individuals aged 9 to 16 with laboratory-confirmed prior dengue infection who live in endemic areas. Meanwhile, Qdenga is not approved in the US and its efficacy varies across different seroty pes. These limitations highlight the pressing need not only for improved dengue vaccines but also for vaccines targeting other emerging flaviviruses that share structural similarities.

[0008] SUMMARY

[0009] Flaviviruses are pathogens that cause severe morbidity and mortality' in humans. These viruses cycle between the arthropod (mosquito or tick) and vertebrate hosts. A few of the most dangerous flaviviruses include Dengue viruses (DENVs), Zika virus (ZIKV), West Nile virus (WNV), Yellow fever virus (YFV), Japanese encephalitis virus, Tick bome encephalitis virus (TBEV), St. Louis Encephalitis virus (SLEV) and emerging viruses like Usutu Virus (USV), Powassan virus (POWV) and Spondweni virus (SPOV) (Pierson et al.. Nat Microbiol. 5, 796-812, 2020)) as well as Ilheus virus (ILHV), Rocio virus (ROCV), Omsk haemorrhagic fever virus (OHFV), Alkhurma haemorrhagic fever virus (AHFV), and Karshi virus (KSIV). Flaviviruses are structurally similar to one another (see, e.g., FIG. 1 A, which illustrates structural similarities between DENV1, DENV2, DENV3. DENV4. and ZIKV). Four dengue virus serotypes (DENV1, 2, 3, and 4) and ZIKV exemplify serologically related viruses that infect humans.

[0010] The envelope (E) protein dimer in its prefusion conformation is a metastable protein that transforms into the stable post-fusion trimeric form upon exposure to an acidic pH. Dengue viruses form particles with an immature lattice of trimeric (prM / Ety spikes, wherein the pr (of prM) is covalently linked to the M transmembrane domain and caps the tip of E. This immature conformation is immunodominant and functions as an antigenic decoy that elicits poorly neutralizing or non-neutralizing responses (Rey et al.. Curr. Opin. Virol. 2018;24: 132-139). In the mature infectious virion, pr is removed by furin cleavage during maturation and the surface reorganizes into pr-free E / M dimers that lie flat along the membrane. Antibodies targeting this Attorney Docket No. 45817-0191WO1 / MTX1505.20 mature prefusion (E / M)2 dimeric E conformation are potently neutralizing and are preferred vaccine targets. Notably, dengue poses a risk of antibody-dependent enhancement (ADE) during secondary heterotypic infection, driven by subneutralizing, cross-reactive antibodies to epitopes such as pr and the E-protein fusion loop.

[0011] Described herein are engineered, non-infectious dengue virus-like particles (VLPs) that present a mature-like surface lattice of E-protein dimers. In the native viral polyprotein. prM lies N-terminal to E, host signal peptidase separates prM from E during translation, and furin subsequently cleaves prM to yield pr and M. To preclude immature epitopes, the disclosed constructs omit the pr segment (including the furin site) and fuse E N-terminally to M as an uncleavable single chain, thereby enforcing stoichiometry and conformation. Using structure-guided design, E-M interfaces are stabilized to produce heterotetrameric (EM)? assemblies in the prefusion arrangement found on mature virions. The resulting (EM)? complexes are locked in the native prefusion E-dimer state to elicit a potent, protective humoral response while reducing responses to immature-state epitopes. By contrast, live-attenuated vaccines (e.g., Dengvaxia) can display mixed maturation states that expose fusion-loop and pr epitopes. Because the flavi viral E and M proteins are structurally highly conserved, the disclosed design is readily transferable across the genus and can be adapted to human-infecting flaviviruses, such as yellow fever virus and Zika virus. Additionally, in alternative embodiments the stabilized VLPs are produced with the conventional gene order (M upstream of E) while retaining the E-M interface-stabilizing substitutions. Designs disclosed herein can be implemented in a linker-free format; no exogenous linker is required because a single M-E precursor is processed by the endogenous signal peptidase to yield separate M and E polypeptides.

[0012] The disclosure, in some aspects, provides a stabilized flavivirus heterotetramer comprising two variant flavivirus envelope (E) proteins and two variant flavivirus membrane (M) proteins, wherein: the two variant E proteins are identical to each other and each comprises amino acid substitutions at at least three positions relative to a corresponding wild-type flavivirus E protein, wherein the at least three positions correspond with positions 76, 106, and 107 of SEQ ID NO:276; and the two variant M proteins are identical to each other and each comprises a N-terminus and a C- Attorney Docket No. 45817-0191WO1 / MTX1505.20 terminus, wherein the N-terminus comprises an N-terminal region comprising at least one amino acid substitution relative to a corresponding wild-ty pe flavivirus M protein.

[0013] In some embodiments of a stabilized flavivirus heterotetramer described herein, the position in the variant E proteins corresponding with position 107 of SEQ ID NO:276 comprises a substitution with a charged bulky residue. In some embodiments, the charged bulky residue is selected from the group consisting of aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q), lysine (K), tyrosine (Y), and arginine (R).

[0014] In some embodiments of a stabilized flavivirus heterotetramer described herein, the position in the variant E proteins corresponding with position 76 of SEQ ID NO:276 comprises a substitution with a charged bulky residue. In some embodiments, the charged bulky residue is selected from the group consisting of aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q), lysine (K), ty rosine (Y), and arginine (R).

[0015] In some embodiments of a stabilized flavivirus heterotetramer described herein, the position in the variant E proteins corresponding with position 106 of SEQ ID NO:276 comprises a substitution with serine (S). threonine (T), asparagine (N), or lysine (K).

[0016] In some embodiments of a stabilized flavivirus heterotetramer described herein, the position in the variant E proteins corresponding with position 106 of SEQ ID NO:276 comprises a substitution with serine (S).

[0017] In some embodiments of a stabilized flavivirus heterotetramer described herein, the at least one substitution within the N-terminal region of the variant M proteins comprises at least one substitution selected from the following positions: 90, 91, 93, 94, 96, 97, 99, 101. 103, 104, and 105, wherein the positions correspond with positions 90, 91, 93, 94, 96, 97, 99, 101, 103, 104, and 105 of SEQ ID NO:275. In some embodiments, the at least one substitution within the N-terminal region of the variant M proteins comprises at least one the following substitutions:

[0018] (a) the amino acid substitution at position 90 is valine (V) or isoleucine (I);

[0019] (b) the amino acid substitution at position 91 is isoleucine (I) or cysteine (C); Attorney Docket No. 45817-0191WO1 / MTX1505.20 (c) the amino acid substitution at position 93 is isoleucine (I), phenylalanine (F), tyrosine (Y), or tryptophan (W);

[0020] (d) the amino acid substitution at position 94 is isoleucine (I), leucine (L), asparagine (N), or lysine (K);

[0021] (e) the amino acid substitution at position 96 is cysteine (C);

[0022] (f) the amino acid substitution at position 97 is isoleucine (I) or cysteine (C);

[0023] (g) the amino acid substitution at position 99 is isoleucine (I) or leucine (L);

[0024] (h) the amino acid substitution at position 101 is methionine (M), isoleucine (I), or phenylalanine (F)

[0025] (i) the amino acid substitution at position 103 is glycine (G), alanine (A), serine (S), or cysteine (C);

[0026] (j) the amino acid substitution at position 104 is serine (S); and (k) the amino acid substitution at position 105 is cysteine (C); wherein the positions correspond with positions 90, 91, 93, 94, 96, 97, 99, 101, 103. 104, and 105 of SEQ IDNO:275.

[0027] In some embodiments of a stabilized flavivirus heterotetramer described herein, the variant E proteins further comprises at least one additional substitution relative to the corresponding wild-type flavivirus E protein, wherein the at least one additional substitution is selected from the group consisting of the position in the variant E proteins corresponding with position 131 of SEQ ID NO:276, the position in the variant E proteins corresponding with position 194 of SEQ ID NO:276, and the position in the variant E proteins corresponding with position 134 of SEQ ID NO:276. In some embodiments, the at least one additional substitution is selected from the group consisting of

[0028] (a) the amino acid substitution at the position in the variant E proteins corresponding with position 131 of SEQ ID NO:276 is alanine (A), asparagine (N), or leucine (L);

[0029] (b) the amino acid substitution at the position in the variant E proteins corresponding with position 194 of SEQ ID NO:276 is aspartic acid (D); and Attorney Docket No. 45817-0191WO1 / MTX1505.20 (c) the amino acid substitution at the position in the variant E proteins corresponding with position 134 of SEQ ID NO:276 is asparagine (N) or aspartic acid (D).

[0030] In some embodiments of a stabilized flavivirus heterotetramer described herein, the variant E proteins further comprise an amino acid substitution at the position corresponding with position 495 of SEQ ID NO:276, and / or the variant M proteins further comprise an amino acid substitution at the position corresponding with position 90 of SEQ ID NO:275. In some embodiments, the amino acid substitution at the position in the variant E proteins corresponding with position 495 of SEQ ID NO:276 is a glycine (G), and / or the amino acid substitution at the position in the variant M proteins corresponding with position 90 of SEQ ID NO:275 is a glycine (G).

[0031] In some embodiments of a stabilized flavivirus heterotetramer described herein, the stabilized flavivirus heterotetramer further comprises a cavity created by: (a) amino acid substitutions relative to the corresponding wild-type flavivirus E protein at the positions in the variant E proteins corresponding with positions 262 and 265 of SEQ ID NO:276; and (b) an amino acid substitution relative to the corresponding wild-type flavivirus M protein at the position in the variant M proteins corresponding with position 97 of SEQ ID NO:275. In some embodiments, the amino acid substitutions at the positions in the variant E proteins corresponding with positions 262 and 265 of SEQ ID NO:276 are each an alanine (A) or serine (S). and wherein the amino acid substitution at the position in the variant M proteins corresponding with position 97 of SEQ ID NO:275 is alanine (A).

[0032] In some embodiments of a stabilized flavivirus heterotetramer described herein, the variant E proteins further comprises the following amino acid substitutions: a tyrosine (Y), glutamine (Q), or asparagine (N) at the position in the variant E proteins corresponding with position 267 of SEQ ID NO:276; and a lysine (K) or arginine (R) at the position in the variant E proteins corresponding w ith position 445 of SEQ ID NO:276.

[0033] In some embodiments of a stabilized flavivirus heterotetramer described herein, the N-terminal region of the variant M proteins comprises at least one amino Attorney Docket No. 45817-0191WO1 / MTX1505.20 acid substitution of a non-cysteine amino acid with a cysteine amino acid, relative to the corresponding wild-ty pe flavivirus M protein.

[0034] In some embodiments of a stabilized flavivirus heterotetramer described herein, the corresponding wild-type flavivirus E protein is SEQ ID NO:401 and the corresponding wild-type flavivirus M protein is SEQ ID NO:400. In some embodiments, the variant E proteins are at least 90% identical to SEQ ID NO:414, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:415. In some embodiments, the variant E proteins are at least 95% identical to SEQ ID NO:414, and wherein the variant M proteins are at least 95% identical to SEQ ID NO: 415. In some embodiments, the variant E proteins are identical to SEQ ID NO:414, and wherein the variant M proteins are identical to SEQ ID NO:415.

[0035] In some embodiments of a stabilized flavivirus heterotetramer described herein, the corresponding wild-type flavivirus E protein is SEQ ID NO:403 and the corresponding wild-type flavivirus M protein is SEQ ID NO:402. In some embodiments, the variant E proteins are at least 90% identical to SEQ ID NO:418, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:419. In some embodiments, the variant E proteins are at least 95% identical to SEQ ID NO:418, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:419. In some embodiments, the variant E proteins are identical to SEQ ID NO:418, and wherein the variant M proteins are identical to SEQ ID NO:419.

[0036] In some embodiments of a stabilized flavivirus heterotetramer described herein, the corresponding wild-type flavivirus E protein is SEQ ID NO:404 and the corresponding wild-type flavivirus M protein is SEQ ID NO:277. In some embodiments, the variant E proteins are at least 90% identical to SEQ ID NO:425, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:426. In some embodiments, the variant E proteins are at least 95% identical to SEQ ID NO:425, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:426. In some embodiments, the variant E proteins are identical to SEQ ID NO:425, and wherein the variant M proteins are identical to SEQ ID NO:426.

[0037] In some embodiments of a stabilized flavivirus heterotetramer described herein, the corresponding wild-type flavivirus E protein is SEQ ID NO:280 and the corresponding wild-type flavivirus M protein is SEQ ID NO:279. In some Attorney Docket No. 45817-0191WO1 / MTX1505.20 embodiments, the variant E proteins are at least 90% identical to SEQ ID NO: 428, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:429. In some embodiments, the variant E proteins are at least 95% identical to SEQ ID NO:428, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:429. In some embodiments, the variant E proteins are identical to SEQ ID NO:428, and wherein the variant M proteins are identical to SEQ ID NO:429.

[0038] In some embodiments of a stabilized flavivirus heterotetramer described herein, the stabilized flavivirus heterotetramer comprises two fusion proteins, wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant M protein and the variant E protein. In some embodiments, each fusion protein comprises a linker between the variant E protein and the variant M protein. In some embodiments, the linker comprises GGGG (SEQ ID NO:364). In some embodiments, the linker comprises GGPG (SEQ ID NO:365). In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein, a linker comprising GGGG (SEQ ID NO:364), and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein, a linker comprising GGPG (SEQ ID NO:365), and the variant M protein.

[0039] In some embodiments of a stabilized flavivirus heterotetramer described herein, the flavivirus is selected from the group consisting of Yellow Fever virus, Dengue virus, Zika virus, West Nile virus, Japanese Encephalitis virus, Tick-Bome Encephalitis virus, Kyasanur Forest virus, Alkhurma haemorrhagic fever virus, Omsk haemorrhagic fever virus, Powassan virus, Ilheus virus, Rocio virus, Karshi virus, Usutu virus, and Spondweni virus.

[0040] In some embodiments of a stabilized flavivirus heterotetramer described herein, the flavivirus is Dengue virus.

[0041] In some embodiments of a stabilized flavivirus heterotetramer described herein, the flavivirus is Zika virus. In some embodiments, the Zika virus E protein further comprises an introduced glycosylation site. In some embodiments, the Attorney Docket No. 45817-0191WO1 / MTX1505.20 introduced glycosylation site comprises an N-X-S motif in positions 67-69, wherein the positions correspond to positions 67-69 of SEQ ID NO: 282.

[0042] In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413; a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417; a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:424; or a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0043] In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:431; or a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432.

[0044] In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413; a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417; a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; or a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0045] In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431; or a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432.

[0046] In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: the amino acid sequence set forth in SEQ ID NO:413; the amino acid sequence set forth in SEQ ID NO:417; the amino acid sequence set forth in SEQ ID NO:424; or the amino acid sequence set forth in SEQ ID NO:427. Attorney Docket No. 45817-0191WO1 / MTX1505.20 In some embodiments of a stabilized flavivirus heterotetramer described herein, each of the fusion proteins of the stabilized flavivirus heterotetramer comprises: the amino acid sequence set forth in SEQ ID NO:431; or the amino acid sequence set forth in SEQ ID NO:432.

[0047] In another aspect, the disclosure provides a vaccine composition comprising a stabilized flavivirus heterotetramer of described herein.

[0048] In some embodiments of a vaccine composition described herein, the vaccine composition comprises:

[0049] a first stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:401 and the wild-type flavivirus M protein is SEQ ID NO:400;

[0050] a second stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-ty pe flavivirus E protein is SEQ ID NQ:403 and the wild-type flavivirus M protein is SEQ ID NO:402;

[0051] a third stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:404 and the wild-type flavivirus M protein is SEQ ID NO: 277; and

[0052] a fourth stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:280 and the wild-type flavivirus M protein is SEQ ID NO:279.

[0053] In some embodiments of the vaccine composition, the vaccine composition further comprises a fifth stabilized flavivirus heterotetramer of any one of claims 41-43, wherein the flavivirus is ZIKV.

[0054] In some embodiments of the vaccine composition:

[0055] the variant E proteins of the first stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:414, and the variant M proteins of the first stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:415; the variant E proteins of the second stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:418, and the variant M proteins of the second stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:419; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins of the third stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO: 425, and the variant M proteins of the third stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:426; and the variant E proteins of the fourth stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:428, and the variant M proteins of the fourth stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:429.

[0056] In some embodiments of the vaccine composition:

[0057] the variant E proteins of the first stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:414, and the variant M proteins of the first stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:415; the variant E proteins of the second stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:418, and the variant M proteins of the second stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:419; the variant E proteins of the third stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:425, and the variant M proteins of the third stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:426; and the variant E proteins of the fourth stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:428, and the variant M proteins of the fourth stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:429.

[0058] In some embodiments of the vaccine composition:

[0059] each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NON 13;

[0060] each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:417;

[0061] each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and

[0062] each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

[0063] In some embodiments of the vaccine composition:

[0064] each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NON 13 or SEQ ID NO:431; Attorney Docket No. 45817-0191WO1 / MTX1505.20 each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;

[0065] each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and

[0066] each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

[0067] In some embodiments of the vaccine composition:

[0068] each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:431;

[0069] each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:417;

[0070] each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and

[0071] each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

[0072] In some embodiments of the vaccine composition:

[0073] each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:413;

[0074] each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:432;

[0075] each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and

[0076] each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

[0077] In some embodiments of the vaccine composition:

[0078] each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:431;

[0079] each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:432;

[0080] each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and Attorney Docket No. 45817-0191WO1 / MTX1505.20 each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

[0081] In another aspect, the disclosure provides a vaccine composition comprising one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein.

[0082] In another aspect, the disclosure provides a vaccine composition comprising one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein.

[0083] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0084] a variant E protein at least 90% identical to SEQ ID NO:414 and a variant M protein at least 90% identical to SEQ ID NO:415;

[0085] a variant E protein at least 90% identical to SEQ ID NO:418 and a variant M protein at least 90% identical to SEQ ID NO:419;

[0086] a variant E protein at least 90% identical to SEQ ID NO:425 and a variant M protein at least 90% identical to SEQ ID NO:426; or

[0087] a variant E protein at least 90% identical to SEQ ID NO:428 and a variant M protein at least 90% identical to SEQ ID NO:429.

[0088] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0089] a variant E protein at least 95% identical to SEQ ID NO: 414 and a variant M protein at least 95% identical to SEQ ID NO:415;

[0090] a variant E protein at least 95% identical to SEQ ID NO:418 and a variant M protein at least 95% identical to SEQ ID NO:419;

[0091] a variant E protein at least 95% identical to SEQ ID NO:425 and a variant M protein at least 95% identical to SEQ ID NO:426; or

[0092] a variant E protein at least 95% identical to SEQ ID NO:428 and a variant M protein at least 95% identical to SEQ ID NO:429.

[0093] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising: Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein identical to SEQ ID NO:414 and a variant M protein identical to SEQ ID NO:415;

[0094] a variant E protein identical to SEQ ID NO:418 and a variant M protein identical to SEQ ID NO: 419;

[0095] a variant E protein identical to SEQ ID NO:425 and a variant M protein identical to SEQ ID NO:426; or

[0096] a variant E protein identical to SEQ ID NO:428 and a variant M protein identical to SEQ ID NO: 429.

[0097] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0098] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;

[0099] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0100] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; or

[0101] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0102] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0103] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:431; or

[0104] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432.

[0105] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0106] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413;

[0107] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0108] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; or Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0109] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0110] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431; or

[0111] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432.

[0112] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0113] the amino acid sequence set forth in SEQ ID NO:413;

[0114] the amino acid sequence set forth in SEQ ID NO:417;

[0115] the amino acid sequence set forth in SEQ ID NO:424; or

[0116] the amino acid sequence set forth in SEQ ID NO:427.

[0117] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0118] the amino acid sequence set forth in SEQ ID NO:431; or

[0119] the amino acid sequence set forth in SEQ ID NO:432.

[0120] In some embodiments, the vaccine composition comprises:

[0121] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;

[0122] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0123] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the ammo acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0124] In some embodiments, the vaccine composition comprises: Attorney Docket No. 45817-0191WO1 / MTX1505.20 a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431;

[0125] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;

[0126] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0127] In some embodiments, the vaccine composition comprises:

[0128] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:431;

[0129] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0130] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0131] In some embodiments, the vaccine composition comprises:

[0132] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;

[0133] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432;

[0134] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and Attorney Docket No. 45817-0191WO1 / MTX1505.20 a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0135] In some embodiments, the vaccine composition comprises:

[0136] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:431;

[0137] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432;

[0138] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0139] In some embodiments, the vaccine composition comprises:

[0140] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413;

[0141] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0142] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0143] In some embodiments, the vaccine composition comprises:

[0144] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431;

[0145] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0146] In some embodiments, the vaccine composition comprises:

[0147] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431;

[0148] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;

[0149] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0150] In some embodiments, the vaccine composition comprises:

[0151] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413:

[0152] a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432;

[0153] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0154] In some embodiments, the vaccine composition comprises:

[0155] a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432;

[0156] a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

[0157] In some embodiments, the vaccine composition comprises:

[0158] a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO:413;

[0159] a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO:417;

[0160] a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and

[0161] a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

[0162] In some embodiments, the vaccine composition comprises:

[0163] a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431;

[0164] a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;

[0165] a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and

[0166] a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

[0167] In some embodiments, the vaccine composition comprises:

[0168] a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 431;

[0169] a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO:417; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and

[0170] a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

[0171] In some embodiments, the vaccine composition comprises:

[0172] a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO:413;

[0173] a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 432;

[0174] a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and

[0175] a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

[0176] In some embodiments, the vaccine composition comprises:

[0177] a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 431;

[0178] a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 432;

[0179] a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and

[0180] a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

[0181] In some embodiments,

[0182] In some embodiments, the vaccine composition further comprises a lipid nanoparticle.

[0183] In some embodiments, the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1,2 distearoyl -sn-glycero-3- phosphocholine (DSPC), and 1-5 mol% PEG-modified lipid.

[0184] In some embodiments, the lipid nanoparticle comprises 1-25:

[0185]

[0186] Attorney Docket No. 45817-0191WO1 / MTX1505.20 (1-25).

[0187] In some embodiments, the lipid nanoparticle comprises A7:

[0188]

[0189] (A7).

[0190] In some embodiments, the PEG-modified lipid is PEG2000-DMG.

[0191] In some embodiments of the vaccine composition, the one or more mRNAs are fully modified with 1-methyl-pseudouridine.

[0192] In another aspect, the disclosure provides a method of inducing an immune response in a human subject, comprising administering to the human subject one or more doses of a stabilized flavivirus heterotetramer described herein or a vaccine composition described herein in an amount effective to produce, in the human subject, an immune response to a flavivirus viral infection.

[0193] In another aspect, the disclosure provides a method of inducing an immune response in a human subject, comprising administering to the human subject a stabilized flavivirus heterotetramer described herein or a vaccine composition described herein in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring flavivirus.

[0194] In some embodiments, the stabilized flavivirus heterotetramer or the vaccine composition is administered intramuscularly.

[0195] In some embodiments, the flavivirus is Yellow Fever virus. Dengue virus, Zika virus, West Nile virus, Japanese Encephalitis virus, Tick-Bome Encephalitis virus, Kyasanur Forest virus, Alkhurma haemorrhagic fever virus, Omsk haemorrhagic fever virus, Powassan virus, Ilheus virus, Rocio virus, Karshi virus, Usutu virus, Spondweni virus, or any combination thereof.

[0196] In some embodiments, the flavivirus is Dengue virus.

[0197] In some embodiments, the flavivirus is Zika virus.

[0198] In some embodiments of a stabilized flavivirus heterotetramer described herein, the flavivirus is Zika virus, the corresponding wild-type Zika virus E protein is Attorney Docket No. 45817-0191WO1 / MTX1505.20 SEQ ID NO:282 and the corresponding wild-type Zika virus M protein is SEQ ID NO:281.

[0199] In some embodiments of the stabilized flavivirus heterotetramer, wherein the flavivirus is Zika virus:

[0200] the variant E proteins are at least 90% identical to SEQ ID NO:450, and the variant M proteins are at least 90% identical to SEQ ID NO:451;

[0201] the variant E proteins are at least 90% identical to SEQ ID NO:452, and the variant M proteins are at least 90% identical to SEQ ID NO:453;

[0202] the variant E proteins are at least 90% identical to SEQ ID NO:454, and the variant M proteins are at least 90% identical to SEQ ID NO:455;

[0203] the variant E proteins are at least 90% identical to SEQ ID NO:456, and the variant M proteins are at least 90% identical to SEQ ID NO:457;

[0204] the variant E proteins are at least 90% identical to SEQ ID NO:458, and the variant M proteins are at least 90% identical to SEQ ID NO:459;

[0205] the variant E proteins are at least 90% identical to SEQ ID NO:460, and the variant M proteins are at least 90% identical to SEQ ID NO:461;

[0206] the variant E proteins are at least 90% identical to SEQ ID NO:462. and the variant M proteins are at least 90% identical to SEQ ID NO:463;

[0207] the variant E proteins are at least 90% identical to SEQ ID NO:464, and the variant M proteins are at least 90% identical to SEQ ID NO:465;

[0208] the variant E proteins are at least 90% identical to SEQ ID NO:466. and the variant M proteins are at least 90% identical to SEQ ID NO:459;

[0209] the variant E proteins are at least 90% identical to SEQ ID NO:467, and the variant M proteins are at least 90% identical to SEQ ID NO:468;

[0210] the variant E proteins are at least 90% identical to SEQ ID NO:471, and the variant M proteins are at least 90% identical to SEQ ID NO:472; or

[0211] the variant E proteins are at least 90% identical to SEQ ID NO:473, and the variant M proteins are at least 90% identical to SEQ ID NO:472.

[0212] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus:

[0213] the variant E proteins are at least 95% identical to SEQ ID NO:450, and the variant M proteins are at least 95% identical to SEQ ID NO:451; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are at least 95% identical to SEQ ID NO:452, and the variant M proteins are at least 95% identical to SEQ ID NO:453;

[0214] the variant E proteins are at least 95% identical to SEQ ID NO:454, and the variant M proteins are at least 95% identical to SEQ ID NO:455;

[0215] the variant E proteins are at least 95% identical to SEQ ID NO:456, and the variant M proteins are at least 95% identical to SEQ ID NO:457;

[0216] the variant E proteins are at least 95% identical to SEQ ID NO:458, and the variant M proteins are at least 95% identical to SEQ ID NO:459;

[0217] the variant E proteins are at least 95% identical to SEQ ID NO:460, and the variant M proteins are at least 95% identical to SEQ ID NO:461;

[0218] the variant E proteins are at least 95% identical to SEQ ID NO:462, and the variant M proteins are at least 95% identical to SEQ ID NO:463;

[0219] the variant E proteins are at least 95% identical to SEQ ID NO:464, and the variant M proteins are at least 95% identical to SEQ ID NO:465;

[0220] the variant E proteins are at least 95% identical to SEQ ID NO:466, and the variant M proteins are at least 95% identical to SEQ ID NO:459;

[0221] the variant E proteins are at least 95% identical to SEQ ID NO:467. and the variant M proteins are at least 95% identical to SEQ ID NO:468;

[0222] the variant E proteins are at least 95% identical to SEQ ID NO:471, and the variant M proteins are at least 95% identical to SEQ ID NO:472; or

[0223] the variant E proteins are at least 95% identical to SEQ ID NO:473. and the variant M proteins are at least 95% identical to SEQ ID NO:472.

[0224] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus:

[0225] the variant E proteins are identical to SEQ ID NO:450, and the variant M proteins are identical to SEQ ID NO:451;

[0226] the variant E proteins are identical to SEQ ID NO:452, and the variant M proteins are identical to SEQ ID NO:453;

[0227] the variant E proteins are identical to SEQ ID NO:454, and the variant M proteins are identical to SEQ ID NO:455;

[0228] the variant E proteins are at identical to SEQ ID NO:456, and the variant M proteins are identical to SEQ ID NO:457; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are identical to SEQ ID NO:458, and the variant M proteins are identical to SEQ ID NO:459;

[0229] the variant E proteins are identical to SEQ ID NO:460, and the variant M proteins are identical to SEQ ID NO:461;

[0230] the variant E proteins are identical to SEQ ID NO:462, and the variant M proteins are identical to SEQ ID NO:463;

[0231] the variant E proteins are identical to SEQ ID NO:464, and the variant M proteins are identical to SEQ ID NO:465;

[0232] the variant E proteins are identical to SEQ ID NO:466, and the variant M proteins are identical to SEQ ID NO:459;

[0233] the variant E proteins are identical to SEQ ID NO:467, and the variant M proteins are identical to SEQ ID NO:468;

[0234] the variant E proteins are identical to SEQ ID NO:471, and the variant M proteins are identical to SEQ ID NO:472; or

[0235] the variant E proteins are identical to SEQ ID NO:473, and the variant M proteins are identical to SEQ ID NO:472.

[0236] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus, the stabilized flavivirus heterotetramer comprises two fusion proteins, wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins. In some embodiments, each fusion protein comprises, from N-terminus to C -terminus, the variant E protein and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant M protein and the variant E protein. In some embodiments, each fusion protein comprises a linker between the variant E protein and the variant M protein. In some embodiments, the linker comprises GGGG (SEQ ID NO:364). In some embodiments, the linker comprises GGPG (SEQ ID NO: 365). In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein, a linker comprising GGGG (SEQ ID NO:364), and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus. the variant E protein, a linker comprising GGPG (SEQ ID NO:365), and the variant M protein. Attorney Docket No. 45817-0191WO1 / MTX1505.20 In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus, each of the fusion proteins comprises: a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:433;

[0237] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:434;

[0238] a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:435;

[0239] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:436;

[0240] a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:437;

[0241] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:438;

[0242] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:439;

[0243] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:440;

[0244] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:441;

[0245] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:442;

[0246] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 444;

[0247] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 445; or

[0248] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:446.

[0249] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus, each of the fusion proteins comprises: a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:433; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:434;

[0250] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:435;

[0251] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:436;

[0252] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:437;

[0253] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:438;

[0254] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:439;

[0255] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:440;

[0256] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:441;

[0257] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:442;

[0258] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 444;

[0259] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 445; or

[0260] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:446.

[0261] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus, each of the fusion proteins comprises: the amino acid sequence set forth in SEQ ID NO:433;

[0262] the amino acid sequence set forth in SEQ ID NO:434;

[0263] the amino acid sequence set forth in SEQ ID NO:435;

[0264] the amino acid sequence set forth in SEQ ID NO:436;

[0265] the amino acid sequence set forth in SEQ ID NO:437;

[0266] the amino acid sequence set forth in SEQ ID NO:438; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the amino acid sequence set forth in SEQ ID NO:439;

[0267] the amino acid sequence set forth in SEQ ID NO:440;

[0268] the amino acid sequence set forth in SEQ ID NO:441;

[0269] the amino acid sequence set forth in SEQ ID NO:442;

[0270] the amino acid sequence set forth in SEQ ID NO:444;

[0271] the amino acid sequence set forth in SEQ ID NO:445; or

[0272] the amino acid sequence set forth in SEQ ID NO:446.

[0273] In another aspect, the disclosure provides a vaccine composition comprising a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is Zika virus. In some embodiments, the vaccine composition comprises one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein. In some embodiments, the vaccine composition comprises one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein.

[0274] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0275] a variant E protein at least 90% identical to SEQ ID NO:450 and a variant M protein at least 90% identical to SEQ ID NO:451;

[0276] a variant E protein at least 90% identical to SEQ ID NO:452 and a variant M protein at least 90% identical to SEQ ID NO:453;

[0277] a variant E protein at least 90% identical to SEQ ID NO:454 and a variant M protein at least 90% identical to SEQ ID NO:455;

[0278] a variant E protein at least 90% identical to SEQ ID NO:456 and a variant M protein at least 90% identical to SEQ ID NO:457;

[0279] a variant E protein at least 90% identical to SEQ ID NO:458 and a variant M protein at least 90% identical to SEQ ID NO:459;

[0280] a variant E protein at least 90% identical to SEQ ID NO:460 and a variant M protein at least 90% identical to SEQ ID NO:461;

[0281] a variant E protein at least 90% identical to SEQ ID NO:462 and a variant M protein at least 90% identical to SEQ ID NO:463; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 90% identical to SEQ ID NO:464 and a variant M protein at least 90% identical to SEQ ID NO:465;

[0282] a variant E protein at least 90% identical to SEQ ID NO:466 and a variant M protein at least 90% identical to SEQ ID NO:459;

[0283] a variant E protein at least 90% identical to SEQ ID NO:467 and a variant M protein at least 90% identical to SEQ ID NO:468;

[0284] a variant E protein at least 90% identical to SEQ ID NO:471 and a variant M protein at least 90% identical to SEQ ID NO.472; or

[0285] a variant E protein at least 90% identical to SEQ ID NO:473 and a variant M protein at least 90% identical to SEQ ID NO:472.

[0286] In some embodiments, the vaccine composition comprises:

[0287] a variant E protein at least 95% identical to SEQ ID NO:450 and a variant M protein at least 95% identical to SEQ ID NO:451;

[0288] a variant E protein at least 95% identical to SEQ ID NO:452 and a variant M protein at least 95% identical to SEQ ID NO:453;

[0289] a variant E protein at least 95% identical to SEQ ID NO:454 and a variant M protein at least 95% identical to SEQ ID NO:455;

[0290] a variant E protein at least 95% identical to SEQ ID NO:456 and a variant M protein at least 95% identical to SEQ ID NO:457;

[0291] a variant E protein at least 95% identical to SEQ ID NO:458 and a variant M protein at least 95% identical to SEQ ID NO:459;

[0292] a variant E protein at least 95% identical to SEQ ID NO:460 and a variant M protein at least 95% identical to SEQ ID NO:461;

[0293] a variant E protein at least 95% identical to SEQ ID NO:462 and a variant M protein at least 95% identical to SEQ ID NO:463;

[0294] a variant E protein at least 95% identical to SEQ ID NO:464 and a variant M protein at least 95% identical to SEQ ID NO:465;

[0295] a variant E protein at least 95% identical to SEQ ID NO:466 and a variant M protein at least 95% identical to SEQ ID NO:459;

[0296] a variant E protein at least 95% identical to SEQ ID NO:467 and a variant M protein at least 95% identical to SEQ ID NO:468; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 95% identical to SEQ ID NO:471 and a variant M protein at least 95% identical to SEQ ID NO:472; or

[0297] a variant E protein at least 95% identical to SEQ ID NO:473 and a variant M protein at least 95% identical to SEQ ID NO:472.

[0298] In some embodiments, the vaccine composition comprises:

[0299] a variant E protein identical to SEQ ID NO:450 and a variant M protein identical to SEQ ID NO:451;

[0300] a variant E protein identical to SEQ ID NO:452 and a variant M protein identical to SEQ ID NO:453;

[0301] a variant E protein identical to SEQ ID NO:454 and a variant M protein identical to SEQ ID NO:455;

[0302] a variant E protein identical to SEQ ID NO:456 and a variant M protein identical to SEQ ID NO:457;

[0303] a variant E protein identical to SEQ ID NO:458 and a variant M protein identical to SEQ ID NO:459;

[0304] a variant E protein identical to SEQ ID NO:460 and a variant M protein identical to SEQ ID NO:461;

[0305] a variant E protein identical to SEQ ID NO:462 and a variant M protein identical to SEQ ID NO:463;

[0306] a variant E protein identical to SEQ ID NO:464 and a variant M protein identical to SEQ ID NO:465;

[0307] a variant E protein identical to SEQ ID NO:466 and a variant M protein identical to SEQ ID NO:459;

[0308] a variant E protein identical to SEQ ID NO:467 and a variant M protein identical to SEQ ID NO:468;

[0309] a variant E protein identical to SEQ ID NO:471 and a variant M protein identical to SEQ ID NO:472; or

[0310] a variant E protein identical to SEQ ID NO:473 and a variant M protein identical to SEQ ID NO: 472.

[0311] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising: Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:433;

[0312] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:434;

[0313] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:435;

[0314] a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:436;

[0315] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:437;

[0316] a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:438;

[0317] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:439;

[0318] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:440;

[0319] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:441;

[0320] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 442;

[0321] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:444;

[0322] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 445; or

[0323] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:446.

[0324] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0325] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:433;

[0326] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:434; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:435;

[0327] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:436;

[0328] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:437;

[0329] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:438;

[0330] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:439;

[0331] a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:440;

[0332] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:441;

[0333] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 442;

[0334] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 444;

[0335] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 445; or

[0336] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:446.

[0337] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0338] the amino acid sequence set forth in SEQ ID NO:433;

[0339] the amino acid sequence set forth in SEQ ID NO:434;

[0340] the amino acid sequence set forth in SEQ ID NO:435;

[0341] the amino acid sequence set forth in SEQ ID NO:436;

[0342] the amino acid sequence set forth in SEQ ID NO:437;

[0343] the amino acid sequence set forth in SEQ ID NO:438;

[0344] the amino acid sequence set forth in SEQ ID NO:439;

[0345] the amino acid sequence set forth in SEQ ID NO:440; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the amino acid sequence set forth in SEQ ID NO:441;

[0346] the amino acid sequence set forth in SEQ ID NO:442;

[0347] the amino acid sequence set forth in SEQ ID NO:444;

[0348] the amino acid sequence set forth in SEQ ID NO:445; or

[0349] the amino acid sequence set forth in SEQ ID NO:446.

[0350] In some embodiments, the vaccine composition further comprises a lipid nanoparticle.

[0351] In some embodiments, the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1,2 distearoyl -sn-glycero-3- phosphocholine (DSPC), and 1-5 mol% PEG-modified lipid.

[0352] In some embodiments, the lipid nanoparticle comprises 1-25:

[0353]

[0354] (1-25).

[0355] In some embodiments, the lipid nanoparticle comprises A7:

[0356]

[0357] (A7).

[0358] In some embodiments, the PEG-modified lipid is PEG2000-DMG. In some embodiments of the vaccine composition, the one or more mRNAs are fully modified with 1-methyl-pseudouridine.

[0359] In another aspect, the disclosure provides a method of inducing an immune response in a human subject, the method comprising administering to the human subject one or more doses of a stabilized flavivirus heterotetramer described herein or a vaccine composition described herein in an amount effective to produce, in the human subject, an immune response to a Zika virus infection. In some embodiments, the stabilized flavivirus heterotetramer is administered intramuscularly. Attorney Docket No. 45817-0191WO1 / MTX1505.20 In another aspect, the disclosure provides a method of inducing an immune response in a human subject, the method comprising administering to the human subject a stabilized flavivirus heterotetramer described herein or a vaccine composition described herein in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring Zika virus. In some embodiments, the vaccine composition is administered intramuscularly.

[0360] In some embodiments of a stabilized flavivirus heterotetramer described herein, the flavivirus is yellow fever virus, the corresponding wild-type yellow fever virus E protein is SEQ ID NO:283 and the corresponding wild-type yellow fever virus M protein is SEQ ID NO:284.

[0361] In some embodiments of the stabilized flavivirus heterotetramer, wherein the flavivirus is yellow fever virus:

[0362] the variant E proteins are at least 90% identical to SEQ ID NO:476, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:477;

[0363] the variant E proteins are at least 90% identical to SEQ ID NO:478, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:479; or the variant E proteins are at least 90% identical to SEQ ID NO:480, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:481.

[0364] In some embodiments of the stabilized flavivirus heterotetramer, wherein the flavivirus is yellow fever virus:

[0365] the variant E proteins are at least 95% identical to SEQ ID NO:476, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:477;

[0366] the variant E proteins are at least 95% identical to SEQ ID NO:478, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:479; or the variant E proteins are at least 95% identical to SEQ ID NO:480, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:481.

[0367] In some embodiments of the stabilized flavivirus heterotetramer, wherein the flavivirus is yellow fever virus:

[0368] the variant E proteins are identical to SEQ ID NO: 476, and wherein the variant M proteins are identical to SEQ ID NO:477; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are identical to SEQ ID NO:478, and wherein the variant M proteins are identical to SEQ ID NO:479; or

[0369] the variant E proteins are identical to SEQ ID NO:480, and wherein the variant M proteins are identical to SEQ ID NO:481.

[0370] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is yellow fever virus, the stabilized flavivirus heterotetramer comprises two fusion proteins, wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus. the variant M protein and the variant E protein. In some embodiments, each fusion protein comprises a linker between the variant E protein and the variant M protein. In some embodiments, the linker comprises GGGG (SEQ ID NO: 364). In some embodiments, the linker comprises GGPG (SEQ ID NO: 365). In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein, a linker comprising GGGG (SEQ ID NO:364), and the variant M protein. In some embodiments, each fusion protein comprises, from N-terminus to C-terminus, the variant E protein, a linker comprising GGPG (SEQ ID NO:365), and the variant M protein.

[0371] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is yellow fever virus, each of the fusion proteins comprises:

[0372] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:447;

[0373] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:448; or

[0374] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:449.

[0375] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is yellow fever virus, each of the fusion proteins comprises: Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:447;

[0376] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:448; or

[0377] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:449.

[0378] In some embodiments of a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is yellow fever virus, each of the fusion proteins comprises:

[0379] the amino acid sequence set forth in SEQ ID NO:447;

[0380] the amino acid sequence set forth in SEQ ID NO:448; or

[0381] the amino acid sequence set forth in SEQ ID NO:449.

[0382] In another aspect, the disclosure provides a vaccine composition comprising a stabilized flavivirus heterotetramer described herein, wherein the flavivirus is yellow fever virus. In some embodiments, the vaccine composition comprises one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein. In some embodiments, the vaccine composition comprises one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers described herein.

[0383] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0384] a variant E protein at least 90% identical to SEQ ID NO:476 and a variant M protein at least 90% identical to SEQ ID NO:477;

[0385] a variant E protein at least 90% identical to SEQ ID NO:478 and a variant M protein at least 90% identical to SEQ ID NO:479; or

[0386] a variant E protein at least 90% identical to SEQ ID NO:480 and a variant M protein at least 90% identical to SEQ ID NO:481.

[0387] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising: Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 95% identical to SEQ ID NO:476 and a variant M protein at least 95% identical to SEQ ID NO:477;

[0388] a variant E protein at least 95% identical to SEQ ID NO:478 and a variant M protein at least 95% identical to SEQ ID NO:479; or

[0389] a variant E protein at least 95% identical to SEQ ID NO:480 and a variant M protein at least 95% identical to SEQ ID NO:481.

[0390] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0391] a variant E protein at identical to SEQ ID NO:476 and a variant M protein identical to SEQ ID NO:477;

[0392] a variant E protein identical to SEQ ID NO:478 and a variant M protein identical to SEQ ID NO:479; or

[0393] a variant E protein identical to SEQ ID NO:480 and a variant M protein identical to SEQ ID NO:481.

[0394] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0395] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:447;

[0396] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:448; or

[0397] a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:449.

[0398] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising:

[0399] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:447;

[0400] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:448; or

[0401] a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:449.

[0402] In some embodiments, the vaccine composition comprises an mRNA encoding a fusion protein comprising: Attorney Docket No. 45817-0191WO1 / MTX1505.20 the amino acid sequence set forth in SEQ ID NO:447;

[0403] the amino acid sequence set forth in SEQ ID NO:448; or

[0404] the amino acid sequence set forth in SEQ ID NO:449.

[0405] In some embodiments, the vaccine composition further comprises a lipid nanoparticle.

[0406] In some embodiments, the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1,2 distearoyl-sn-glycero-3- phosphocholine (DSPC). and 1-5 mol% PEG-modified lipid.

[0407] In some embodiments, the lipid nanoparticle comprises 1-25:

[0408]

[0409] (1-25).

[0410] In some embodiments, the lipid nanoparticle comprises A7:

[0411]

[0412] (A7).

[0413] In some embodiments, the PEG-modified lipid is PEG2000-DMG. In some embodiments of the vaccine composition, the one or more mRNAs are fully modified with 1-methyl-pseudouridine.

[0414] In another aspect, the disclosure provides a method of inducing an immune response in a human subject, the method comprising administering to the human subject one or more doses of a stabilized flavivirus heterotetramer described herein or a vaccine composition described herein in an amount effective to produce, in the human subject, an immune response to a yellow fever virus infection. In some embodiments, the stabilized flavivirus heterotetramer is administered intramuscularly.

[0415] In another aspect, the disclosure provides a method of inducing an immune response in a human subject, the method comprising administering to the human subject a stabilized flavivirus heterotetramer described herein or a vaccine

[0416] 31 Attorney Docket No. 45817-0191WO1 / MTX1505.20 composition described herein in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring yellow fever virus. In some embodiments, the vaccine composition is administered intramuscularly.

[0417] BRIEF DESCRIPTION OF THE DRAWINGS FIGs. 1A-1C show regions of mutations described herein. FIG. 1 A is a sequence alignment between four dengue virus serotypes and Zika virus. The top panel shows the sequence alignment between prM proteins (rows 1-2; DENV1, SEQ ID NO: 273 A; DENV2, SEQ ID NO: 275; DENV3, SEQ ID NO: 277; DENV4, SEQ ID NO: 279; ZIKV, SEQ ID NO: 281). The gray arrow indicates the furin cleavage site between pr and M proteins. The lower panel shows the sequence alignment between E proteins from five viruses (rows 3-8; DENV1, SEQ ID NO: 274; DENV2, SEQ ID NO: 276; DENV3, SEQ ID NO: 278; DENV4, SEQ ID NO: 280; ZIKV, SEQ ID NO: 282). Black background highlights the identical sequences among viruses and black solid boxes indicate similar sequence. Dotted boxes indicate the areas mutated in antigens described herein. FIGs. IB and 1C illustrate the structure of a flavivirus (M / E)2 heterotetramer from a virion. The flavivirus E protein ectodomain consists of three domains (EDI, EDII, and EDIII) followed by a transmembrane region including “stem” at its N-terminus in the figure. The E protein interacts with the transmembrane protein (M) that provides a scaffold and curvature to the E protein dimer. FIG. IB shows the top view of (M / E)2 heterotetramer domain (top panel). The M protein and the stem region provide a scaffold for the E protein homodimer ectodomain region as shown in the side view (bottom panel). Stabilizing mutations are indicated by arrows. FIG. 1C provides an illustration of the stem and M protein scaffold and E dimer (top panel) and an open book view of the same (bottom panel). The antigens described herein are unique because they comprise heterotetramer structures, which stabilize the antigen in a prefusion conformation and lead to a stronger immune response than E-dimers or wild-type proteins.

[0418] FIG.2 shows electron microscopy analysis of virus-like particles (VLPs) formed using engineered proteins described herein. Negative stain electron microscopy and cryogenic (cryo-EM) imaging were used. VLPs imaged included Attorney Docket No. 45817-0191WO1 / MTX1505.20 DENV1 52 (DENV1_52_E / M), DENV2 102 (DENV2-M / E_102,) DENV3 54 (DENV3 54 E / M VLP) and ZIKV 50 (ZIKV_50_E / M). DENV2 102 + Fab C8 indicates DENV2-M / E_102 VLPs in complex with Fab fragments of bnAb C8. ZIKV 50 + Fab C8 indicates ZIKV_50_E / M VLPs in complex with Fab fragments of bnAb C8. The box in each panel highlights the VLPs. VLPs of sizes 40 to 60 nm were observed for each construct.

[0419] FIG. 3 shows an SDS-PAGE gel of ZIKV_HA_50_E / M_VLPs following purification, demonstrating the presence of covalent (EM)2 heterotetramer VLPs. Expi293 cells were transfected using plasmid containing a ZIKV_HA_50_E / M gene. The supernatant was harvested after 72 hours and the VLPs were purified using sucrose gradient method as described previously (Shen et al., eLife 7:e38970). These partially purified VLPs were further purified by affinity chromatography using Fab C8 as bait. Purified samples were run on SDS-PAGE in reducing (+ 0ME) and nonreducing conditions (- ME). M; molecular weight marker. In this E / M design, E and M proteins are a single chain and the engineered (EM)2 heterotetramer is covalently stabilized and thus in non-reducing conditions this protein runs at a molecular weight of -130 kDa. The Fab C8 band can be seen at approximately 50 kDa, which also contains the covalently linked heavy and light chains. Under reducing conditions, the EM single chain protein was observed at a molecular weight of approximately 65 kDa (M protein - 8.5 kDa + E protein - 55 kDa). Fab C8 was also reduced into heavy chain (HC) and light chain (LC) bands. The first two lanes show Fab C8 in nonreducing and reducing conditions, respectively. In reducing conditions (+ 0ME), the Fab C8 heavy chain (HC) and light chain (LC) are separated. M; marker.

[0420] FIGs. 4A-4B show the relative abundance of intracellular and surface proteins (FIG. 4A) and of soluble fractions (VLPs) (FIG. 4B) following monovalent transfection (left graphs) and following tetravalent transfection (right graphs). AS indicates exemplary' designed proteins (VI candidates) and WT indicates wild type proteins of 4 exemplary Dengue viruses. Briefly, 72 hours post-transfection in 24 well plate, 100 ul of cell suspension was taken out and pelleted using by centrifugation at 500g for 5 min. In FIG. 4A, pelleted cells were washed with PBS and subjected to mass-spectrometry evaluation for quantifying the relative expression of designs vs WT. High relative abundance for designs was observed compared to the WT. FIG. 4B Attorney Docket No. 45817-0191WO1 / MTX1505.20 shows the supernatant tested for secreted VLP / protein presence using mass-spectrometry after centrifugation. The relative peptide count between the design and WT protein was determined, for e.g. in monovalent transfection, there was approximately a 40000 higher peptide count for AS DI compared to the WT DI.

[0421] FIG. 5 shows electron microscopy analysis of (ME)2 stabilized VLPs engineered VLPs using negative stain electron microscopy and cryogenic (cryo-EM) imaging. VLPs imaged included DV1-V2, DV2-V2, DV3-V2, and DV4-V2. The box in each panel highlights the VLPs. VLPs of sizes 40 to 60 nm were observed for each construct.

[0422] FIG. 6 shows an SDS-PAGE gel of DENV VLPs (V2 designs) following purification as described in FIG.3, demonstrating the presence of covalent (EM)2 heterotetramers in Expi203 cells.

[0423] FIGs. 7A-7D show flow cytometry' results demonstrating selected DENV antigen (VI designs) binding to specific antibodies. Each antigen, designed (denoted as “Stab”, right bar) or wild-ty pe (WT, left bar), was tested individually (DENV 1, DENV2, DENV3, DENV4) and together (“All 4”). The percent of positive cells (top row) and the mean fluorescence intensity (bottom row) are shown. Cell samples were prepared as described in FIG. 4A. All; mAb EDE2 Al 1, G-Al 1; agermline version of the EDE2 mAb Al 1, B7; mAb EDE2 B7, C8, mAb EDEI C8, CIO; mAb EDEI CIO, G-C10; a germline version of the EDEI mAb CIO, and mAb SlgN3C are the bnAbs that cross-react with all four DENVs to varying extent. D1-F4; mAb 1F4 (specific to DENV1), 2D22; mAb 2D22 (specific to DENV2), 5J7; mAb 5J7 (specific to DENV3), and 5H2; mAb 5H2 (specific to DENV4). 24211; mAb ADI-24211, 24220; mAb ADI-24211 and Z6; mAb Z6 are anti-fusion loop antibodies that crossreact with all four DENVs.

[0424] FIG. 8 comprises four graphs showing monovalent homologous antibody responses (neutralization titers) in vivo. Briefly, BALB / c mice were immunized with the LNPs containing rnRNA that encoded for wild ty pe (WT) DENVs 1-4 VLPs or the (ME)2 stabilized VLPs (VI). PBS; no LNPs were injected - sterile PBS used instead, WT 1; 1 ug of LNPs encoding WT DENV VLP were injected. VI 1; 1 ug of the VI encoding LNPs were injected. VI 4; 4 ug of the V 1 encoding LNPs were injected. A prime (day 1) boost (day 22) regime was followed and blood samples were collected Attorney Docket No. 45817-0191WO1 / MTX1505.20 from mice on day 57. Sera from the collected blood samples were used for neutralization experiments and the results of neutralization (NT50) are shown here. The table below the NT50 bars shows the strains used in immunization and neutralization assays.

[0425] FIGs. 9A-9D show cross-reactive antibody responses (neutralization titers) following DENV1 vaccination (FIG. 9 A), DENV2 vaccination (FIG. 9B), DENV3 vaccination (FIG. 9C), and DENV4 vaccination (FIG. 9D). Control is WT samples.

[0426] FIG. 10 is four graphs showing serotype-specific responses following administration of the tetravalent composition (measured by neutralization titer).

[0427] FIG. 11 shows the immunological balance across the four DENV serotypes at the 1 pg (left graph) and 4 pg (right graph) doses.

[0428] FIGs. 12A-12L are graphs showing binding of anti-DENV monoclonal antibodies to DENV1 wild type (Fig. 12A), DENV2 wild type (Fig. 12B), DENV3 wild type (Fig. 12C), DENV4 wild type (Fig. 12D), DVl_005_E / M (Fig. 12E), DV2-029_E / M (Fig. 12F), DENV3_HA_60_E / M (Fig. 12G), DV4-Ind_005_E / M (Fig. 12H). DVl_005-A_E / M (Fig. 121), DV2-029-A_E / M (Fig. 12J), AS_V3_DV3_013A_E / M (Fig. 12K), and DV4-Ind_005-A_E / M (Fig. 12L) VLPs.

[0429] FIG. 13A shows dot-blot expression profiles performed on supernatant collected from Expi-293 cells transfected with plasmids encoding engineered DENV4 VLPs.

[0430] FIG. 13B shows dot-blot expression profiles performed on supernatant collected from Expi-293 cells transfected with plasmids encoding engineered DENV1, DENV2, DENV3, and DENV4 VLPs.

[0431] FIGs. 14A-14L are graphs showing binding of anti-DENV monoclonal antibodies to DENV1 wild type (Fig. 14A), DENV2 wild type (Fig. 14B), DENV3 wild type (Fig. 14C), DENV4 wild type (Fig. 14D), DVl_005_E / M (Fig. 14E), DV2-029_E / M (Fig. 14F), DENV3_HA_60_E / M (Fig. 14G), DV4-Ind_005_E / M (Fig. 14H), AS_V4_DVl-EM_007 (Fig. 141), AS_V4_DV2-EM_003 (Fig. 14J), AS_V4_DV3-EM_006 (Fig. 14K), and AS_V3.1_DV4-EM_005 (Fig. 14L) VLPs.

[0432] FIGs. 15A-15D are graphs showing DENV 1 -specific responses (Fig. 15A). DENV2-specific responses (Fig. 15B), DENV3-specific responses (Fig. 15C), and DENV4-specific responses (Fig. 15D) following monovalent immunizations with Attorney Docket No. 45817-0191WO1 / MTX1505.20 wild-type dengue VLPs (DENV1 prM / E, DENV2 prM / E, DENV3 prM / E, or DENV4 prM / E) or designed VLPs (DENV1 V4, DENV2 V4, DENV3 V4, or DENV4 V4). FIGs. 15E-15H are graphs showing DENV 1 -specific responses (Fig. 15E). DENV2-specific responses (Fig. 15F), DEN V3 -specific responses (Fig. 15G), and DENV4-specific responses (Fig. 15H) following immunizations with tetraval ent formulations comprising either wild-type dengue VLPs for each serotype (Tetra prME) or four designed VLPs for each serotype (Tetra V4 or Tetra V2).

[0433] FIG. 16A shows dot-blot expression profiles performed on supernatant collected from Expi-293 cells transfected with plasmids encoding engineered DENV2 VLPs.

[0434] FIG. 16B shows dot-blot expression profiles performed on supernatant collected from Expi-293 cells transfected with plasmids encoding engineered Zika virus VLPs.

[0435] FIG. 16C shows dot-blot expression profiles performed on supernatant collected from Expi-293 cells transfected with plasmids encoding engineered yellow fever virus VLPs.

[0436] DETAILED DESCRIPTION

[0437] Flaviviruses are icosahedral structures having a lipid envelope covered densely with surface projections composed of multiple copies of M (membrane) and multiple copies of E (envelope) glycoproteins. The E glycoproteins are organized as dimers, paired horizontally head to tail, on the virion surface. Flaviviruses are approximately 50 nm spherical particles that, in their mature, infectious form have an outer shell made of 90 membrane (M) protein and envelope (E) protein heterotetramers (M / Ety arranged in a herringbone pattern. This (M / Ety outer shell is the main target of the neutralizing antibody response and cross-reactivity among flaviviruses has been reported as the M and E proteins are not only structurally conserved among these viruses but can also have a high sequence identity of > 50% (Rey et al., Cell, 172(6), 1319-1334, 2018; Duquerroy et al., Encyclopedia of Virol. 1, 290-302, 2021) (FIG. 1A).

[0438] While the immune response against the prefusion (M / Ety heteroterameric form is protective in nature, the response against immature form is often non-neutralizing Attorney Docket No. 45817-0191WO1 / MTX1505.20 and can lead to antibody-dependent enhancement (ADE) of the disease. Protective antibody responses during natural infection mostly comprise serotype-specific antibodies, and very rarely by broadly neutralizing antibodies (bnAbs). These protective antibodies target the mature shell of virus particles and lock the outer shell in a pre-fusion conformation. The only known class of bnAbs that targets all four DENVs and ZIKV is called anti-E dimer epitope antibodies (Fey et al., EMBO Rep.

[0439] 2018 Feb; 19(2):206-224; Dejnirattisai et al., Nature Immunology, 16, 170-177; Sharma et al., Cell. 2021 Dec 9;184(25):6052-6066).

[0440] Previous flavivirus vaccine designs focused on stabilizing the E dimer interface present on the ectodomain or generating soluble E proteins (Rouvinski et al., Nature Commun., 8, 15411, 2017; Sion-Campos et al., Nat Immunol., 20. 1291-1298, 2019; Kudlacek et al., Science Advances, 7(42). 2021; Phan et al., J of Biol Chem., 298(7): 102079, 2022). Such soluble E dimers have a conformation that is different from that seen in naturally occurring flaviviruses. That conformation may not promote the formation of antibodies that are optimal for generating a protective immune response against flavivirus infections.

[0441] Thus, described herein are engineered non-infectious Virus-Like Particles (VLPs) that form a lattice of heterotetramers formed from E and M proteins (FIGs. IB and 1C). Because the engineered heterotetramers are stabilized in a native conformation, they elicit an efficacious protective immune response. The engineered VLPs described herein, are stabilized in a prefusion conformation through a combination of mutations in the E protein and the M protein resulting in covalent and non-covalent interactions. Such mutations can be made to sequences of structurally related Flaviviridae. For example, FIG. 1 A shows a sequence alignment between the four DENV serotypes and ZIKV, where exemplary positions mutated for stabilization are boxed. This sequence alignment is based on the conformational similarity among these viruses and the numbering of positions amenable to mutation in a reference sequence (e.g., Dengue 2) can be used to determine those positions in related sequences that are mutated to achieve the same result. In particular, mutations in the be loop and fusion loop of the E protein, as well as the N-terminal of the M protein were found to stabilize the E protein in its prefusion conformation. Attorney Docket No. 45817-0191WO1 / MTX1505.20 As is described in the Examples, the structure-guided antigen designs were applied to multiple different flaviviruses, demonstrating the applicability of the substitutions to flavivirus due to the high structural similarity between the flaviviruses. Stabilized heterotetramers were designed for DENV (all four serotypes) and ZIKV and were then tested for expression and presence of the prefusion conformation heterotetramer. Additionally, engineered VLPs for yellow fever vims (YFV) designed using the structure-guided approach described herein showed improved expression and presence of the prefusion heterotetramer conformation.

[0442] Stabilized Flavivirus Heterotetramers

[0443] Described herein are engineered flavivirus antigens comprising at least one amino acid substitution relative to their respective wild-type proteins and which form stabilized heterotetramers. A stabilized flavivirus heterotetramer, as used herein, refers to a complex of four flavivirus proteins, including two E proteins and two M proteins having amino acid substitutions relative to wild-type E and M proteins. The amino acid substitutions stabilize the complex of four proteins in a prefusion heterotetramer conformation. As is shown in the instant Examples, stabilizing the heterotetramer in its prefusion conformation elicits an optimal immune response because the native curvature of the E protein is preserved. In the instant constructs, each of the two E proteins includes at least a substitution at positions 76, 106, and 107 (corresponding to a wild-type DENV2 E protein; SEQ ID NO:276). Position 76 of the DENV E protein is located in the be loop region of the E protein. The be loop is a hydrophobic loop found in the second domain of the E protein and is linked to the Fusion loop via a disulfide bond. Positions 106 and 107 of the DENV E protein are located in the fusion loop region of the E protein. The fusion loop of the E protein forms the tip of the second domain of the E protein and is required for the low-pH-driven membrane fusion of the viral membrane with a host endosomal membrane. As the flaviviruses are structurally similar to one another, the corresponding positions (e.g., positions 76, 106, and 107 of the wild-type DENV E protein) can be applied to any other flavivirus E protein; for example, FIG. 1 A illustrates the analogous regions of DENV 1-4 and ZIKV). One of ordinary skill in the art would recognize that a substitution at position 76 of DENV2 (in FIG. 1A) corresponds to a substitution at Attorney Docket No. 45817-0191WO1 / MTX1505.20 position 76 of DENV1, DENV3, and DENV4, and position 77 ofZIKV, for example. For each of the amino acid substitutions described below, the numbered positions refer to DENV2 E and M proteins; however, as described above, each substitution can be applied to any flavivirus owing to their structural similarity'.

[0444] In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-ty pe amino acid (e.g., SEQ ID NO: 276) with an amino acid comprising a charged bulky residue. In some embodiments, the charged bulky residue is selected from the group consisting of: aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q), lysine (K), tyrosine (Y), and arginine (R). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-type amino acid with aspartic acid (D). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-type amino acid with glutamic acid (E). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-type amino acid with asparagine (N). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-type amino acid with glutamine (Q). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wdld-type amino acid with lysine (K). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the wild-ty pe amino acid with tyrosine (Y). In some embodiments, the amino acid substitution at position 76 of the E protein comprises a substitution of the w ild-type amino acid with arginine (R).

[0445] In some embodiments, the amino acid substitution at position 106 of the E protein comprises a substitution of the wild-type amino acid (e.g., SEQ ID NO: 276) with serine (S). In some embodiments, the amino acid substitution at position 106 of the E protein comprises a substitution of the wild-type amino acid (e.g., SEQ ID NO: 276) with threonine (T). In some embodiments, the amino acid substitution at position 106 of the E protein comprises a substitution of the wild-type amino acid (e.g., SEQ ID NO: 276) with asparagine (N). In some embodiments, the amino acid substitution at position 106 of the E protein comprises a substitution of the wild-type amino acid (e.g., SEQ ID NO: 276) with lysine (K). Attorney Docket No. 45817-0191WO1 / MTX1505.20 In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid (e.g., SEQ ID NO: 276) with an amino acid comprising a charged bulky residue. In some embodiments, the charged bulky residue is selected from the group consisting of: aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q), lysine (K), tyrosine (Y), and arginine (R). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with aspartic acid (D). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with glutamic acid (E). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-ty pe amino acid with asparagine (N). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with glutamine (Q). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with lysine (K). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with tyrosine (Y). In some embodiments, the amino acid substitution at position 107 of the E protein comprises a substitution of the wild-type amino acid with arginine (R).

[0446] In some embodiments, the E protein comprises a further amino acid substitution. The further amino acid substitution, in some embodiments, is located at the inter-dimer interface of the resulting VLP (e.g., corresponding to SEQ ID NO: 276). For each of the amino acid substitutions, the numbered positions refer to DENV2 E protein; however, as described above, each substitution can be applied to any flavivirus owing to their structural similarity’. In some embodiments, the further amino acid substitution comprises an amino acid substitution at position 131. In some embodiments, the amino acid substitution at position 131 is selected from the group consisting of: alanine (A), asparagine (N), and leucine (L). In some embodiments, the amino acid substitution at position 131 is alanine (A). In some embodiments, the amino acid substitution at position 131 is asparagine (N). In some embodiments, the amino acid substitution at position 131 is leucine (L). In some embodiments, the amino acid substitution at position 194 is aspartic acid (D). In some embodiments, the Attorney Docket No. 45817-0191WO1 / MTX1505.20 amino acid substitution at position 134 is asparagine (N) or aspartic acid (D). In some embodiments, the amino acid substitution at position 134 is asparagine (N). In some embodiments, the amino acid substitution at position 134 is aspartic acid (D). In some embodiments the E protein comprises an amino acid substitution at position 131, at position 134, and at position 194. The further E protein amino substitutions may comprise, in positions 131, 134, and 194 any of the following combinations: AND, ADD, NND, NDD, LND, or LDD.

[0447] In some embodiments, the E protein comprises further amino acid substitution in order to stabilize its interactions with its stem region. For each of the amino acid substitutions, the numbered positions refer to DENV2 E protein; however, as described above, each substitution can be applied to any flavivirus owing to their structural similarity. In some embodiments, the E protein comprises an amino acid substitution at position 267 and / or 445 corresponding to SEQ ID NO: 276. In some embodiments, the E protein amino acid mutation is a tyrosine (Y), a glutamine (Q), or an asparagine (N) at position 267. In some embodiments, the E protein amino acid mutation is a lysine (K) or an arginine (R) at position 445. In some embodiments, the E protein comprises, in position 267 and 445, any of the following combinations: YK, YR, QK, QR, NK, or NR.

[0448] Without wishing to be bound by theory', it is thought that increasing hydrophobic interactions between the M protein and the bottom interface of the E dimer serves to stabilize the heterotetramer. This, in some embodiments, is accomplished by introducing at least one amino acid mutation in the N-terminal region of the M protein (e.g., corresponding to SEQ ID NO: 275).

[0449] In some embodiments, the at least one amino acid substitution within the N-terminal region on the M protein is located within the N-terminal 38 amino acids (e.g., corresponding to SEQ ID NO: 275). For each of the amino acid substitutions, the numbered positions refer to DENV2 M protein; however, as described above, each substitution can be applied to any flavivirus owing to their structural similarity'. In some embodiments, the at least one amino substitution within the N-terminal region of the M protein is selected from the following positions: 90, 91, 93, 94, 96, 97, 99, 101, 103, 104, and 105. In some embodiments, the at least one amino acid substitution within the N-terminal region of the M protein comprises an amino acid substitution at Attorney Docket No. 45817-0191WO1 / MTX1505.20 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all 11 of the following positions: 90, 91, 93, 94, 96, 97, 99, 101, 103, 104, and 105. In some embodiments, the M protein comprises an amino acid substitution at position 90. In some embodiments, the M protein comprises an amino acid substitution at position 91. In some embodiments, the M protein comprises an amino acid substitution at position 93. In some embodiments, the M protein comprises an amino acid substitution at position 94. In some embodiments, the M protein comprises an amino acid substitution at position 96. In some embodiments, the M protein comprises an amino acid substitution at position 97. In some embodiments, the M protein comprises an amino acid substitution at position 99. In some embodiments, the M protein comprises an amino acid substitution at position 101. In some embodiments, the M protein comprises an amino acid substitution at position 103. In some embodiments, the M protein comprises an amino acid substitution at position 104. In some embodiments, the M protein comprises an amino acid substitution at position 105.

[0450] In some embodiments, the amino acid substitution at position 90 of the M protein is valine (V). In some embodiments, the amino acid substitution at position 90 of the M protein is isoleucine (I).

[0451] In some embodiments, the amino acid substitution at position 91 of the M protein (e.g., corresponding to SEQ ID NO: 275) is cysteine (C). In some embodiments, the amino acid substitution at position 91 of the M protein is isoleucine (I). In some embodiments, the amino acid substitution at position 91 of the M protein (i.e., cysteine) is paired with an amino acid substitution of cysteine (C) at position 262 of the E protein, to form a disulfide bond.

[0452] In some embodiments, the amino acid substitution at position 93 of the M protein (e.g., corresponding to SEQ ID NO: 275) is phenylalanine (F). In some embodiments, the amino acid substitution at position 93 of the M protein is tyrosine (Y). In some embodiments, the amino acid substitution at position 93 of the M protein is tryptophan (W).

[0453] In some embodiments, the amino acid substitution at position 94 of the M protein (e.g., corresponding to SEQ ID NO: 275) is isoleucine (I). In some embodiments, the amino acid substitution at position 94 of the M protein is leucine (L). In some embodiments, the amino acid substitution at position 94 of the M protein Attorney Docket No. 45817-0191WO1 / MTX1505.20 is asparagine (N). In some embodiments, the amino acid substitution at position 94 of the M protein is lysine (K).

[0454] In some embodiments, the amino acid substitution at position 96 of the M protein (e.g., corresponding to SEQ ID NO: 275) is cysteine (C). In some embodiments, the amino acid substitution at position 96 of the M protein (i.e., cysteine) is paired with an amino acid substitution of cysteine (C) at position 267 of the E protein, to form a disulfide bond.

[0455] In some embodiments, the amino acid substitution at position 97 of the M protein (e.g., corresponding to SEQ ID NO: 275) is isoleucine (I). In some embodiments, the amino acid substitution at position 97 of the M protein is cysteine (C). In some embodiments, the amino acid substitution at position 97 of the M protein (i.e., cysteine) is paired with an amino acid substitution of cysteine (C) at position 495 of the E protein, to form a disulfide bond.

[0456] In some embodiments, the amino acid substitution at position 99 of the M protein (e.g., corresponding to SEQ ID NO: 275) is isoleucine (I). In some embodiments, the amino acid substitution at position 99 of the M protein is leucine (L).

[0457] In some embodiments, the amino acid substitution at position 101 of the M protein (e.g., corresponding to SEQ ID NO: 275) is methionine (M). In some embodiments, the amino acid substitution at position 101 of the M protein is isoleucine (I). In some embodiments, the amino acid substitution at position 101 of the M protein is phenylalanine (F).

[0458] In some embodiments, the amino acid substitution at position 103 of the M protein (e.g., corresponding to SEQ ID NO: 275) is glycine (G). In some embodiments, the amino acid substitution at position 103 of the M protein is alanine (A). In some embodiments, the amino acid substitution at position 103 of the M protein is serine (S). In some embodiments, the amino acid substitution at position 103 of the M protein is cysteine (C). In some embodiments, the amino acid substitution at position 103 of the M protein (i.e., cysteine) is paired with an amino acid substitution of cysteine (C) at position 280 of the E protein, to form a disulfide bond. Attorney Docket No. 45817-0191WO1 / MTX1505.20 In some embodiments, the amino acid substitution at position 104 of the M protein (e.g., corresponding to SEQ ID NO: 275) is serine (S).

[0459] In some embodiments, the amino acid substitution at position 105 of the M protein (e.g., corresponding to SEQ ID NO: 275) is cysteine (C). In some embodiments, the amino acid substitution at position 105 of the M protein (i.e., cysteine) is paired with an amino acid substitution of cysteine (C) at position 280 of the E protein, to form a disulfide bond.

[0460] In some embodiments, the E protein and the M protein comprise a fusion protein. In some embodiments, the fusion protein comprises, from N-terminus to C-terminus, the M protein and the E protein.

[0461] In some embodiments, the fusion protein comprises, from N-terminus to C-terminus. the E protein and the M protein. In some embodiments, a linker is positioned between the E protein and the M protein (i.e., from N-terminus to C-terminus, the fusion protein comprises the E protein, the linker, and the M protein). In some embodiments, the linker is a flexible linker. Without wishing to be bound by theory, it is thought that the inclusion of the flexible linker facilitates assembly of the heterotetramer and VLPs. In some embodiments, the linker comprises, or consists of, GGGG (SEQ ID NO: 364). In some embodiments, the linker comprises, or consists of, GGPG (SEQ ID NO: 365). In some embodiments, further amino acid substitutions are introduced to increase the flexibility of the linker region. In some embodiments, the further amino acid substitutions comprise an amino acid substitution at position 495 of the E protein and an amino acid substitution at position 90 of the M protein. In some embodiments, the further amino acid substitutions comprise a glycine (G) at position 495 of the E protein and a glycine (G) at position 90 of the M protein.

[0462] In some embodiments, amino acid substitutions were used to generate a cavity between the E protein and the M protein to facilitate entry of the linker. In some embodiments, the cavity is introduced by amino acid substitutions at positions 262 and 265 of the E protein and position 97 of the M protein. In some embodiments, the amino acid substitutions comprise an alanine (A) or a serine (S) at each of position 262 and position 265 of the E protein; and an alanine (A) at position 97 of the M protein. Attorney Docket No. 45817-0191WO1 / MTX1505.20 The tables below present a number of different engineered flavivirus fusion proteins. In some embodiments, the antigens for VLPs and the Pr protein sequence is followed by the M protein and then the E protein C'PrM / E"). In some embodiments, the protein comprises the M and E proteins (either M / E or E / M order). In some embodiments, the protein is a single chain (e.g., the mRNA encoding a single chain protein). In some embodiments, stabilizing mutations are included. In some embodiments, when the antigen is in the E / M order, the E protein is connected to the M protein via a linker (e.g., a GS linker), or a Rosetta-based linker.

[0463] In some embodiments, the flavivirus fusion protein further comprises a Capsid (C) protein and the NS2b / NS3 protease sequences from the corresponding virus (e.g., DENV or ZIKV) (denoted as “C-NS2B3” in the tables below). Capsid and NS2b / NS3 protease are involved in the maturation process of flaviviruses and their inclusion, it is thought, results in a higher yield of the VLPs. In some embodiments, the inclusion of a Capsid protein and NS2b / NS3 protease may result in the symmetric assembly of the E / M or M / E heterotetramers. In some embodiments, the Capsid protein is further mutated to reduce the basic charge (e.g., with an R85M mutation relative to NCBI Reference Sequence: NP 739591.2).

[0464] In some embodiments, the engineered flavivirus protein comprises amino acid mutations resulting in formation of a glycosylation site. In some embodiments, the glycosylation site is introduced in an engineered ZIKV E protein, for example, using a N67X68S69motif relative to SEQ ID NO: 282. It is thought that this mutation immune-focuses the response from the ZIKV VLPs to the E-dimer interface, eliciting broadly neutralizing antibodies.

[0465] Non-limiting examples of DENV and ZIKV and YFV proteins of the present disclosure are provided in Tables 1-4. The signal peptide (e.g., MLRLLLRHHFHCLLLCAVWATPCLA (SEQ ID NO: 271) or MKAILVVLLYTFTTANA (SEQ ID NO: 272)) in any one or more of the proteins of Tables 1-4 may be included, modified, omitted, or exchanged for a different signal peptide. Amino acid substitutions relative to the corresponding wild-type sequence are shown in bold below.

[0466] In some embodiments, a flavivirus is of a particular strain of flavivirus. In some embodiments, a YFV is an Asibi strain. In some embodiments, a YFV is a 17D Attorney Docket No. 45817-0191WO1 / MTX1505.20 strain. In some embodiments, a YFV is Brazilian strain (e.g., YFV2015-2018). In some embodiments, a YFV is a Venezuelan strain (e.g., Venezuela 2000). In some embodiments, a YFV is an African strain (e.g., West Africa I. West Africa II. East Africa, East / Central Africa, or Angola). In some embodiments, YFV is a South American strain (e.g.. South America I or South America II).

[0467] Non-limiting examples of wild-ty pe DENV, ZIKV and YFV sequences may be found atGenBank Accession Nos: QHJ14106.1 (DENV1), QWZ14573.1 (DENV1), QBK46950.1 (DENV2), WAX05073.1 (DENV2), UJT50354.1 (DENV3), WQE65107.1 (DENV3), UDW38823.1 (DENV4), AZS35368.1 (ZIKV), AAX47570. l / NP_041726.1 (YFV) and are listed below.

[0468] DENV1 M Proteins

[0469] AFHLTTRGGEPHMIVSKQERGKSLLFKTSAGVNMCTLIAMDLGELCEDTMTYKCPQI TETEPDDVDCWCNATDTWVTYGTCFQTGEHRRDKRSVALAPHVGLGLETRTETWMSS EGAWKQIQRVETWALRHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0470] (SEQ ID NO: 273 )

[0471] AFHLTTRGGEPHMIVSKQERGKSLLFKTSAGVNMCTLIAMDLGELCEDTMTYKCPRI TEAEPDDVDCWCNATDTWVTYGTCSQTGEHRRDKRSVALAPHVGLGLETRTETWMSS EGAWKQIQRVETWALRHPGFTVIALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0472] (SEQ ID NO: 400 )

[0473] DENV1 E Proteins

[0474] MRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLR KLCIEAKISNTTTDSRCPTQGEATLVEEQDANFVCRRTFVDRGWGNGCGLFGKGSLI TCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAPTT EIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHKQWFLDLPLPWTSGASTSQ ETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQTSGTTTI FAGHLKC RLKMDKLTLKGMS YVMCTGS FKLEKELAETQHGTVLVQIKYEGTDAPCKI PFSTQDE KGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIG

[0475]

[0476] Attorney Docket No. 45817-0191WO1 / MTX1505.20 KMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMK IGIGVLLTWLGLNSRSTSLSMTCIAVGLVTLYLGVMVQA (SEQ ID NO: 274 )

[0477] MRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLR KLCIEAKISNTTTDSRCPTQGEATLVEEQDANFVCRRTFVDRGWGNGCGLFGKGSLI TCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAPTT EIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHKQWFLDLPLPWTSGASTSQ ETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQTSGTTTI FAGHLKC RLKMDKLTLKGMS YVMCTGS FKLEKEVAETQHGTVLVQIKYEGTDAPCKI PFSTQDE KGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIG KMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMK IGIGVLLTWLGLNSRSTSLSMTCIAVGLVTLYLGVMVQA (SEQ ID NO: 401)

[0478] DENV2 M Proteins

[0479] AFHLTTRNGEPHMIVSRQEKGKSLLFKTEDGVNMCTLMAMDLGELCEDTITYKCPLL RQNEPEDIDCWCNSTSTWVTYGTCTTMGEHRREKRSVALVPHVGMGLETRTETWMSS EGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0480] (SEQ ID NO: 275 )

[0481] AFHLTTRNGEPHMIVSRQEKGKSLLFKTENGVNMCTLMAMDLGELCEDTITYNCPLL RQNEPEDIDCWCNSTSTWVTYGTCTATGEHRREKRSVALVPHVGMGLETRTETWMSS EGAWKHAQRIETWVLRHPGFTIMAALLAYTIGTTYFQRVLIFILLTAVAPSMT

[0482] (SEQ ID NO: 402 )

[0483] DENV2 E Proteins

[0484] MRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLR KYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIV TCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSS IT EAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG SNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKI PFEIMDL

[0485]

[0486] Attorney Docket No. 45817-0191WO1 / MTX1505.20 EKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIG QMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMK ILIGVI ITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA (SEQ ID NO: 276)

[0487] MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKHPATLR KYCIEAKLTNTTTASRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIV TCAMFTCKKNMEGKIVQPENLEYTIVITPHSGEENAVGNDTGKHGKEIKVTPQSS IT EAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG SNWIQKETLVTFKNPHAKKQDWVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKI PFEIMDL EKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLSWFKKGSSIG QMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMK ILIGWITWIGMNSRSTSLSVSLVLVGWTLYLGVMVQA ( SEQ ID NO: 403 )

[0488] DENV3 M Proteins AFHLTSRDGEPRMIVGKNERGKSLLFKTASGINMCTLI MDLGEMCDDTVTYKCPHI TEVEPEDIDCWCNLTSTWVTYGTCNQAGEHRRDKRSVALAPHVGMGLDTRTQTWMSA EGAWRQVEKVETWALRHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0489] (SEQ ID NO: 277 )

[0490] DENV 3 E Proteins

[0491] MRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR KLCIEGKITNITTDSRCPTQGEATLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLV TCAKFQCLEPIEGKWQYENLKYTVI ITVHTGDQHQVGNETQGVTAEITPQASTTEA ILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPT WNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRL KMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG KAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKM FEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIG IGVLLTWIGLNSKNTSMS FSCIAIGI ITLYLGAWQA (SEQ ID NO: 278 ) Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0492] MRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIELQKTEATQLATLR KLCIEGKITNITTDSRCPTQGEAVLPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLV TCAKFQCLEPIEGKWQYENLKYTVI ITVHTGDQHQVGNETQGITAEITPQASTTEA ILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPT WNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSGGTSIFAGHLKCRL KMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG KAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGTGDNALKINWYKKGSSIGKM FEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYTALFSGVSWVMKIG IGVLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQA (SEQ ID NO: 404 )

[0493] DENV4 M Protein AFHLSTRDGEPLMIVAKHERGRPLLFKTTEGINKCTLIAMDLGEMCEDTVTYKCPLL VNTEPEDIDCWCNLTSTWVMYGTCTQSGERRREKRSVALTPHSGMGLETRAETWMSS E GAWKH AQRVE S WI L RN P G FAL L AG FMAYM I G QT G I QRT VF FVLMMLVAP S Y G

[0494] (SEQ ID NO: 279)

[0495] DENV4 E Protein MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLR TYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDWDRGWGNGCGLFGKGGW TCAKFLCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSPSV EVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSE VHWNYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFAGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRIISSTPFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIG KMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIR ILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA (SEQ ID NO: 280)

[0496] ZIKV M Protein AAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIQIMDLGHMCDATMSYECPML DEGVEPDDVDCWCNTTSTWWYGTCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTWL ESREYTKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0497] (SEQ ID NO: 281 )

[0498]

[0499] Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0500] ZIKV E Protein IRCIGVSNRDFVEGMSGGTWVDWLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR S YC YEAS I S DMAS DS RC PTQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGL FGKGS LV TCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITP NSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAG ADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLS SGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVP AQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHH WHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSL FGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA ( SEQ ID

[0501] NO: 282 )

[0502] YFV E Protein'.

[0503] AHCIGITDRDFIEGVHGGTWVSATLEQGKCVTVMAPDKPSLDISLQTVAIDGPAEAR KVCYSAVLTHVKINDKCPSTGEAHLAEENDGDNACKRTYSDRGWGNGCGLFGKGS IV ACAKFTCAKSMSLFEVDRTKIQYVIRAQLHVGAKQENWNTDIKTLKFDALSGSQEAE FTGYGKATLECQVQTAVDFGNSYIAEMEKDSWIVDRQWAQDLTLPWQSGSGGTWREM HHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDENDNNLYKLHGGHVSCRV KLSALTLKGTS YKMCTDKMS FVKNPTDTGHGTWMQVKVPKGAPCKI PVIVADDLTA AVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSIGKL FTQTMKGAERLAVMGDAAWDFSSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVI MGAVLIWVGINTRNMTMSMSMILVGVIMMFLSLGVGA (SEQ ID NO: 283 )

[0504] YFV M Protein'.

[0505] AIDLPTHENHGLKTRQEKWMTGRMGERQLQKIERWFVRNPFFAVTALTIAYLVGSNM TQRWIALLVLAVGPAYS (SEQ ID NO: 284 )

[0506] Table 1. PrM / E based proteins

[0507] SEQ ID NO: > DENV2 -prM / E AS1 1 MLRLLLRHHFHCLLLCAWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E TRT E TWMS S E GAWRHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPTMTMRCIGMSNRDFVEGVSGG

[0508]

[0509] SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK Attorney Docket No. 45817-0191WO1 / MTX1505.20 RFVCRHSMVDRGWGNGCGQFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L F TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEISETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGATYGAAFSGVSWTMKILIGVITTWTGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0510] > DENV2-prM / E AS2 2 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL CEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMVVKKRSKRSIALIPHVGMGLE TRTETWMSSE GAWRHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGKFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0511] > DENV2-prM / E AS 3 3 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E TRT E TWMS S E GAWRHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGKFGRGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PHEKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0512] > DENV2-prM / E AS 4 4 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E TRT E TWMS S E GAWRHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGKFGRGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PHEKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0513] > DENV2-prM / E AS 5 5 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E TRT E TWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGKFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNRMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGRALHQ VFGEIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0514]

[0515] > DENV2-prM / E AS 6 6 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRS VAL I PHVGMGL E CRT E TWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTWTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0516] > DENV2-prM / E AS7 7 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E TRT E TWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNRMVLLQMENKAWLVYRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGRALHQ VFGEIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0517] > DENV2-prM / E AS 8 8 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSKRSI AL I PHVGMGL E CRT E TWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPTMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGRFGRGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PHEKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLFCGHLKCRL RMD KL QL KGMS YSMCTGKFKWKETAETQHGTTVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPTVTEKDSPVNIE AEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGRALHQ VFGDIYRTVFSGVSWTMKILIGVIITWIGMNSRSTSLSVTFVLVGIVTLYLGVMVQA

[0518] > DENV2-prM / E AS 9 9 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSRQEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMSVSKRRARSVAL I PHVGMGL E TRCE TWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0519] > DENV2-prM / E AS10 10 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSI AL I PHVGMGL E TRC ETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PHEKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS

[0520]

[0521] YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE Attorney Docket No. 45817-0191WO1 / MTX1505.20 AEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRVARRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0522] > DENV2-prM / E ASH 11 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSI AL I PHVGMGL E TR TETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PHEKKQD VI VL GS QE GAMHTAL T GAT E I QMS S GNL L FT GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRVARRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0523] > DENV2-prM / E AS 12 12 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL CEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGVSKRRARSIALQPHVGMGLE TRCETWMSSE GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0524] > DENV2-prM / E AS13 13 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSFAWQ PHVGMGL E TRC ETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0525] > DENV2-prM / E AS14 14 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSIAWQ PHVGMGL E TRCETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0526] > DENV2-prM / E AS15 15 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSIAFQ PHVGMGL E TRC ETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK

[0527]

[0528] RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH Attorney Docket No. 45817-0191WO1 / MTX1505.20 GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0529] > DENV2-prM / E AS 16 16 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMGVSKRRARSI AYQ PHVGMGL E TRC ETVJMS S E GAWKHVQRIETWTLRHPGFTMMAATLAYTIGTTHFQRALIFTLLTAVTPS'MTMRCTGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0530] > DENV2-prM / E AS 17 17 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL CEDTITYKCPLLRQNEPEDID CWCN S T S T WVT YGT C T TMSVSKRRARSFAWQ PHVGMGL E YR YETWMS S E GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRYGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT E I QMS S GNL L F YGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0531] > DENV2-prM / E AS18 18 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL CEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMWKKRSKRSIALQPHVGMGLE YRCETWMSSE GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRLGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRYGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLFCGHLKCRL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIIIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQV

[0532] > DENV2-prM / E AS 19 19 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL CEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMWKKRSKRSVALQPHVGMGLE TRTETVJMSSE GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRLGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VWL GS QE GAMHTAL T GAT EIQMSSGNLLF TGHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQHGTIIIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQV

[0533] > DENV2-prM / E AS20 20 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL

[0534]

[0535] CEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMWKKRSRRSVALIPNVGMGLE TRCETWMSSE Attorney Docket No. 45817-0191WO1 / MTX1505.20 GAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCKHSMVDRGWGNGCGRFGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VT VL GS QE GAMHTAL T GAT E I QMS S GNL L FC GHL KC RL RMD KL QL KGMS YSMCTGKFKWKEIAETQQGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGRALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0536] > DENV2-prM / E AS21 21 MLRLLLRHHFHCLLLCAVWATPCLAAFHLTTRNGEPHMIVSROEKGKSLLFKTEDGVNMCTLMAMDLGEL C E DT I T YKC P L L RQNE PE D I D CWCN S T S T WVT YGT C T TMWKKRSRRS VAL I PNVGMGL E TRC ETWMS S E GAWKIVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTIVTPSMTMRCIGMSNRDFVEGVSGG SWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDK RFVCRHSMVDRGWGNGCGRFGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEEHAVGNDTGKH GKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQG S NWI QKE T L VT F KN PH AKKQD VT VL GS QE GAMHTAL T GAT EIQMSSGNLLFCGHLKCRL RMD KL QL KGMS YSMCTGKFKWKEIAETQQGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE AEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQ VFGTIYRAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA

[0537] > ZIKV-prM / E AS1 22 MLRLLLRHHFHCLLLCAVWATPCLAAAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIOIMDLGHM CDATMS YECPMLDEGVEPDDVDCWCNTTSTWWYGTCHHKKGEARRSRRAFTIPSHSTRKLQTRSQTWLE SREHTKHL IRVENWIFRNPGFALAAAAIAWLLGSSTSQKVI YLVMILL IAPAYS IRCIGVSNRDFVEGMS GGTWDWLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRS YCYEAS ISDMASDSRC PTQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGRFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQHSGMIVNDT GHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWH AGADTGT PHWNNKEALVE FKDAHAKRQTWVLGSQEGAVHTALAGALEAEMDGAKGRL S S GHLKCRLKMD KLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVIT ESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHREGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGG ALNSLGKGIHQIFGAAFRSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMFLALGGVLIFLSTAVSA

[0538] > ZIKV-prM / E AS2 23 MLRLLLRHHFHCLLLCAVWATPCLAAAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIOIMDLGHM CDATMS YECPMLDEGVEPDDVDCWCNTTSTWWYGTCHHKKGEARRSRRSITLPSHSTRKLQTRCQTWLE SREHTKHL IRVENWIFRNPGFALAAAAIAWLLGSSTSQKVI YLVMILL IAPAYS IRCIGVSNRDFVEGMS GGTWVDWLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRS YCYEAS ISDMASDSRC PTQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGRFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQHSGMIVNDT GHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWH AGADTGTPHWNNKEALVEFKDAHAKRQTWVLGSQEGAVHTALAGALEAEMDGAKGRLSCGHLKCRLKMD KLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVIT ESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHREGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGG ALNSLGKGIHQIFGAAFRSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMFLALGGVLIFLSTAVSA

[0539] > ZIKV-prM / E AS3 24 MLRLLLRHHFHCLLLCAVWATPCLAAAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIOIMDLGHM CDATMS YECPMLDEGVEPDDVDCWCNTTSTWWYGTCHHKKGEARRSRRSITLPSHSTRKLQTRCQTWLE SREHTKHL IRVENWIFRNPGFALAAAAIAWLLGSSTSQKVI YLVMILL IAPAYS IRCIGVSNRDFVEGMS GGTWVDWLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRS YCYEAS ISNMTSDSRC PTQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGRFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQHSGMIVNDT GHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWH AGADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLSCGHLKCRLKMD KLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVIT ESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHREGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGG ALNSLGKGIHQIFGAAFRSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMFLALGGVLIFLSTAVSA

[0540]

[0541] Attorney Docket No. 45817-0191WO1 / MTX1505.20 > ZIKV-prM / E AS4 25 MLRLLLRHHFHCLLLCAVWATPCLAAAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIOIMDLGHM CDATMS YECPMLDEGVEPDDVDCWCNTTSTWWYGTCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTWLE SREHTKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMS GGTWDWLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGLFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQHSGMIVNDT GHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWH AGADTGT PHWNNKEALVE FKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRL S SGHLKCRLKMD KLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVIT ESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS'GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGG

[0542]

[0543] ALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA Table 2. M / E based VLP proteins

[0544] SE Q ID NO

[0545] > DENV2-M / E 101 26 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0546] > DENV2-M / E 102 27 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC

[0547] > DENV2-M / E 103 28 MLRLLLRHHFHCLLLCAVWAT PCLAgVALVPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCNHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0548]

[0549] > DENV2-M / E 104 29 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGLVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC

[0550] > DENV2-M / E 105 30 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQNGVIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFAAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0551] > DENV2-M / E 106 31 MLRLLLRHHFHCLLLCAVWAT PCLASALVPHCGMGLE TRTETWMSSEGAWKHVORIETWILR HPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCFGMSNRDFVEGVSGGSWVDIVL EHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQD KRFVCKHSMVDRGWGNGCGRNGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEH AVGNDTGKHGKE IKITPQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQ WFL D L P L PWL PGAD TQGSNWLQKETLVTFKN PH AKKQDVWL GS QE GAMHTAL TGAT E L QMS SGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAESQHGTIAIRVQYEGDGSPCKI PFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYGAAFSGVSWTMKILI GVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC

[0552] > DENV2-M / E 107 32 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCFGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRNGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAESQHGTIAIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFAAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0553] > DENV2-M / E 108 33 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCFGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRVGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAESQHGTIAIRVQYEGDGSPCK

[0554]

[0555] IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS Attorney Docket No. 45817-0191WO1 / MTX1505.20 SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0556] > DENV2-M / E 109 34 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCFGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRNGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAESQNGVIAIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT I VL VG I VT L YL GVMVQC

[0557] > DENV2-M / E 110 35 MLRLLLRHHFHCLLLCAVWAT PCLASVAFVPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0558] > DENV2-M / E 111 36 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENIEYT IVIT PHSGEE HAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECS PRTGLDWNEMVLLQMENKAWIVHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLIFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0559] > DENV2-M / E 112 37 MLRLLLRHHFHCLLLCAVWAT PCLASIAWVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0560] > DENV2-M / E 113 38 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE

[0561]

[0562] HAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNQMVLLQMENKAWLVYR Attorney Docket No. 45817-0191WO1 / MTX1505.20 QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFAAIYKAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0563] > DENV2-M / E 114 39 MLRLLLRHHFHCLLLCAVWAT PCLASVAFVPHVGMGLE TRCETWMS SEGQWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0564] > DENV2-M / E 115 40 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSGGG CCMTSCCSCLKGCCSCGSCCK GGPGGGS RSTSLSVTLVLVGIVTLYLGVMVQA

[0565] > DENV2-M / E 116 41 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHVGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSGGGCCMTSCCSCLKGCCSCGSCCK

[0566] > DENV2-M / E 117 42 MLRLLLRHHFHCLLLCAVWAT PCLASIALOPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHCVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0567]

[0568] > DENV2-M / E 118 43 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWAT PCLASIAFOPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSLVTCAMFRCKKNMEGKTVQPENLEYTLVLTPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0569] > DENV2-M / E 119 44 MLRLLLRHHFHCLLLCAVWAT PCLASIALQPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHWALTGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0570] > DENV2-M / E 120 45 MLRLLLRHHFHCLLLCAVWAT PCLASIALKPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWLQKETLVTFKNPHAKKQDVWLGSQEGAMHWALTGATELQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0571] > DENV2-M / E 121 46 MLRLLLRHHFHCLLLCAVWAT PCLASIALQPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHWALMGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0572] > DENV2-M / E 122 47 MLRLLLRHHFHCLLLCAVWAT PCLASIALQPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK

[0573]

[0574] IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS Attorney Docket No. 45817-0191WO1 / MTX1505.20 SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGTIYRAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0575] > DENV2-M / E 123 48 MLRLLLRHHFHCLLLCAVWAT PCLASIALOPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGAIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHWALVGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGTIYRAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0576] > DENV2-M / E 124 49 MLRLLLRHHFHCLLLCAVWAT PCLACGSI AL Q PHVGMGL E TRC E TWMS S E GAWKHVQR I E TW ILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTGCMRCIGMSNRDFVEGVSGGSW VDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSL NEEQDKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLE YT IVIT PH SGEEHAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAW LVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALVGAT EIQMSSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDG SPCKIPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWF KKGS SI GQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWT MKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0577] > DENV2-M / E 125 50 MLRLLLRHHFHCLLLCAVWAT PCLASIALQPCVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGCTEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWF KKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0578] > DENV2-M / E 126 51 MLRLLLRHHFHCLLLCAVWAT PCLASIALOPHCGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0579] > DENV2-M / E 127 52 MLRLLLRHHFHCLLLCAVWAT PCLASIALRPHVGMGLE TRCETWMS SEGAWKHVQRIEDWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE

[0580]

[0581] HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR Attorney Docket No. 45817-0191WO1 / MTX1505.20 QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYL GVMVQA

[0582] > DENV2-M / E 128 53 MLRLLLRHHFHCLLLCAVWAT PCLASVALKPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHWALVGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0583] > DENV2-M / E 129 54 MLRLLLRHHFHCLLLCAVWAT PCLASVGLKPHVGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGSIVTCAMFRCKKNMEGKTVQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHWALVGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGTIYRAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0584] > DENV2-M / E 130 55 MLRLLLRHHFHCLLLCAVWAT PCLASVAFVPHCGMGLE TRTETWMSSEGAWKHVORIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLF TGHLKCRLRMDKLQLKGMS YSMCTGKFKWKE I AETQHGTIVIRVQYEGDGS PCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYKAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC

[0585] > DENV2-M / E 131 56 MLRLLLRHHFHCLLLCAVWAT PCLASVAFVPHCGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE LTGYGTVTMECSPR TGL DFNEMVL L QME NKAWL VHR QWFLDL PL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHT AL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYKAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC

[0586] > DENV2-M / E 132 57 MLRLLLRHHFHCLLLCAVWAT PCLASVAFVPHVGMGLE TRCETWMS SEGQWKHVQRIETWIL

[0587]

[0588] RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV Attorney Docket No. 45817-0191WO1 / MTX1505.20 LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE L T G YGT VTME C S P R TGL DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT 1 YL GVMVQA

[0589] > DENV2-M / E 133 58 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE 7RCETWMS SEGQWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEE HAVGND T GKHGKE I KI T P QS S I T E AE L T G YGT VTME C S P R TGI DFNEMVL L QME NKAWL VHR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFAAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0590] > DENV2-M / E 134 59 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEE HAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNQMVLLQMENKAWLVYR QWFLDL PL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHT AL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0591] > DENV2-M / E 135 60 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGKFGKGGIVTCAMFRCKKNMEGKWNPENLEYT IVIT PHSGEE HAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNQMVLLQMENKAWLVYR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0592] > DENV2-M / E 136 61 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPHCGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGKFGKGGIVTCAMFRCKKNMEGKWNPENLEYT IVIT PHSGEE HAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECS PRTGLDFNQMVLLQMENKAWLVYR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFE IMDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RSTSLSVTLVLVGIVTLYL GVMVQC

[0593]

[0594] Attorney Docket No. 45817-0191WO1 / MTX1505.20 > DENV2-M / E 137 62 MLRLLLRHHFHCLLLCAVWAT PCLASVALVPH VGMGLE TRCETWMS SEGAWKHVQRIETWIL RHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIV LEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQ DKRFVCKHSMVDRGWGNGCGKFGKGGIVTCAMFRCKKNMEGKWNPENLEYTIVITPHSGEE HAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECS PRTGLDFNQMVLLQMENKAWLVYR QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQM SSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCK IPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKIL I GVI I T WI GMNS RS T S L S VT L VL VG I VT L YL GVMVQA

[0595] > ZIKV-M / E 1 63 MLRLLLRHHFHCLLLCAVWAT PCLAAVTLPDHSTRKLQTRCQTWLESREHTKHLIRVENWIF RNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDW LEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPKQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGNFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQH SGMIVNDTGHETDENRAKVEITPNS PRAEATLGGFGSLGLDCE PRTGLDFSDLYYLTMNNKH WL VHKEWFHD I PL PWHAGADT GT PHWNNKEALVE FKDAHAKRQTVWL GS QE GAVHTALAGA LEAEMDGAKGRLSCGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKI THHVJHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFAAAFKSLFG GMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

[0596] > ZIKV-M / E 2 64 MLRLLLRHHFHCLLLCAVWAT PCLAAVTLPSHSTRKLOTRCOTWLESREHTKHLIRVENWIF RNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDW LEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPKQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGNFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQH SGMIVNDTGHETDENRAKVEITPNS PRAEATLGGFGSLGLDCE PRTGLDFSDLYYLTMNNKH WL VHKEWFHD I PL PWHAGADT GT PHWNNKEALVE FKDAHAKRQTVWL GS QE GAVHTALAGA LEAEMDGAKGRLSCGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKI THHWHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFAAAFKSLFG GMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

[0597] > ZV-AS1 M / E 65 MLRLLLRHHFHCLLLCAVWAT PCLASIT L PSHS T RKL QT RC QT WL E S REHT KHL I RVE NWI F RNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDW LEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPKQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGDFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQH SGMIVNDTGHETDENRAKVEITPNS PRAEATLGGFGSLGLDCE PRTGLDFSDLYYLTMNNKH WL VHKEWFHD I PL PWHAGADT GT PHWNNKEALVE FKDAHAKRQTVWL GS QE GAVHTALAGA LEAEMDGAKGRLSCGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKI THHWHRS'GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFG GMSWFSQILIGTLLMWLGLNTKNGS ISLMCLALGGVL IFLSTAVS A

[0598] > ZV-AS2 M / E 66 MLRLLLRHHFHCLLLCAVWAT PCLASIT L PSHS T RKL QC R TQT WL E S REHT KHL I RVE NWI F RNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDW LEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPKQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGDFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQH SGMIVNDTGHETDENRAKVEITPNS PRAEATLGGFGSLGLDCE PRTGLDFSDLYYLTMNNKH WL VHKEWFHD I PL PWHAGADT GT PHWNNKEALVE FKDAHAKRQTVWL GS QE GAVHSALAGA LEAEMDGAKGRLSCGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG

[0599]

[0600] TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKI Attorney Docket No. 45817-0191WO1 / MTX1505.20 THHVJHRSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFG GMSWFSQILIGTLLMWLGLNTKNGS ISLMCLALGGVL IFLSTAVS A

[0601] > DV1 AS1 M / E 67 MLRLLLRHHFHCLLLCAVWATPCLASVAL APHCGL GL E T RT E T WMS S E GAWKQI QRVE TWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPKQGEATLVEEQ DANFVCRRTFVDRGWGNGCGNFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNQMVLLTMKEKSWLVYK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFAGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQC

[0602] > DV1 AS2 M / E 68 MLRLLLRHHFHCLLLCAVWATPCLASVALAPH VGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPKQGEATLVEEQ DANFVCRRTFVDRGWGNGCGNFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNQMVLLTMKEKSWLVYK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQ A

[0603] > DV1 AS 3 M / E 69 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPH VGLGLECRTETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPKQGEATLVEEQ DANFVCRRTFVDRGWGNGCGNFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNQMVLLTMKEKSWLVYK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQ A

[0604] > DV1 AS 4 M / E 70 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPHCGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFDAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPKQGEATLVEEQ DANFVCRRTFVDRGWGNGCGNFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNQMVLLTMKEKSWLVYK QWFL DL PL PWT S GAS T S QETWNRQDLL VT FKTAHAKKQE VWL GS QEGAMHT AL TGAT E I QT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQC

[0605] > DV1 AS 5 M / E 71 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPHCGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ

[0606]

[0607] HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK Attorney Docket No. 45817-0191WO1 / MTX1505.20 QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFATAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQC

[0608] > DV1 AS 6 M / E 72 MLRLLLRHHFHCLLLCAVWATPCLASVAFAPHCGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFJVEMVLLTMKEKSWLVHK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFATAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVKC

[0609] > DV1 AS7 M / E 73 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK QWFL DL PL PWT S GAS T S QETWNRQDLL VT FKTAHAKKQE VWL GS QEGAMHT AL TGAT E I QT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYRVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVKC

[0610] > DV1 AS 8 M / E 74 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGLGLE TRCETWMS SEGAWKQIQRVETWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVYK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYRVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVKC

[0611] > DV1 AS 9 M / E 75 MKAILWLLYTFTTANASVAFAPHCGLGLETRCETWMSSEGAWKOIORVETWALRHPGFTVM ALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVT TMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRR TFVDRGWGNGCGRFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNEST EHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVfiKQWFLDLPL PWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQTSGTTTIFC GHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDE KGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEA TARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFATAYKVLFSGVSWTMKIGIGVLLTWL GLNS RS T S L SMT C IAVGL VTL YL GVMVQC

[0612] > DV1 AS 10 M / E 76 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGL GL ECR TETWMS SE GAWKQI QRVE TWAL

[0613]

[0614] RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW Attorney Docket No. 45817-0191WO1 / MTX1505.20 LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGATEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFATAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQC

[0615] > DV1 AS 11 M / E 77 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGL GL ECR TETWMS SE GAWKQI QRVE TWAL RHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDW LEHGSCVTTMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQ DANFVCRRTFVDRGWGNGCGRFGKGSL ITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQ HQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHTALTGAVEIQT SGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCK IPFSTQDEKGVTQNGRLITANPLVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGS SIGKMFEATARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFATAYKVLFSGVSWTMKIG I GVL LTWLGLNSRSTSLSMTC IAVGL VT L YL GVMVQC

[0616] > DV3 AS1 M / E 78 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPHCGMGL D TR TQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPKQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGNFGKGSLVTCAKFQCLEPIEGKWNYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNQMILLTMKNKAWMVYRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEWVLGSQEGAMHTALTGATEIQNSG GTSIFAGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0617] > DV3 AS2 M / E 79 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPH VGMGL D TRC QT WMS AE GAWRQVE KVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPKQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGNFGKGSLVTCAKFQCLE PIEGKWNYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFDQMILLTMKNKAWMVYRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQA

[0618] > DV3 AS 3 M / E 80 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPH VGMGL DC R TQT WMS AE GAWRQVE KVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPKQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGNFGKGSLVTCAKFQCLE PIEGKWNYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFDQMILLTMKNKAWMVYRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQA

[0619]

[0620] Attorney Docket No. 45817-0191WO1 / MTX1505.20 > DV3 AS 4 M / E 81 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPHCGMGLD TRCOTWMSAE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPKQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGNFGKGSLVTCAKFQCLEPIEGKWNYHNLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFDQMILLTMKNKAWMVYRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEWVLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0621] > DV3 AS 5 M / E 82 MLRLLLRHHFHCLLLCAVWAT PC LASVAFAPHCGMGL D TRCQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPRQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGQFGKGSLVTCAKFQCLEPIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFWEMILLTMKNKAWMVHRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEWVLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0622] > DV3 AS 6 M / E 83 MLRLLLRHHFHCLLLCAVWAT PCLAgVAFAPHCGMGL D TRCQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPRQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGQFGKGSLVTCAKFQCLE PIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFAffiMILLTMKNKAWMVYRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYRALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0623] > DV3 AS7 M / E 84 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGMGL D TRCQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNTTTDSRCPQQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGRFGKGSLVTCAKFQCLE PIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFWEMILLTMKNKAWMVHRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0624] > DV3 AS 8 M / E 85 MLRLLLRHHFHCLLLCAVWAT PCLASVALAPHCGMGL D TRCQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGRFGKGSLVTCAKFQCLE PIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFWFMILLTMKNKAWMVHRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP

[0625]

[0626] FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI Attorney Docket No. 45817-0191WO1 / MTX1505.20 GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0627] > DV3 AS 9 M / E 86 MKAILWLLYTFTTANASVAFAPHCGMGLDTRCOTWMSAEGAWROVEKVETWALRHPGFTIL ALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDWLEHGGCVT TMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQDQNYVCKH TYVDRGWGNGCGRFGKGSLVTCAKFQCLEPIEGKWQYENLKYTVIITVHTGDQHQVGNETQ GVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPW TSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSGGTSIFCGH LKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG KAHNGRL I TAN P WT KKE E PVN I E AE PPFGESNIVIGI GDNAL K INWYKKGS S I GKMF EATA RGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIGVLLTWIGL NSKNTSMSFSCIAIGIITLYLGAWQC

[0628] > DV3 AS 10 M / E 87 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGMGLDCR TQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGRFGKGSLVTCAKFQCLE PIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGATEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0629] > DV3 AS 11 M / E 88 MLRLLLRHHFHCLLLCAVWAT PCLASVAFAPHCGMGLDCR TQTWMS AE GAWRQVEKVE TWAL RHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDW LEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQ DQNYVCKHTYVDRGWGNGCGRFGKGSLVTCAKFQCLE PIEGKWQYENLKYTVI ITVHTGDQ HQVGNETQGVTAEITPQASTTEAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQW FFDLPLPWTSGATTETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHTALTGAVEIQNSG GTSIFCGHLKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIP FSTEDGQGKAHNGRLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSI GKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFASAYKALFSGVSWVMKIGIG VLLTWIGLNSKNTSMSFSCIAIGIITLYLGAWQC

[0630] > DV4 AS1 E / M 89 MLRLLLRHHFHCLLLCAVWAT PCLASVAL T PHSGMGL E TRC E T WMS S E GAWKHAQRVE S WIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPYQGEPYLKEEQ DQQYICRRDWDRGWGNGCGEFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFRQMILMKMKKKTWLVYK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA

[0631] > DV4 AS 2 E / M 90 MLRLLLRHHFHCLLLCAVWAT PCLASVAL T PHSGMGL ECRAETWMS SE GAWKHAQRVE SWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPYQGEPYLKEEQ DQQYICRRDWDRGWGNGCGEFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT

[0632]

[0633] HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFRQMILMKMKKKTWLVYK Attorney Docket No. 45817-0191WO1 / MTX1505.20 QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQA

[0634] > DV4 AS 3 E / M 91 MLRLLLRHHFHCLLLCAVWAT PCLASVALT PHCGMGL E TRAETWMS SE GAWKHAQRVE SWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNTTTATRCPYQGEPYLKEEQ DQQYICRRDWDRGWGNGCGEFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFRQMILMKMKKKTWLVYK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFAGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0635] > DV4 AS 4 E / M 92 MLRLLLRHHFHCLLLCAVWAT PCLASVAL T PHCGMGL E TRCETWMS SE GAWKHAQRVE SWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPYQGEPYLKEEQ DQQYICRRDWDRGWGNGCGEFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFRQMILMKMKKKTWLVYK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0636] > DV4 AS 5 E / M 93 MLRLLLRHHFHCLLLCAVWAT PC LASVAFT PHCGMGL E TRCETWMS SE GAWKHAQRVE SWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQ DQQYICRRDWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTWVTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFVEMILMKMKKKTWLVHK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0637] > DV4 AS 8 E / M 94 MLRLLLRHHFHCLLLCAVWAT PC LASVAFT PHCGMGL E TRCETWMS SE GAWKHAQRVE SWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQ DQQYICRRDWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTWVTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFVHMILMKMKKKTWLVHK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFASVYKTMFGGVSWMIRIL IGFLVLWIGTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0638] > DV4 AS 6 E / M 95 MLRLLLRHHFHCLLLCAVWAT PC LASVALT PHCGMGL E TRCETWMS SE GAWKHAQRVE SWIL

[0639]

[0640] RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV Attorney Docket No. 45817-0191WO1 / MTX1505.20 LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQ DQQYICRRDWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIETRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFASVYKTMFGGVSWMIRIL IGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0641] > DV4 AS 7 E / M 96 MKAILWLLYTFTTANASVAFTPHCGMGLETRCETWMSSEGAWKHAORVESWILRNPGFALL AGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVT TMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRR DWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTS NHGVTATITPRS PSVEVKLPDYGELTLDCEPRSGIDFWEMILMKMKKKTWLVHKQWFLDL PL PWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFC GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFES TYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFASVYKTMFGGVSWMIRIL IGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0642] > DV4 AS 9 E / M 97 MLRLLLRHHFHCLLLCAVWATPCLASVAFTPHCGMGLECRTETWMSSEGAWKHAORVESWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQ DQQYICRRDWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTWVTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDF1VEMILMKMKKKTWLVHK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFASVYKTMFGGVSWMIRIL IGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0643] > DV4 AS 10 E / M 98 MLRLLLRHHFHCLLLCAVWATPCLASVAFTPHCGMGLECRTETWMSSEGAWKHAORVESWIL RNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLV LEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQ DQQYICRRDWDRGWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDT HAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHK QWFLDLPLPWTTGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGAVEVDS GDGNHMFCGHLKCKVRMEKLRIKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCK VPIEIRDVNKEKWGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGS SIGKMFESTYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFASVYKTMFGGVSWMIRIL IGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0644] > DENV2-007 15

[0645] 6 MKAILWLLYTFTTANASVALVPCVGMGLETRTETWMSSEGAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGCTEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHCVFGAIYGAAFSGVSWTMKILIGVIITWI

[0646]

[0647] GMNS RS T S L S VT LVLVGI VTL YL GVMVQA Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0648] > DENV2-008 15

[0649] 7 MKAILWLLYTFTTANASVCLVPWGMGLETRTETWMSSEGAWKHVQRIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHCAL TGATEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVTRVQYEGDGSPCKIPFETMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIP IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQA

[0650] > DENV2-009 15

[0651] 8 MKAILWLLYTFTTANASVALVPWGMGLETRTETWMSSECAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALCGATEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVTRVQYEGDGSPCKIPFETMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQA

[0652] > DENV2-010 15

[0653] 9 MKAILWLLYTFTTANASVALVPHVGMGLE TRTETWMS S E GAWKHVQRIETWILRC PGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSCVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQA

[0654] > DENV2-011 16

[0655] 0 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLE YT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS I T EAE L T G YGT VTME C S P R TGL DFNRMVL LQMENKAWLVD RQWF L D L P L PWL PGAD T QGS NW IQKE TL VTFKNPHAKKQDVWLGS QEGAMHSALAGAVE I QMS S GNL LF TGHL KC RL RMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLSWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVF TSIGKALHQVFGAIYGSAFSGVSWTMKLL IG VIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPGKVALN PHAGMGI ET ST Q TWAGEQGRWDHAQRI EKWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPSMT

[0656] > DENV2-012 16

[0657] 1 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL

[0658]

[0659] IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR Attorney Docket No. 45817-0191WO1 / MTX1505.20 FGKGGIVTCAMFTCKKNMEGKWQPENLEYTIVITPHSGEENAVGNDTGKHGKEIKVTPQSS I T EAE L T G YGT VTME C S P R TGL DFNRMVL LQMENKAWLVD RQWF L D L P L PWL PGAD T QGS NW IQKE TL VTFKNPHAKKQDVWLGS QEGAMHSALAGAVE I QMS S GNL LFCGHL KC RL RMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGD TAWDFGSLGGVF TSIGKALHQVFGAIYGSAFSGVSWTMKLL IG VIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPGKVALN PHAGMGI EC ST Q TWAGEQGRWDHAgRI EKWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPSMT

[0660] > DENV2-013 16

[0661] 2 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLEYTIVITPHSGEENAVGNDTGKHGKEIKVTPQSS I T EAE L T G YGT VTME C S P R TGL DFNRMVL LQMENKAWLVD RQWF L D L P L PWL PGAD T QGS NW IQKE TL VTFKNPHAKKQDVWLGS QEGAMHSALAGAVE I QMS S GNL LFCGHL KC RL RMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGD TAWDFGSLGGVF TSIGKALHgVFGAIYGSAFSGVSWTMKLL IG VIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPGKVAIN PHAGMGI IC ST QVWAGEQGRWDHAgRI EKWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPSMT

[0662] > DV2 - 014_C-NS 2b3-M / E 16

[0663] 3 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMGGGSGGGTGRSADLELERAA DVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWDVPSPPPMGKAEL EDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYG GGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDK KGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPE IEDDIFRKILNRRRRSAGMIIMLIPTV MASVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWILRHPGFTMMAAILAYT IGTTHFQR ALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIK TEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFG KGGIVTCAMFRCKKNMEGKWQPENLE YT IVITPHSGEEHAVGNDTGKHGKE IKIT PQSS IT EAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSNWIQ KETLVTFKNPHAKKQDWVLGSQEGAMHTAL TGATEIQMSSGNLLF TGHLKCRLRMDKLQLK GMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPI VTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGDTA WDFGSLGGVFTS IGKALHgVFGAIYGAAFSGVSWTMKIL IGVI ITWIGMNSRSTSLSVTLVL VGIVTLYLGVMVQC

[0664] > DV2 - 015_C-NS 2b3-HA-M / E 16

[0665] 4 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMGGGSGGGTGRSADLELERAA DVKWEDQAEISGSS PILS ITISEDGSMS IKNEEEEQTLEVKKQRAGVLWDVPSPPPMGKAEL EDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYG GGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDK KGKWGLYGNGWT RS GA YVSAIAOTEKS IEDNPE IEDDIFRKILNRRRRSAGMKAILWLL YTFTTANASVALVPHCGMGLE 7RTETWMS SEGAWRHVQRIETWILRHPGFTMMAAILAYT IG TTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTL DFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGN GCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYT IVITPHSGEEHAVGNDTGKHGKE IKIT PQSS TTEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWL PGADTQ GSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQMS SGNLLF TGHLKCRLRM DKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRL

[0666]

[0667] ITVNPIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMA Attorney Docket No. 45817-0191WO1 / MTX1505.20 ILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSL SVTLVLVGIVTL YLGVMVQC

[0668] > DV2-017_NS2b3-C-M / E 16

[0669] 5 MTGRSADLELER7XADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVL WDVPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIE PSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSL DFS PGTSGS PTIDKKGKWGL YGNGWTRSGAYVSAIAQTEKS TEDNPEIEDDIFRKGGGSG GGNILNRRRRSAQ1MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFM ALVAFLRFLTIPPTAGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRGACT1IIMLIP TVMASVAL VPHC GMGL E TRT E TWMS S E GAWKHVQR IETWILRHPGF TMMAAI LAYT I GT T HF QRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCRHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWQPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKTPFEIMDLEKRHVLGRLTTVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTL YLGVMVQC

[0670] > DV2 - 018_C-NS 2b3-M / E 16

[0671] 6 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMGGGSGGGTGRSADLELERAA DVKWEDQAEISGSS PILE ITISEDGSMS IKNEEEEQTLEVKKQRAGVLWDVPSPPPMGKAEL EDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYG GGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFS PGTSGS PIIDK KGKWGLYGNGWTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKILNRRRRSAGMIIMLIPTV MRSVALVPHCGMGLE TRTETWMS SEGAWKHVQRIETWILRHPGFTMMAAILAYT IGTTHFQR ALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIK TEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCAHSMVDRGWGNGCGRFG KGGIVTCAMFRCKKNMEGKWQPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS IT EAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSNWIQ KETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQMSSGNLLF TGHLKCRLRMDKLQLK GMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPI VTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS SIGQMFETTMRGAKRMAILGDTA WDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVL VGIVTL YLGVMVQC

[0672] > YF_Br_M / E_AS 1 16

[0673] 7 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PT HENH GL KCR QE KWMT GRMGE RQL QK I E RWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLKTAL TGAMRVTKDTNNSK LYKLHCGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGTNTRNMTMSMSMILVGVTMMFLSLGVGA

[0674] > YF_Br_M / E_AS 2 16

[0675]

[0676] 8 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWATPCLAAIDLPTHENHGLKTRCEKWMTGRMGERQLQKIERWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLK7AL TGAMRVTKDTNNSK LYKLHCGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGINTRNMTMSMSMILVGVIMMFLSLGVGA

[0677] > YF_Br_M / E_AS 3 16

[0678] 9 MLRLLLRHHFHCLLLCAVWATPCLAAIDLPTHCNHGLKTROEKWMTGRMGERQLQKIERWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLK7AL TGAMRVTKDTNNSK LYKLHGGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGINTRNMTMSMSMILVGVIMMFLSLGVGC

[0679] > Rl_YF_Br_M / E 23

[0680] 8 MLRLLLRHHFHCLLLCAVWATPCLAAI DL PT HENH GL K TRCE KWMT GRMGE RQL QK I E RWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QEWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLK7AL TGAMRVTKDTNNSK LYKL73CGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGINTGGDEDDSEPGGALPGNPDHREMGEALPEELGEYRKPSGGSVPVSPGPPSGLE PTRS SS YGGGSATS PSNFNEMEKQLKDALEKNTQWLL YNEQREVYVRGLHARIFELEQQLET VNT

[0681] > R2_YF_Br_M / E 23

[0682] 9 MLRLLLRHHFHCLLLCAVWATPCLAAI OL PT HENH GL K TRCE KWMT GRMGE RQL QK I E RWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLK7AL TGAMRVTKDTNNSK LYKLHCGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGINTGGDEDDSEPGGAL PGNPDHREMGETLPEEVGEYRQPSGGSVPVS PGPPSGLE PTSSSPYGGGSFNSSINNIHEMEIQLKDALEKNQQWLVYDQQREVYVKGLLAKIFELEKKTE TAA

[0683] > R3_YF_Br_M / E 24

[0684]

[0685] 0 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PTHENHGLKTROEKWMTGRMGERQLQKIERWLV RNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKCPRTGEAHLEEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIKVLALGNQEGSLK7AL TGAMRVTKDTNNSK LYKLHGGHVACRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPV MVADDLTAAVNKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMG WLIWVGINTGGDEDDSEPGGALPGNPDHREMGETLPEEVGEYRQPSGGSVPVSPGPPSGLE PTSSSPYGGGSFNSSINNIHEMEIQLKDALEKNQQWLVYDQQREVYVKGLLAKIFELEKKTE TAA

[0686] > YF_As b_M / E_AS 4 24

[0687] 1 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PTHENHGLKTRCEKWMTGRMGERQLQKIERWLV RNPFFAVTALTIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKCPRTGEAHLAEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVTRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNN LYKLHCGHVSCRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPV IVADDLTAAINKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFS SAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMG AVLIWVGINTRNMTMSMSMILVGVIMMFLSLGVGA

[0688] > YF_As b_M / E_AS 5 24

[0689] 2 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PTHENHGLKCRQEKWMTGRMGERQLQKIERWLV RNPFFAVTALTIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKCPRTGEAHLAEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QEWNTDIKTLKFDALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNN LYKLffCGHVSCRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPV IVADDLTAAINKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFS SAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMG AVLIWVGINTRNMTMSMSMTLVGVIMMFLSLGVGA

[0690] > YF_As b_M / E_AS 6 24

[0691] 3 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PT HCNH GL K TR QE KWMT GRMGE RQL QK I E RWLV RNPFFAVTALTIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKCPRTGEAHLAEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNN LYKLHGGHVSCRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPV IVADDLTAAINKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFS SAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMG AVLIWVGINTRNMTMSMSMILVGVIMMFLSLGVGC

[0692] > R4_YF_Asb_M / E 24

[0693] 4 MLRLLLRHHFHCLLLCAVWAT PCLAAIDL PT HENH GL K TRCE KWMT GRMGE RQL QK I E RWLV RNPFFAVTALTIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT

[0694]

[0695] LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKCPRTGEAHLAEEN Attorney Docket No. 45817-0191WO1 / MTX1505.20 EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNN LYKLHCGHVSCRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPV IVADDLTAAINKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFS SAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMG AVLIWVGINTGGDEDDSE PGGAL PGNPDHREMGETLPEEVGEYRQPSGGSVPVS PGPPSGLE PTS S S P YGGGSFNS SINNIHEMEIQLKDALEKNQQWLVYDQQREVYVKGLLAKIFELEKKTE TAA

[0696] > R5_YF_Asb_M / E 24

[0697] 5 MLRLLLRHHFHCLLLCAVWATPCLAAIDLPTHENHGLKTRCEKWMTGRMGERQLQKIERWLV RNPFFAVTALTIAYLVGSNMTQRWIALLVLAVGPAYSAHCIGITDRDFIEGVHGGTWVSAT LEQDKCVTVMAPDKPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKCPRTGEAHLAEEN EGDNACKRTYSDRGWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAK QENWNTDIKTLKFDALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWA QDLTLPWQSGSGGVWREMHHLVEFEPPHAATIRVLALGNQEGSLKTALTGAMRVTKDTNDNN LYKLHCGHVSCRVKLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPV IVADDLTAAINKGILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSI GKLFTQTMKGAERLAVMGDAAWDFS SAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMG AVLIWVGINTGGDEDDSE PGGAL PGNPDHREMGEALPEELGEYRKPSGGSVPVS PGPPSGLE PTRSSSYGGGSATSPSNFNEMEKQLKDALEKNTQWLLYNEQREVYVRGLHARIFELEQQLET VNT

[0698] > DV1_OO 9_M / E 24

[0699] 6 MKAILWLLYTFTTANA. S'VAFAPHCGLGIEGRCETWMSSEGAWKOIORVETWALRHPGFTVM ALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVT TMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPQQGEATLVEEQDANFVCRR TFVDRGWGNGCGRFGKGSLITCAKFKCVTKLEGKIVAYSNLKYSVIVTVHTGDQHQVGNEST EHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPL PWT S GAS T S QETWNRQDL LVT FKTAHAKKQE VWL GS QE GAMH TAL TGAAE I QT S GTT T I FC GHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDE KGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEA TARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWL GLNS RS T S L SMT C IAVGL VTL YL GVMVQC

[0700] > DVl_010_M / E 24

[0701] 7 MKAILWLLYTFTTANA. S' VAFAPC VGL GI EGRCETWMS S EGAWKQI QRVETWAL RH PGFT VM ALFLAHAIGTSITQKGIIFILLMLVTPSMAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVT TMAKDKPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRCPQQGEATLVEEQDANFVCRR TFVDRGWGNGCGRFGKGSLITCAKFKCVTKLEGKIVAYSNLKYSVIVTVHTGDQHQVGNEST EHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPL PWT S GAS T S QETWNRQDL LVT FKTAHAKKQE VWL GS QE GAMH TAL TGCAE I QT S GTT T I FC GHLKCRLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDE KGVTQNGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEA TARGARRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWL GLNS RS T S L SMT C IAVGL VTL YL GVMVQA

[0702] > DV2-038_M / E 24

[0703] 8 MKAILWLLYTFTTANASWXFVPHCGMGIEGRCETWMSSEGAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPQQGEPSLNEEQDKRFVCKH

[0704]

[0705] SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTG Attorney Docket No. 45817-0191WO1 / MTX1505.20 KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGAAEIQMSSGNLLFC GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQC

[0706] > DV2-039_M / E 24

[0707] 9 MKAILWLLYTFTTANASVAFVPC VGMGIEGRCETWMSSEGAWKHVQRIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPQQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGCAEIQMSSGNLLFC GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWF SAGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQA

[0708] > DV2-040_M / E 25

[0709] 0 MKAILWLLYTFTTANA. S'VAFVPCCGMGIEGRCETWMSSEGAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPQQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGCAEIQMSSGNLLFC GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQC

[0710] > DENV3_007_M / E 25

[0711] 1 MKAILWLLYTFTTANAS VAFAPHCGMGL DCR TQTWMS AEGAWRQVEKVETWAL RH PGFT IL ALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDWLEHGGCVT TMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQDQNYVCKH TYVDRGWGNGCGRFGKGSLVTCAKFQCLEPIEGKWLYENLKYTVIITVHTGDQHQVGNETQ GVTAE I T P QAS T TE Al L P E YGT L GL E C S P RT GL D F 7VEMI L L TMKNKAWMVHRQWF F DL PL PW T S GAT TETPTWNRKEL L VT FKNAHAKKQE VWL GS QE GAMH TAL TG AAE I QN S GGT S I FC GH LKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG KAHNGRL I TAN P WT KKE E PVN I E AE PPFGESNIVIGI GDNAL K INWYKKGS S I GKMF EATA RGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGL NSKNTSMSFSCIAIGIITLYLGAWQC

[0712] > DENV3_008_M / E 25

[0713] 2 MKAILWLLYTFTTANAS VAFAPC VGMGL DCR TQTWMS AEGAWRQVEKVETWAL RH PGFT IL ALFLAHYIGTSLTQKWIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDWLEHGGCVT TMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQDQNYVCKH TYVDRGWGNGCGRFGKGSLVTCAKFQCLEPIEGKWLYENLKYTVIITVHTGDQHQVGNETQ GVTAE I T P QAS T TE Al L P E YGT L GL E C S P RT GL D F 7VEMI L L TMKNKAWMVHRQWF F DL PL PW T S GAT TETPTWNRKEL LVT FKNAHAKKQE VWL GS QE GAMH TAL TGCAE I QN S GGT S I FC GH LKCRLKMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQG

[0714]

[0715] KAHNGRL I TAN P WT KKE E PVN I E AE PPFGESNIVIGI GDNAL K INWYKKGS S I GKMF EATA Attorney Docket No. 45817-0191WO1 / MTX1505.20 RGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGL NSKNTSMSFSCIAIGIITLYLGAWQA

[0716] > DV4- Ind_006_M / E 25

[0717] 3 MKAILWLLYTFTTANASVAFT PHCGMGI EGRCETWMS S EGAWKHAQRVE SWIL RN PGFALL AGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVT TMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITTATRCPQQGEPYLKEEQDQQYICRR DWDRGWGNGCGRFGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTS NHGVTATITPRS PSVEVKLPDYGELTLDCEPRSGIDFWEMILMKMKKKTWLVDKQWFLDL PL PWTAGADTSEVHWNYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAG^AEVDSGDGNHMFC GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRIISSTPFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFES TYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0718] > DV4-Ind_007_M / E 25

[0719] 4 MKAILWLLYTFTTANAS VAL T PCSGMGI EGRCETWMS S EGAWKHAQRVE SWIL RN PGFALL AGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVT TMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITTATRCPQQGEPYLKEEQDQQYICRR DWDRGWGNGCGRFGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTS NHGVTATITPRS PSVEVKLPDYGELTLDCEPRSGIDFWEMILMKMKKKTWLVDKQWFLDL PL PWTAGADTSEVHWNYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFC GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRIISSTPFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFES TYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQA

[0720] > DV4-Ind_008_M / E 25

[0721] 5 MKAILWLLYTFTTANAS VAL T PCCGMGI EGRCETWMS S EGAWKHAQRVE SWIL RN PGFALL AGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVT TMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITTATRCPQQGEPYLKEEQDQQYICRR DWDRGWGNGCGRFGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTS NHGVTATITPRS PSVEVKLPDYGELTLDCEPRSGIDFWEMILMKMKKKTWLVDKQWFLDL PL PWTAGADTSEVHWNYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFC GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRIISSTPFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFES TYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWI GTNSRNTSMAMTCIAVGGITLFLGFTVQC AS_V3_DV2_055-M / E 30

[0722] 4 MKAILWLLYTFTTANAS VAIVPCCGMGIETRTETWMSSEGAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYTIVITPHSGEEHAVGNDTG KHGKE I KI T P QS S I T E AE L T G YGT VTME C S P R TGL SFD EMVL L QME NKAWL VNRQWFL DL PL PWLPGADTQGSNWTQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGCTEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQC AS_V3_DV2_° 58 -M / E 30

[0723] 7 MKAILWLLYTFTTANAS VAIVPCCGMGIE YR TETWMSSEGAWKHVORIETWILRHPGFTMM

[0724]

[0725] AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT Attorney Docket No. 45817-0191WO1 / MTX1505.20 TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPYQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWEPANLEYTIVITPHSGEEHAVGNDTG KHGKE I KI T P QS S I T E AE L T G YGT VTME C S P R TGL DFE EMVL 1 QME NKAWL VNKQWFL DL PL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDWVLGSQEGAMHTAL TGCTEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGS S IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQC AS_ V3_ DV2_ 063-M / E 31

[0726] 2 MKAILWLLYTFTTANASVAWNPCIGMGILARCETWMSSEGAWKHVORIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYTIVITPHSGEEHAVGNDTG KHGKE I KI T P QS S I T E AE L T G YGT VTME C S P R TGI DFD HMVL L QME NKAWL VNRQWFL DL PL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDWVLGSQEGAMHSALAGCIEIQMSSGNLLFC GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL EKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLNWFKKGSS IGQMFET TMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQA AS_DV2 - 065_C-NS2b3 -HA-ME 31

[0727] 3 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFMKEIGRMLNILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGMKAILWLLYTFTTANAS VAWVPCCGMGI E TR TE T WMS S E G AWKHVQRI E T WI L RH P GF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGS CVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFV CKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYTIVITPHSGEEHAVGN DTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLD LPLPWL PGADTQGSNWIQKETLVTFKNPHAKKQDWVLGSQEGAMH TAL TGC IE IQMSSGNL IF TGHLKCRLRMDKLQLKGMS YSMCTGKFKWKEI AETQHGTIVIRVQYEGDGS PCKI PFEI MDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSSIGQM FETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVII TWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC AS_DV2 - 066_C-NS2b3 -HA-ME 31

[0728] 4 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTTPPT AGILKRWGTIKKSKAINVLRGFQKEIGRMLNILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGMKAILWLLYTFTTANA5 VAWVPCCGMGIE TRTETWMS SEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGS CVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFV CKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYTIVITPHSGEEHAVGN DTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLD LPLPWL PGADTQGSNWIQKETLVTFKNPHAKKQDWVLGSQEGAMH TAL TGC TE IQMSSGNL IF TGHLKCRLRMDKLQLKGMS YSMCTGKFKWKEI AETQHGTIVIRVQYEGDGS PCKI PFEI MDLEKRHVLGRLITVNPIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSSIGQM FETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVII

[0729]

[0730] TWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC Attorney Docket No. 45817-0191WO1 / MTX1505.20 AS_DV2 -067_C-NS2b3 -HA-ME 31

[0731] 5 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFQKEIGRMLNILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGGGSGGGSGGGSGGAGMKAILWLLYTFTTANASVAWVPCCGMGIE YR YE TWMS S E G AWK HVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEG VSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPE QGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTCTXMFRCKKNMEGKWAPENLEYT IVITPHSGEEHAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRYGLDFDEMVLLQ MENKAWLVNRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHY AL YGCYEIQMSSGNLLF YGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQVGYIVIRV QYEGDGS PCKIPFE IMDLEKRHVLGRL ITVNPIVTEKDS PVNIEAE PPFGDS YI IIGVEPGQ LKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS I GKALHQVF GA I YGAAF SGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC AS_DV2 -068_C-NS2b3 -HA-ME 31

[0732] 6 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFQKEIGRMLNILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGGGSGGGSGGGSGGAGMKAILWLLYTFTTANASVAWVPCCGMGIE YR YE TWMS S E G AWK HVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEG VSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPE QGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYT I VI T PH S GE E HAVGNDT GKHGKE I K I T PQ S S I T EAE L T G YGT VTME C S PR TGL DFD FMVL LQ MENKAWLVNRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHT AL TGCTEIQMSSGNLLF TGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQVGTIVIRV QYEGDGS PCKIPFE IMDLEKRHVLGRL ITVNPIVTEKDS PVNIEAE PPFGDS YI IIGVEPGQ LKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS I GKALHQVF GA I YGAAF SGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC AS_DV2 - 069_C-NS2b3 -HA-ME 31

[0733] 7 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRSEISRMLEILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGGGSGGGSGGGSGGAGMKAILWLLYTFTTANASVAWVPCCGMGIE YR YE TWMS S E G AWK HVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEG VSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPE QGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVITPHSGEEHAVGNDTGKHGKEIKITPQSSITEAELTGYGTVTMECSPRYGLDFDEMVLLQ MENKAWLVNRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHY AL YGCYEIQMSSGNLLFYGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQVGYIVIRV QYEGDGS PCKIPFE IMDLEKRHVLGRL ITVNPIVTEKDS PVNIEAE PPFGDS YI IIGVEPGQ LKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS I GKALHQVF GA I YGAAF SGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQC AS_DV2 - 070_C-NS2b3 -HA-ME 31

[0734]

[0735] 8 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRSEISRMLEILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGGGS GGGS GGGS GGAGMKAILWLLYTFTTANAAFHLTTRNGE PHMIVS RQE KGKS LL FK TEDGVNMCTLMAMDLGELCEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGSHRR GKRSVAWVPCIGMGIETRCETWMSSEGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQ RALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELI KTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRF GKGGIVTCAMFRCKKNMEGKWAPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSSI TEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNWI QKE T L VT F KN PH AKKQDVWL GS QE GAMH TAL TGCVE I QMS S GNL L FC GHL KC RL RMD KL QL KGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNP IVTEKDS PVNIEAE PPFGDS YII IGVE PGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGDT AWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLV LVGIVTLYLGVMVQA AS_DV2-071_C-NS2b3-HA-ME 31

[0736] 9 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRSEISRMLEILNRRRRSAGMGGGSGGGSGGGSGGGSGGGT GRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWD VPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPS WADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDF S PGTSGS PIIDKKGKWGLYGNGWTRSGAYVSAIAQTEKS IEDNPEIEDDIFRKILNRRRR SAGGGS GGGS GGGS GGAGMKAILWLLYTFTTANAS VAWVPCI GMGIE TRCE TWMS S E GAWK HVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEG VSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPE QGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWAPENLEYT I VI T PH S GE E HAVGNDT GKHGKE I K I T PQ S S I T EAE L T G YGT VTME C S PR TGL DFD EMVL LQ MENKAWLVNRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHT AL TGCVEIQMSSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRV QYEGDGS PCKIPFE IMDLEKRHVLGRL ITVNPIVTEKDS PVNIEAE PPFGDS YI IIGVEPGQ LKLNWFKKGS S IGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTS I GKALHQVF GA I YGAAF SGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQA AS_M / E_DENV4-I_05-A 41 MKAILWLLYTFTTANAS IALTPCCGMGIEGRCETWMSSEGAWKHAQRVESWILRNPGFALL AGFMAYMIGQTGIQRTVFFVLMMLVAPSYGMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVT TMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITTATRCPQQGEPYLKEEQDQQYICRR DWDRGWGNGCSRFGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTS NHGVTATITPRS PSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVDKQWFLDL PL PWTAGADTSEVHWNYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFC GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDV NKEKWGRIISSTPFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFES TYRGAKRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRIL IGFLVLWI

[0737]

[0738] GTNSRNTSMAMTCIAVGGITLFLGFTVQC

[0739] Table 3. E / M based VLP proteins

[0740] SE Q ID NO

[0741] > DENV2-E / M 50 99

[0742]

[0743] Attorney Docket No. 45817-0191WO1 / MTX1505.20 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCXHSMVDR GWGNGCGLFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVURQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQAGGGGSVALVPHVGMGLE TRTETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0744] > DENV2-E / M_51 10

[0745] 0 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCXHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVURQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTS IGKALHQVFGAI YGAAFSGVSWTMKILIGVIITWIGMNSR S T S L S VT L VL VG IVT L YL GVMVQAGGGGSVAL VPHAGMGL E TRT E T WMS S E G AWKHVQR I E T WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0746] > DENV2-E / M_52 10

[0747] 1 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCXHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPffSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQNGVIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTS IGKALHQVFAAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQAGGGGSVALVPHAGMGLE TRTETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0748] > DENV2-E / M_53 10

[0749] 2 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCXHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNQMVLLQMENKAWLVYRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFTGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTS IGKALH2VFAAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQAGGGGSVALVPHAGMGLE TRTETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0750] > DENV2-E / M_54 10

[0751] 3 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCXHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWL PG

[0752]

[0753] ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFTGHLKC Attorney Docket No. 45817-0191WO1 / MTX1505.20 RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQGGGGGSVALVPHAGMGLE TRTETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0754] > DENV2-E / M_55 10

[0755] 4 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCKHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTSIGKALHQVFAAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQGGGGGSVALVPHAGMGLE TRCETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0756] > DENV2-E / M_56 10

[0757] 5 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCKHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQGGGGGSVALVPHAGMGLE TRCETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0758] > DENV2-E / M_57 10

[0759] 6 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCKHSMVDR GWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNQMVLLQMENKAWLVYRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQGGGGGSVALVPHAGMGLE TRCETWMSSEGAWKHVQRIET WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0760] > DENV2-E / M_58 10

[0761] 7 MLRLLLRHHFHCLLLCAVWATPCLAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKN KPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRC PDQGEPSLNEEQDKRFVCKHSMVDR GWGNGCGKFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFNQMVLLQMENKAWLVYRQWFLDLPLPWL PG ADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKC RLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHV LGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGA KRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYKAAFSGVSWTMKILIGVIITWIGMNSR STSLSVTLVLVGIVTLYLGVMVQGGGGGSVALVPHAGMGLE TRCETWMSSEGAWKHVQRIET

[0762]

[0763] WILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMT Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0764] > ZIKV_50_E / M 10

[0765] 8 MLRLLLRHHFHCLLLCAVWAT PCLAIRC I GVS NRD FVE GMS GGTWVDWL EHGGC VTVMAQD KPTVDIELVTTTVSNMAEVRSYCYEASISDMASDS RCPKQGEAYLDKQSDTQYVCKRTLVDR GWGNGCGDFGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETD ENRAKVEITPNS PRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDI PL PWHAGADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLS CGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAV DMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVTGVGEKKITHHWHRSGSTIGK AFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL LMWL GL NT KNGS I S LM CL AL GGVL I FL S T AVGGGGGGGI T L P S HAT RKL QT RCQTWL E S RDH TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0766] > ZIKV_51_E / M 10

[0767] 9 MLRLLLRHHFHCLLLCAVWAT PCLAIRC I GVS NRD FVE GMS GGTWVDWL EHGGC VTVMAQD KPTVDIELVTTTVSNMAEVRSYCYEASISDMASDS RCPKQGEAYLDKQSDTQYVCKRTLVDR GWGNGCGDFGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETD ENRAKVEITPNS PRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDI PL PWHAGADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLS CGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAV DMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVTGVGEKKITHHWHRSGSTIGK AFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL LMWLGLNTKNGS ISLMCLALGGVLIFLSTAVSGGGGGAVTL PSHATRKLQTRCQTWLESRDH TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0768] > DENV1_5O_E / M 11

[0769] 0 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKD KPTLDIELLKTEVTD PAVL RKLCIEAKISNTTTDSRC PKQGEAT L VEE QD AN FVC RRT FVDR GWGNGCGNFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTT ATIT PQAPTTEIQLTDYGALTLDCS PRTGLDFNQMVLLTMKEKSWLVYKQWFLDLPLPWTSG ASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGATEIQTSGTTTIFCGHLKC RLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQ NGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGA RRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSR S T S L SMT C IAVGLVT L YL GVMVQGGGGGSVAL APHAGL GL E TRC E TWMS S E GAWKQ I QRVET WALRHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0770] > DENV1_51_E / M 11

[0771] 1 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKD KPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRC PDQGEATLVEEQDANFVCRRTFVDR GWGNGCGRFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTT ATIT PQAPTTEIQLTDYGALTLDCS PRTGLDFNHMVLLTMKEKSWLVHKQWFLDLPLPWTSG ASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGATEIQTSGTTTIFCGHLKC RLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQ NGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGA RRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSR S T S L SMT C IAVGLVT L YL GVMVQ AGGGGSVAL APHAGL GL E TRC E TWMS S E GAWKQ I QRVET WALRHPGFTVMALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0772] > DENV1_52_E / M 11

[0773] 2 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL

[0774]

[0775] LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR Attorney Docket No. 45817-0191WO1 / MTX1505.20 FGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGATEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGGGSVAL APHAGLGL E TRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0776] > DENV1_53_E / M 11

[0777] 3 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKD KPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRC PDQGEATLVEEQDANFVCRRTFVDR GWGNGCGRFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTT ATIT PQAPTTEIQLTDYGALTLDCS PRTGLDFNHMVLLTMKEKSWLVHKQWFLDLPLPWTSG ASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGATEIQTSGTTTIFCGHLKC RLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQ NGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGA RRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSR S T S L SMT C IAVGLVT L YL GVMVQ AGGGGSVAL APHAGL GL E C R TE T WMS S E GAWKQ I QRVET WALRHPGFTVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0778] > DENV1_54_E / M 11

[0779] 4 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKD KPTLDIELLKTEVTDPAVLRKLCIEAKISNTTTDSRC PDQGEATLVEEQDANFVCRRTFVDR GWGNGCGRFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTT ATIT PQAPTTEIQLTDYGALTLDCS PRTGLDFNHMVLLTMKEKSWLVHKQWFLDLPLPWTSG ASTSQETWNRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAVEIQTSGTTTIFCGHLKC RLKMDKLTLKGMSYVMCTGSFKLEKELAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQ NGRLITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGA RRMAILGDTAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSR S T S L SMT C IAVGLVT L YL GVMVQ AGGGGSVAL APHAGL GLECRTETWMSSE GAWKQ I QRVET WALRHPGFTVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0780] > DENV3_50_E / M 11

[0781] 5 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKN KPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPKQGEATLPEEQDQNYVCKHTYVDR GWGNGCGNFGKGSLVTCAKFQCLEPIEGKWNYENLKYTVIITVHTGDQHQVGNETQGVTAE ITPQASTTEAIL PE YGTLGLECS PRTGLDFDQMILLTMKNKAWMVYRQWFFDLPLPWTSGAT TETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHSALAGATEIQNSGGTS IFCGHLKCRL KMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNG RLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARR MAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNT SMSFSCIAIGIITLYLGAWQGGGGGSVALAPHAGMGLDTRCQTWMSAEGAWRQVEKVETWA LRHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0782] > DENV3_53_E / M 11

[0783] 6 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKN KPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQDQNYVCKHTYVDR GWGNGCGRFGKGSLVTCAKFQCLEPIEGKWQYENLKYTVIITVHTGDQHQVGNETQGVTAE ITPQASTTEAIL PE YGTLGLECS PRTGLDFNHMILLTMKNKAWMVHRQWFFDLPLPWTSGAT TETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHSALAGATEIQNSGGTS IFCGHLKCRL KMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNG

[0784]

[0785] RLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARR Attorney Docket No. 45817-0191WO1 / MTX1505.20 MAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNT SMSFSCIAIGIITLYLGAWQAGGGGSVALAPHAGMGLDCRTQTWMSAEGAWRQVEKVETWA LRHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0786] > DENV3_54_E / M 11

[0787] 7 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKN KPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPQQGEATLPEEQDQNYVCKHTYVDR GWGNGCGRFGKGSLVTCAKFQCLEPIEGKWQYENLKYTVIITVHTGDQHQVGNETQGVTAE ITPQASTTEAIL PE YGTLGLECS PRTGLDFWEMILLTMKNKAWMVHRQWFFDLPLPWTSGAT TETPTWNRKELLVTFKNAHAKKQEVWLGSQEGAMHSALAGAVEIQNSGGTS IFCGHLKCRL KMDKLELKGMSYAMCTNTFVLKKEVSETQHGTILIKVEYKGEDAPCKIPFSTEDGQGKAHNG RLITANPWTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARR MAILGDTAWDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNT SMSFSCIAIGIITLYLGAWQAGGGGSVALAPHAGMGLDCRTQTWMSAEGAWRQVEKVETWA LRHPGFTILALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0788] > DENV4_50_E / M 11

[0789] 8 MLRLLLRHHFHCLLLCAVWATPCLANRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPYQGEPYLKEEQDQQYICRRDWDR GWGNGCGEFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFRQMILMKMKKKTWLVYKQWFLDLPLPWTTG ADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQGGGGGS'VALTPHAGMGLE TRCETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0790] > DENV4_51_E / M 11

[0791] 9 MLRLLLRHHFHCLLLCAVWATPCLANRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRRDWDR GWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTTG ADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQAGGGGSVALTPHAGMGLE TRCETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0792] > DENV4_52_E / M 12

[0793] 0 MLRLLLRHHFHCLLLCAVWATPCLANRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRRDWDR GWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVYKQWFLDLPLPWTTG ADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQAGGGGSVALTPHAGMGLE TRCETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0794]

[0795] Attorney Docket No. 45817-0191WO1 / MTX1505.20 > DENV4_53_E / M 12

[0796] 1 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRRDWDR GWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVYKQWFLDLPLPWTTG ADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQAGGGGSVALTPHAGMGLE TRCETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0797] > DENV4_54_E / M 12

[0798] 2 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEALISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFSCSGKITGNLVQIENLEYTWVTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDF7VEMILMKMKKKTWLVHKQWFLDLPLPWTTGADTSEVHW NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKCKVRMEKLR IKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRVISAT PLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGGGSVAL T PHAGMGL E TRC E T WMS S E GAWKHAQRVE S WI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0799] > DENV4_55_E / M 12

[0800] 3 MLRLLLRHHFHCLLLCAVWATPCLAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRRDWDR GWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTTG ADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGAT’EVDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQAGGGGSVALTPHAGMGLECRTETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0801] > DENV4_56_E / M 12

[0802] 4 MLRLLLRHHFHCLLLCAVWATPCLANRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG KPTLDFELTKTTAKEVALLRTYCIEALISNITTATRCPQQGEPYLKEEQDQQYICRRDWDR GWGNGCGRFGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVT ATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTTG ADTSEVHWNYKE RMVTFKVPHAKRQDVTVLGSQEGAMHSAL AGAVE VDSGDGNHMFCGHLKC KVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKV VGRVISATPLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGA KRMAILGETAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSR NTSMAMTCIAVGGITLFLGFTVQAGGGGSVALTPHAGMGLECRTETWMSSEGAWKHAQRVES WILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0803] > ZIKV_Ngly_51A_E / M 17

[0804] 0 MLRLLLRHHFHCLLLCAVWAT PCLAIRC I GVS NRD FVE GMS GGTWVDWL EHGGC VTVMAQD KPTVDIELVTTTVSNMAEVRSYCYEASISNMSSDSRCPKQGEAYLDKQSDTQYVCKRTLVDR

[0805]

[0806] GWGNGCGDFGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETD Attorney Docket No. 45817-0191WO1 / MTX1505.20 ENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPL PWHAGADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLS CGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAV DMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK AFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL LMWLGLNTKNGS TSLMCLALGGVLTFLSTAVSGGGGGAVTL PSHATRKLQTRCQTWLESRDH TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0807] > ZIKV_Ngly_50A_E / M 17

[0808] 1 MLRLLLRHHFHCLLLCAVWAT PCLAIRC I GVS NRD FVE GMS GGTWVDWL EHGGC VTVMAQD KPTVDIELVTTTVSNMAEVRSYCYEASISNMSSDSRCPKQGEAYLDKQSDTQYVCKRTLVDR GWGNGCGDFGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETD ENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPL PWHAGADTGTPHWNNKEALVEFKDAHAKRQTVWLGSQEGAVHTALAGALEAEMDGAKGRLS CGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAV DMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK AFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL LMWL GLNTKNGSISLM CL AL GGVL L FL S T AVGGGGGGGI T L P S HAT RKL QT RCQTWL E S RDH TKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0809] > ZV-Ngly_AS2a_E / M 17

[0810] 2 MLRLLLRHHFHCLLLCAVWATPCLASITLPSHSTRKLQCRTQTWLESREHTKHLIRVENWIF RNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEGMSGGTWVDW LEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISNMSSDSRCPKQGEAYLDKQS DTQYVCKRTLVDRGWGNGCGDFGKGSLVTCAKFACSKKMTGKS IQPENLEYRIMLSVHGSQH SGMIVNDTGHETDENRAKVEITPNS PRAEATLGGFGSLGLDCE PRTGLDFSDLYYLTMNNKH WL VHKEWFHD I PL PWHAGADT GT PHWNNKEALVE FKDAHAKRQTVWL GS QE GAVHSALAGA LEAEMDGAKGRLSCGHLKCRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKI THHWHRSGSTTGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQTFGAAFKSLFG GMSWFSQILIGTLLMWLGLNTKNGS ISLMCLALGGVL IFLSTAVS A

[0811] > DENV1_HA_6O_E / M 17

[0812] 3 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVQYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGATEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC T AVGL VT L YL GVMVQGGGGGGIAL APHAGLGL E TRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0813] > DENV2-HA_M / E_102 17

[0814] 4 MKAILWLLYTFTTTVNASVALVPHCGMGLETRTETWMSSEGAWKHVQRIETWILRHPGFTMM AAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVT TMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKH SMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKWQPENLEYTIVITPHSGEEHAVGNDTG KHGKEIKITPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPL PWLPGADTQGSNWIQKETLVTFKNPHAKKQDVWLGSQEGAMHTAL TGATEIQMSSGNLLFT GHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDL

[0815]

[0816] EKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFET Attorney Docket No. 45817-0191WO1 / MTX1505.20 TMRGAKRMALLGDTAWDFGSLGGVFTSLGKALHQVFGATYGAAFSGVSWTMKTLTGVTTTWI GMNS RS T S L S VT LVLVGI VTL YL GVMVQC

[0817] > DENV3_HA_60_E / M 17

[0818] 5 MKAILWLLYTFTTANMRCVGVGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWCYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EALLPEYGTLGLECSPRTGLDFNEMLLLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEWVLGSQEGAMHSALAGAVEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQLFGSAYKALFSGVSWVMKTGIGVLLTWTGLNSKNTSMSFSCTA LGLTTLYLGAWQGGGGGGIALAPHAGMGLDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0819] > DENV4_HA_60_E / M 17

[0820] 6 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEALISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFSCSGKITGNLVQIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTTGADTSEVHW NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFCGHLKCKVRMEKLR IKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRVISAT PLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMLRILLGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQGGGGGGIAL T PHAGMGL E TRC E TWMS S E GAWKHAQRVE S WL L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0821] > ZLKV_HA_Ngly_50A_E / M 17

[0822] 7 MKAILWLLYTFTTANAIRCIGVSNRDFVEGMSGGTWVDWLEHGGCVTVMAODKPTVDIEL VTTTVSNMAEVRSYCYEASISNMSSDSRC PKQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGD FGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVET TPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDLPLPWHAGADT GT PHWNNKEAL VE F KDAHAKRQT VWL GS QE GAVHTAL AGAL E AEMDGAKGRL S CGHL KC RL KMDKL RL KGVS Y S L C T AAFT F T K I PAE T L HGT VT VE VQ YAGT D G PC KVPAQMAVDMQT L T PV GRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNT KNGSLSLMCLAL GGVL I FL S T AVGGGGGGGI T L P S HAT RKL QT RCQTWL E S RDHT KHL I RVE NWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0823] > ZLKV_HA_50_E / M 17

[0824] 8 MKAILWLLYTFTTANAIRCIGVSNRDFVEGMSGGTWVDWLEHGGCVTVMAODKPTVDIEL VTTTVSNMAEVRSYCYEASISDMASDSRCPKQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGD FGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVET TPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDLPLPWHAGADT GT PHWNNKEAL VE F KDAHAKRQT WVL GS QE GAVHTAL AGAL E AEMDGAKGRL S C GHL KC RL KMDKL RL KGVS Y S L C T AAFT F T K I PAE T L HGT VTVEVQ YAGT D G PC KVPAQMAVDMQT L T PV GRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNT KNGSLSLMCLAL GGVL I F L S T AVGGGGGGGI T L P S HAT RKL QT RCQTWL E S RDHT KHL I RVE NWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0825] > DENV2-001_Rfd 17

[0826]

[0827] 9 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRC PGQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGK FGKGGIVTCAMFTCKKNMEGKWQPENLE YT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECSPRGSFDFNARTVFVQMENKAWMVDRQWFLDLPLPWLPGADTQGSN WIQKEKGAVRFKNPHAKKQDVWLGSQEGAMHBALAGATEIQMSSGNLFFTGHLKCRLRMDK LQLKGMS YSMCTGKFKWKEIAETQHGT TVTRVQYEGDGS PCKTPFEIMDLEKRHVLGRL IT VNPIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLSWFKKGS S IGQMFETTMRGAKRMAIL GDAWDFGSLGGVFEAIGRALHDVFGAIYTSAFSGVSWTMKLLIGAIITWIGMNSRSTSLSVS L VL VGWT L YL GVMVRSNGGPGRVARR PH SDLGFGT S T S T WMAD E GAWEHARRI ETWVL AH P GFTIMAAILAYTIGTTYFQRVLIFILLTAVAPLLA

[0828] > DENV2 - 002_Rf d 18

[0829] 0 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGK FGKGGIVTCAMFTCKKNMEGKWQPENLE YT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECSPRGSFDFNARTVFVQMENKAWMVDRQWFLDLPLPWLPGADTQGSN WI QKE TL VTF KN PHAKKQD VWL GS QE GAMH SAL AGAT E I QMS S GNLF FT GHL KC RL RMD KL QLKGMS YSMCTGKFKWKEIAETQHGT TVTRVQYEGDGS PCKI PFE IMDLEKRHVLGRLITV NPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLSWFKKGSS IGQMFETTMRGAKRMAILG DAWDFGSLGGVFEAIGRALHDVFGAIYTSAFSGVSWTMKLLIGAIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPSKVAIKPHSDLGFGT ST ETWMSSEGAWEHAQRI ETWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPLLA

[0830] > DENV2 - 003_Rf d 18

[0831] 1 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECSPRGSFDFNARTVFVQMENKAWMVDRQWFLDLPLPWLPGADTQGSN WI QKE TL VTF KN PHAKKQD VWL GS QE GAMH SAL AGAT E I QMS S GNLF FT GHL KC RL RMD KL QLKGMS YSMCTGKFKWKEIAETQHGT TVTRVQYEGDGS PCKI PFE IMDLEKRHVLGRLITV NPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLSWFKKGSS IGQMFETTMRGAKRMAILG DAWDFGSLGGVF TSIGRALHDVFGAIYTSAFSGVSWTMKLL IGAIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPGGVAINPHAGANLIT STQVWAGEQGRWKHAQRI ETWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPSW

[0832] > DENV4 - 004_Rf d 18

[0833] 2 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS I T EAE L T G YGT VTME C S P R TGI D FNRMVLVQMENKAWLVD RQWF L D L P L PWL PGAD T QGS NW IQKE TL VTFKNPHAKKQDVWLGS QEGAMHSALAGAVE I QMS S GNL LF TGHL KC RL RMDKLQ LKGMS YSMCTGKFKWKEIAETQHGT TVTRVQYEGDGS PCKTPFEIMDLEKRHVLGRLTTVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLSWFKKGS S IGQMFETTMRGAKRMAILG^ TAWDFGSLGGVF TSIGKALHQVFGAIYGSAFSGVSWTMKLL IG VIITWIGMNSRSTSLSVSL VL VGWTL YL GVMVQGGGPGAVAINPHAGMGLET RTQ TWMADQGRWKHAQRI ETWVL RH PGF T IMAAI LAYT IGTT YFQRVL I F I LL TAVAPSW

[0834] > DENV2 - 005_Rf dMNP 18

[0835] 3 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS I T EAE L T G YGT VTME C S P R TGI D FNRMVLVQMENKAWIVD RQWF L D L P L PWL PGAD T QGS NW

[0836]

[0837] IQKE TL VTFKNPHAKKQDVWLGS QEGAMHSALAGAVE I QMS S GNL LF TGHL KC RL RMDKLQ Attorney Docket No. 45817-0191WO1 / MTX1505.20 LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLSWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVF TGIGKALHQVFGAIYGSAFSGVSWTMKLL IG VIITWIGMNSRGTSLSVSL VL VGWTL YL GVMVQGGGPGS PAHRPHAGQGI ET STKVWMEDQGRWEHAQRI ETWVL RH PGF TIMAAILAYTIGTTYFQRVLIFILLTAVAPGMT

[0838] > DENV2 - 006_Rf dMNP 18

[0839] 4 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFTCKKNMEGKWQPENLE YT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECSPRGSFDFNARTVFVQMENKAWLVDRQWFLDLPLPWLPGADTQGSN WI QKE TL VTF KN PHAKKQD VWL GS QE GAMH SAL AGAVE I QMS S GNLL F TGHL KC RL RMD KL QLKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITV NPIVTEKDS PVNIEAEPPFGDS YII IGVE PGQLKLSWFKKGSS IGQMFETTMRGAKRMAILG R TAWDFGSLGGVF TGIGKALHQVFGAIYGSAFSGVSWTMKLLIGVIITWIGMNSRGTSLSVS LVLVGWTLYLGVMVQGGGPGSPANKPHAGQGIETGTKVWMEDQGRWEHAQRIETWVLRHPG FTIMAAILAYTIGTTYFQRVLIFILLTAVAPGMT

[0840] > DV2 - 016_C-NS 2b3-E / M 18

[0841] 5 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMGGGSGGGTGRSADLELERA ADVKWEDQA EISGSS PILS IT ISEDGSMS IKNEEEEQTLEVKKQRAGVLWDVPS PPPMGKAELEDGAYRIK QKGI LGYS QI GAGVYKEGT FHTMWHVT RGAVLMHKGKRI E P SWADVKKDL I S YGGGWKLE GE WKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDKKGKWGLY GNGWT RS GAYVS AIAQT EKSIEDNPEIEDDIFRKIL NRRRRS AGMIIMLI PTVMAMRC I GM SNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNT TTESRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTCAMFRCKKNMEGKW QPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLD FNRMVLLQMENKAWLVDRQWFLDLPLPWLPGADTQGSNWIQKEKLVTFKNPHAKKQDVWLG SQEGAMHSALAGAVEIQMSSGNLLFCGHLKCRLRMDKLQLKGMSYSMCTGKFKWKEIAETQ EGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYI IIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVF GAIYKAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQGGGGPGKV ALNPHAGMGIECRTETWMSSEGAWDHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIF ILLTAVTPSMT

[0842] > DV2-019_C-NS2b3-E / M 18

[0843] 6 MNNQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLFMALVAFLRFLTIPPT AGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMGGGSGGGTGRSADLELERAA DVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLEVKKQRAGVLWDVPSPPPMGKAEL EDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLTSYG GGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDK KGKWGLYGNGWTRSGAYVSAIAOTEKS IEDNPE IEDDIFRKILNRRRRSAGMKAILWLL YTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKHPA TLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGRFGKGGIVTC AMFTCKKNMEGKWQPENLEYTIVITPHSGEENAVGNDTGKHGKEIKVTPQSSITEAELTGY GTVTMECS PRTGLDFNRMVLLQMENKAWLVDRQWFLDLPLPWL PGADTQGSNWIQKE TL VTF KNPHAKKQDVWLGSQEGAMHSALAGAVEIQMSSGNLLFCGHLKCRLRMDKLQLKGMSYSMC TGKFKWKEIAETQHGTIVIRVQYEGDGS PCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSP VNIEAEPPFGDSYTIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLG GVF TGI GRALH QVFGAI Y GSAF S GVS WTMKL LIGVIITWI GMN S AST S L S VS L VL VGWT L Y LGVMVQGGGPGKVAINPHAGMGIICSTQVWAGEQGRWDHAQRIEKWVLRHPGFT IMAAILAY

[0844]

[0845] T I GT T Y F Q RVL I F I L L T AVAP GMT Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0846] > YF_Br_E / M_AS-50 18

[0847] 7 MLRLLLRHHFHCLLLCAVWATPCLAAHCIGITDRDFIEGVHGGTWVSATLEQGKCVTVMAPD KPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKC PRTGEAHLEEENEGDNACKRTYSDR GWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAKQENWNTDIKTLKF DALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWAQDLTLPWQSGSGG VWREMHHLVEFEPPHAATIKVLALGNQEGSLKSALAGAMRVTKDTNNSKLYKLHHCGHVACRV KLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPVMVADDLTAAVNKG ILVTVNPIASTNDDEVLIEVNPPFGDS YI IVGTGDSRLT YQWHKEGSS IGKLFTQTMKGAER LAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMGWL IWVGINTRNM TMSMSMILVGVIMMFLSLGVGGGGGGAIDLPTHANHGLKTRQEKWMTGRMGERQLQKIERWL VRNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYS

[0848] > YF_Br_E / M_AS-51 18

[0849] 8 MLRLLLRHHFHCLLLCAVWATPCLAAHCIGITDRDFIEGVHGGTWVSATLEQGKCVTVMAPD KPSLDISLETVAIDGPAEARKVCYSAVLTNVKINDKC PRTGEAHLEEENEGDNACKRTYSDR GWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAKQENWNTDIKTLKF DALSGSQEAEFTGYGRATLECQVQTAVDFSNSYIAEMEKESWIVDKQWAQDLTLPWQSGSGG VWREMHHLVEFEPPHAATIKVLALGNQEGSLKSALAGAMRVTKDTNNSKLYKLffGGHVACRV KLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTAVMQVKVPKGAPCRIPVMVADDLTAAVNKG ILVTVNPIASTNDDEVLIEVNPPFGDSYI IVGTGDSRLT YQWHKEGSS IGKLFTQTMKGAER LAVMGDAAWDFGSAGGFFTSVGKGIHTVFGSAFQGLFGGLSWITKVIMGWL IWVGINTRNM TMSMSMILVGVIMMFLSLGVGGGGGGAIDLPTHANHGLKTRQEKWMTGRMGERQLQKIERWL VRNPFFAATALAIAYLVGSNMTQRWIALLVLAVGPAYS

[0850] > DV2-020_E / M 18

[0851] 9 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWQPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGGGSVAL VPHAGMGL E TRC E T WMS S E G AWKHVQRI E T WI L RH P GF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0852] > DV2-021_E / M 19

[0853] 0 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWQPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYL GVMVQ AGGGGSVALVPHAGMGLEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0854] > DV2-022_E / M 19

[0855]

[0856] 1 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWQPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGATEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKTPFEIMDLEKRHVLGRLTTVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGSVAL VPHAGMGL E TRC E T WMS S E G AWKHVQRI E T WI L RH P GF TMMAAI L AYT I GTT HFQRAL I F I L L TAVT PSMT

[0857] > DV2-023_E / M 19

[0858] 2 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFE EMVL LQMENKAWL VHRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQVGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDSYI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYL GVMVQ AGGGGSVALVPHAGMGLEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0859] > DV2-024_E / M 19

[0860] 3 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFE EMVL LQMENKAWL VHRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQVGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYL GVMVQ AGGPGSIALVPHAGMGLEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0861] > DV2-025_E / M 19

[0862] 4 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFESQVLLQMENKAWLVDRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAVEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQVGTIVIRVQYEGDGSPCKTPFEIMDLEKRHVLGRLTTVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFRGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYL GVMVQ AGGGGSIALVPHAGMGHEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0863] > DV2-026_E / M 19

[0864] 5 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPNQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGQ FGKGGIVTCAMFRCKKNMEGKWLPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DEE EMVL LQMENKAWL VHRQWF L D L P L PWL PGAD T QGS NW

[0865]

[0866] IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLIFCGHLKCRLRMDKLQ Attorney Docket No. 45817-0191WO1 / MTX1505.20 LKGMSYSMCTGKFKWKEIAETQ17GTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYLGVMVQAGGGGSIALVPHAGMGLEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0867] > DV2 - 027_RFdR3_E / M 19

[0868] 6 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGI P FTDMVL LQMENKAWL VKRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAPEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQ17GTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKSGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYLGVMVQAGGGGGIALVPHAGMGREFRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0869] > DV2 - 028_RosR7_E / M 19

[0870] 7 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VKRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VLVGIVTLYLGVMVQAGGGGGIALVPHAGMGLEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0871] > DV2-029_E / M 19

[0872] 8 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLFTGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0873] > DV2-030_E / M 19

[0874] 9 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF

[0875]

[0876] TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT Attorney Docket No. 45817-0191WO1 / MTX1505.20

[0877] > DV2-031_E / M 20

[0878] 0 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI ITGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0879] > DV2-032_E / M 20

[0880] 1 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPSQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVPRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLFFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIITGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGFGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0881] > DVl_001_E / M 20

[0882] 2 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVTGAGEKALKLSWFKKGSSIGKMFEATARGARRMATLGD TAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGGGSVAL APHAGLGL EGRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0883] > DVl_002_E / M 20

[0884] 3 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAPEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVTGAGEKALKLSWFKKGSSIGKMFEATARGARRMATLGD TAWDFGSIGGVFTSVGKLVHQIFGTAYKVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGGGSVAL APHAGLGL EGRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTSITQKGIIFILLMLVTPSMA

[0885] > DVl_003_E / M 20

[0886] 4 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL

[0887]

[0888] LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR Attorney Docket No. 45817-0191WO1 / MTX1505.20 FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGTGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APHAGLGL EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0889] > DV1_OO4_E / M 20

[0890] 5 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFNEQVLLTMKEKSWLVDKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFRGVSWTMKIGTGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGSVALAPHAGLGH EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0891] > DVl_005_E / M 20

[0892] 6 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGTGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APCAGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0893] > DV4-001_E / M 20

[0894] 7 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEALISNITTATRCPDQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFSCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHKQWFLDLPLPWTTGADTSEVHW NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGAAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRVISAT PLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGGGGIAL T PHAGMGL EGRC E TWMS S E GAWKHAQRVE S WI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0895] > DV4-002_E / M 20

[0896] 8 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEALISNITTATRCPDQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFSCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFEEMILMKMKKKTWLVNKQWFLDLPLPWTTGADTSEVHW NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGAAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRVISAT

[0897]

[0898] PLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE Attorney Docket No. 45817-0191WO1 / MTX1505.20 TAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGPGGIAL T PHAGMGL EGRC E TWMS S E GAWKHAQRVE SWI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0899] > DV4-003_E / M 20

[0900] 9 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEALISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFSCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVDKQWFLDLPLPWTTGADTSEVHW NYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMSYTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRVISAT PLAENTNSVTNIELEPPFGDSYIVIGVGNSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGPGGIAL T PC AGMGI EGRC E TWMS S E GAWKHAQRVE SWI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0901] > DV3-001_E / M 21

[0902] 0 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWQYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFDEMILLTMKNKAVJMVNRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGAVEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQGGGGGGIALAPHAGMGIDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0903] > DV3-002_E / M 21

[0904] 1 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWAYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFDEMILLTMKNKAVJMVNRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGCAEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQGGGPGGIALAPCAGMGIDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0905] > ZV-001_Ngly_E / M 21

[0906] 2 MKAILWLLYTFTTANAIRCIGVSNRDFVEGMSGGTWVDWLEHGGCVTVMAODKPTVDIEL VTTTVSNMAEVRSYCYEASISNMSSDSRC PKQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGD FGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEI TPNS PRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDI PL PWHAGADT GT PHWNNKEAL VE F KDAHAKRQT WVL GS QE GAVHTAL AGC I E AEMDGAKGRL S CGHL KC RL KMDKL RL KGVS Y S L C T AAFT F T K I PAE T L HGT VT VE VQ YAGT D G PC KVPAQMAVDMQT L T PV GRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNT KNGSISLMCIAL GGVL I F L S T AVGPGGGGGI T L P S CAT RAL Q S RCQTWL E S RDHT KHL I RVE NWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0907]

[0908] Attorney Docket No. 45817-0191WO1 / MTX1505.20 > ZV-002_E / M 21

[0909] 3 MKAILWLLYTFTTANAIRCIGVSNRDFVEGMSGGTWVDWLEHGGCVTVMAODKPTVDIEL VTTTVSNMAEVRSYCYEASISDMASDSRC PKQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGD FGKGSLVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEI TPNS PRAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDI PL PWHAGADT GT PHWNNKEAL VE F KDAHAKRQT WVL GS QE GAVHTAL AGC I E AEMDGAKGRL S CGHL KC RL KMDKL RLKGVSYSLCTAAFTFTKI PAE T L HGT VT VE VQ YAGT D G PC KVPAQMAVDMQT L T PV GRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNT KNGS I S LM CI AL GGVL I F L S T AVGPGGGGGI T L P S CAT RAL Q S RCQTWL E S RDHT KHL I RVE NWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYS

[0910] > YF_Asb_E / M_AS-52 21

[0911] 4 MLRLLLRHHFHCLLLCAVWATPCLAAHCIGITDRDFIEGVHGGTWVSATLEQGKCVTVMAPD KPSLDISLETVAIDGPAEARKVCYNAVLTHVKINDKC PRTGEAHLAEENEGDNACKRTYSDR GWGNGCGNFGKGSIVACAKFTCAKSMSLFEVDQTKIQYVIRAQLHVGAKQENWNTDIKTLKF DALSGSQEAEFTGYGKATLECQVQTAVDFGNSYIAEMEKESWIVDRQWAQDLTLPWQSGSGG VWREMHHLVEFEPPHAATIRVLALGNQEGSLKSALAGAMRVTKDTNDNNLYKLHCGHVSCRV KLSALTLKGTSYKMCTDKMSFVKNPTDTGHGTWMQVKVPKGAPCKIPVIVADDLTAAINKG ILVTVNPIASTNDDEVLIEVNPPFGDSYIIVGTGDSRLTYQWHKEGSSIGKLFTQTMKGAER LAVMGDAAWDFSSAGGFFTSVGKGIHTVFGSAFQGLFGGLNWITKVIMGAVLIWVGINTRNM TMSMSMILVGVIMMFLSLGVGGGGGGAIDLPTHANHGLKTRQEKWMTGRMGERQLQKIERWL VRN P F FA VT AL T IAYL VGS NMT QRWI AL LVL AVG PAYS

[0912] > DVl_006_E / M 21

[0913] 5 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APC AGLGI EGRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0914] > DVl_007_E / M 21

[0915] 6 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCGR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGAAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQCGGPGGIAL APHCGLGI EGRC E T WMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA

[0916] > DV1_OO8_E / M 21

[0917] 7 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCGR

[0918]

[0919] FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP Attorney Docket No. 45817-0191WO1 / MTX1505.20 TTEIQLTDYGALTLDCSPRTGLDFDFMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQCGGPG

[0920] > DV2-034_E / M 21

[0921] 8 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWLPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDQMVLLQMENKAWLVYRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQIIGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0922] > DV2-035_E / M 21

[0923] 9 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWLPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFVEMVLLQMENKAWLVffRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGGIAL VPHCGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT

[0924] > DV2-036_E / M 22

[0925] 0 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWLPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDQMVLLQMENKAWLVYRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGAAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGGIAL VPHCGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAILAYTTGTTHFQRALIFILLTAVTPSMT

[0926] > DV2-037_E / M 22

[0927] 1 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWLPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDQMVLLQMENKAWLVYRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD

[0928]

[0929] TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL Attorney Docket No. 45817-0191WO1 / MTX1505.20 VLVGIVTLYLGVMVQCGGPGGIALVPCCGMGIEGRCETWMSSEGAWKHVQRIETWILRHPGF TMMAAI L AYT I GTT HFQRAL I F I L L TAVT PSMT

[0930] > DV2-041_E / M 22

[0931] 2 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPNQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGQ FGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECSPRYGLDFEFMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCYEIQMSSGNLLF YGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGYIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E YR YE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMT

[0932] > DV2-042_E / M 22

[0933] 3 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPNQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGQ FGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECSPRYGLDFEFMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLIFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGYIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDSYI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGGGGIAL VPC AGMGI EGRC E T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMT

[0934] > DV2-043_E / M 22

[0935] 4 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWLPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSS ITEAELTGYGTVTMECSPRYGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCYEIQMSSGNLLF YGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E YR YE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVTPSMT

[0936] > DV4_004_E / M_Ind 22

[0937] 5 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEASISNITTATRCPDQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDF7VFMILMKMKKKTWLVHKQWFLDLPLPWTAGADTSEVHW NYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGAAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMS YTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPIEIRDVNKEKWGRI IS ST PFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYKTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGGGGIAL T PHAGMGL EGRC E TWMS S E GAWKHAQRVE S WI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0938] > DV4_005_E / M_Ind 22

[0939]

[0940] 6 Attorney Docket No. 45817-0191WO1 / MTX1505.20 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEASISNITTATRCPDQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFEEMILMKMKKKTWLVNKQWFLDLPLPWTAGADTSEVHW NYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGAAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMS YTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPTEIRDVNKEKWGRI IS ST PFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYTTMF GGVSWMIRIL IGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGPGGIAL T PHAGMGL EGRC E TWMS S E GAWKHAQRVE SWI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0941] > DV4_006_E / M_Ind 22

[0942] 7 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEASISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVDKQWFLDLPLPWTAGADTSEVHW NYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMS YTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPTEIRDVNKEKWGRI IS ST PFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVYTTMF GGVSWMIRIL IGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQ AGGPGGIAL T PC AGMGLEGRC E TWMS S E GAWKHAQRVE SWI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0943] > DV4 - Ind_004_E / M 22

[0944] 8 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEASISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVDKQWFLDLPLPWTAGADTSEVHW NYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAG25AEVDSGDGNHMFCGHLKCKVRMEKLR IKGMS YTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPTEIRDVNKEKWGRI IS ST PFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVY TT MF GGVSWMIRIL IGFLVLWIGTNSRNTSMAMTC I AVGGI T L FL GF TVQCGGPGGIAL T PHCGMGI EGRC E TWMS S E GAWKHAQRVE SWI L RN P GF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0945] > DV4 - Ind_005_E / M 22

[0946] 9 MKAILWLLYTFTTANAMRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFEL TKTTAKEVALLRTYCIEASISNITTATRC PQQGEPYLKEEQDQQYICRRDWDRGWGNGCGR FGKGGWTCAKFLCSGKITGNLVAIENLEYTVWTVHNGDTHAVGNDTSNHGVTATITPRSP SVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVDKQWFLDLPLPWTAGADTSEVHW NYKERMVTFKAPHAKRQDVTVLGSQEGAMHSALAGCAEVDSGDGNHMFCGHLKCKVRMEKLR IKGMS YTMCSGKFS IDKEMAETQHGTTWKVKYEGAGAPCKVPTEIRDVNKEKWGRI IS ST PFAENTNSVTNIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGE TAWDFGSVGGLFTSLGKAVHQVFGSVY TT MF GGVSWMIRIL IGFLVLWIGTNSRNTSMAMTC IAVGGITLFLGFTVQCGGPGGIALTPCCGMGIEGRCETWMSSEGAWKHAQRVESWILRNPGF ALLAGFMAYMIGQTGIQRTVFFVLMMLVAPSYG

[0947] > DENV3_003_E / M 23

[0948] 0 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWLYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFNEMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWNR

[0949]

[0950] KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGCAEIQNSGGTSIFCGHLKCRLKMDKLELK Attorney Docket No. 45817-0191WO1 / MTX1505.20 GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQGGGGGGIALAPCAGMGLDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0951] > DENV3_004_E / M 23

[0952] 1 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWLYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFNHMILLTMKNKAVJMVHRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGAAEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQCGGGGGIALAPHCGMGLDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0953] > DENV3_005_E / M 23

[0954] 2 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWLYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFNHMILLTMKNKAVJMVHRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGCAEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQCGGGGGIALAPCCGMGLDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT

[0955] > DENV3_006_E / M 23

[0956] 3 MKAILWLLYTFTTANAMRCVGVGNRDFVEGLSGATWVDWLEHGGCVTTMAKNKPTLDIEL QKTEATQLATLRKLCIEGKITNITTDSRC PQQGEATL PEEQDQNYVCKHTYVDRGWGNGCGR FGKGSLVTCAKFQCLEPIEGKWQYENLKYTVIITVHTGDQHQVGNETQGVTAEITPQASTT EAILPEYGTLGLECSPRTGLDFNHMILLTMKNKAWMVHRQWFFDLPLPWTSGATTETPTWNR KELLVTFKNAHAKKQEVWLGSQEGAMHSALAGAAEIQNSGGTSIFCGHLKCRLKMDKLELK GMS YAMC TNT FVLKKE VS ETQHGTILI KVE YKGE DAP CKIPFSTED GQGKAHNGRL I T AN PV VTKKEEPVNIEAEPPFGESNIVIGIGDNALKINWYKKGSSIGKMFEATARGARRMAILGDTA WDFGSVGGVLNSLGKMVHQIFGSAYKALFSGVSWVMKIGIGVLLTWIGLNSKNTSMSFSCIA IGIITLYLGAWQCGGGGGIALAPHCGMGLDCRTQTWMSAEGAWRQVEKVETWALRHPGFTI LALFLAHYIGTSLTQKWIFILLMLVTPSMT DVl_005-A_E / M 33

[0957] 5 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKTVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APC AGLGI EGRC E T WMS S E GAWKQ I QRVE T WAL RH P GF

[0958]

[0959] TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA Attorney Docket No. 45817-0191WO1 / MTX1505.20 AS_V4_DVl-EM_00341

[0960] 1 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQGGNASTEGGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQAGG PGG IAL APC AGLG I E GRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA AS_V4_DV1- EM_00441

[0961] 2 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGDESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAETQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQAGG PGG IAL APC AGLG I E GRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DVl_005-B_E / M 33

[0962] 6 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCTR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APC AGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DVl_005-C_E / M 33

[0963] 7 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCNR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQ AGGPGGIAL APC AGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA AS_V4_DVl-EM_00741

[0964] 3 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTNPAVLRKLCIEAKISNTTTDSRCPDQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN

[0965]

[0966] PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD Attorney Docket No. 45817-0191WO1 / MTX1505.20 TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQAGG PGG IAL APC AGLG I E GRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVIALFLAHAIGTS ITQKGIIFILLMLVT PSMA E Protein portion of AS_V4_DVl-EM_007 41

[0967] 4 MRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRKLCIE AKISNTTTDSRC PDQGEATLVEEQDANFVCRRTFVDRGWGNGCSRFGKGSLITCAKFKCVTK LEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCS PRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQ EVWLGSQEGAMHSALAGCAETQTSGTTTIFCGHLKCRLKMDKLTLKGMSYVMCTGSFKLEK ELAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQNGRLITANPIVTDKEKPVNIEAEPP FGES YIVIGAGEKALKLSWFKKGSS IGKMFEATARGARRMAILGDTAWDFGS IGGVFTSVGK LVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTCIAVGLVTLYLGVMVQA M Protein portion of AS_V4_DV1-EM_O 07 41

[0968] 5 GIALAPCAGLGIEGRCETWMS SEGAWKQIQRVETWALRHPGFTVIALFLAHAIGTS ITQKGI IFILLMLVTPSMA DVl_008-A_EM 33

[0969] 8 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQCGGPGGIAL APCCGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DVl_008-B_EM 33

[0970] 9 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCTR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC TGSFKLEKELAETQHGTVLVQTKYEGTDAPCKIPFSTQDE KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQCGGPGGIAL APCCGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DVl_008-C_EM 34

[0971] 0 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCNR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCAEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC I AVGL VT L YL GVMVQCGGPGGIAL APCCGLGI EGRC E TWMS S E GAWKQ I QRVE T WAL RH P GF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DVl_011_EM 35

[0972] 3 MKAILWLLYTFTTANAMRCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL

[0973]

[0974] LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCGR Attorney Docket No. 45817-0191WO1 / MTX1505.20 FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDEMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCIEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I T AN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGTGVLLTWLGLNSRSTSLSMTC IAVGLVTLYLGVMVQCGGPGGVALNPCCGLGIEGRCETWMSSEGAWKQIQRVETWALRHPGF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA DV1_O12-A_EM 35

[0975] 4 MKAILWLLYTFTTANAJ9RCVGIGSRDFVEGLSGATWVDWLEHGSCVTTMAKDKPTLDIEL LKTEVTDPAVLRKLCIEAKISNTTTDSRC PQQGEATLVEEQDANFVCRRTFVDRGWGNGCSR FGKGSLITCAKFKCVTKLEGKIVAYENLKYSVIVTVHTGDQHQVGNESTEHGTTATITPQAP TTEIQLTDYGALTLDCSPRTGLDFDFMVLLTMKEKSWLVNKQWFLDLPLPWTSGASTSQETW NRQDLLVTFKTAHAKKQEVWLGSQEGAMHSALAGCIEIQTSGTTTIFCGHLKCRLKMDKLT L KGMS YVMC T GS FKL E KE L AE T QHGT VL VQ I KYE GT DAP C K I P F S T QD E KGVT QNGRL I TAN PIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGD TAWDFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTC IAVGLVTLYLGVMVQCGGPGGVALNPCCGLGIEGRCETWMSSEGAWKQIQRVETWALRHPGF TVMALFLAHAIGTS ITQKGIIFILLMLVT PSMA AS_V3_DV2_050- EM 35

[0976] 8 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PQQGEPSLNEEQDKRFVCNHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKTPFEIMDLEKRHVLGRLTTVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMTAS_V3_DV2_°51- EM 35

[0977] 9 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI EGRC E T WMS S E G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT AS_V3_DV2_052-EM 36

[0978] 0 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRC PEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCAEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGGIAL VPCCGMGI EGRC E T WMS S E G AWNHVQRI E TWILRHPGF

[0979]

[0980] TMMAAI L AYT I GTT HFQRAL I F I L L TAVT PSMT Attorney Docket No. 45817-0191WO1 / MTX1505.20 DV2-029-A_E / M 32

[0981] 8 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKEIKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQffGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT AS_V4_DV2 - EM_00141

[0982] 6 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAGGNATGKGGKE IKIT PQSS ITEAELTGYGTVTMECS PRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTETQMSSGNLLFTGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VLVGIVTLYLGVMVQAGGPGGIALVPCAGMGIETRTETWMSSEGAWKHVQRIETWILRHPGF TMMAAILAYTIGTTHFQRALIFILLTAVTPSMT AS_V4_DV2- EM_00341

[0983] 7 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFTCKKNMEGKIVAPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLFTGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLSWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGWITWIGMNSRSTSLSVSL VLVGWTLYLGVMVQAGGPGGIALVPCAGMGIETRTETWMSSEGAWKHAQRIETWVLRHPGF TIMAALLAYTIGTTYFQRVLIFILLTAVAPSMT E Protein Portion of AS_V4_DV2-EM_00341

[0984] 8 MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKHPATLRKYCIE AKLTNTTTASRC PDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSRFGKGGIVTCAMFTCKKN MEGKIVAPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECS PRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQ DVWLGSQEGAMHSALAGCTE IQMS SGNLLFTGHLKCRLRMDKLQLKGMS YSMCTGKFKWK EIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPP FGDSYIIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGK ALHQVFGAIYGAAFSGVSWTMKILIGWITWIGMNSRSTSLSVSLVLVGWTLYLGVMVQA M Protein Portion of AS_V4_DV2-EM_00341

[0985] 9 GIALVPCAGMGIETRTETWMSSEGAWKHAQRIETWVLRHPGFTIMAALLAYTIGTTYFQRVL IFILLTAVAPSMT AS_V4_DV2- EM_00842

[0986] 0 MKAILWLLYTFTTANAMRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKHPATLRKYCIEAKLTNTTTASRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFTCKKNMEGKIVAPENLEYT IVIT PHSGEENAVGNDTGKHGKE IKVT PQSS ITEAELTGYGTVTMECS PRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW

[0987]

[0988] IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLIFTGHLKCRLRMDKLQ Attorney Docket No. 45817-0191WO1 / MTX1505.20 LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLSWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGWITWIGMNSRSTSLSVSL VLVGWTL YLGVMVQAGGPGGIALVPCAGMGIETRTETWMS SEGAWKHAQRIETWVLRHPGF TIMAALLAYTIGTTYFQRVLIFILLTAVAPSMT DV2-029-B_E / M32

[0989] 9 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCTR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI L AYT I GTT HFQRAL I F I L L TAVT PSMT DV2-029-C_E / M33

[0990] 0 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCNR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFDFMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI L AYT I GTT HFQRAL I F I L L TAVT PSMT DV2-029-D_E / M33

[0991] 1 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPDQGEPSLNEEQDKRFVCKHSMVDRGWGNGCKR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQEGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YL IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTTGTTHFQRALIFILLTAVT PSMT AS_V3_DV2_°63-EM33

[0992] 2 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHCALAGCVEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQEGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGG VC L VPCCGMGI E S RC E T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTTGTTHFQRALIFILLTAVT PSMTAS_V3_DV2_°64-EM33

[0993] 3MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL

[0994]

[0995] IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR Attorney Docket No. 45817-0191WO1 / MTX1505.20 FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGIDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCIEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS L GKAL H QVF GA LYGAAFSGVSWTMKLL IGVILTWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGGIAL VPCCGMGI EGRC E T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMT AS_V3_DV2_065- EM 33

[0996] 4 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCSR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGIDFDFMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCIEIQMSSGNLLFCGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YI IIGVEPGQLKLNWFKKGS S IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGG VALN PCCGMGI EGRCETWMSSE G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMT AS_V3_DV2_053- EM 30

[0997] 2 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLE YT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS I T EAE L T G YGT VTME C S P R TGL DFD EMVL LQMENKAWL VNRQWF L D L P L PWL PGAD T QGS NW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKETAETQHGTLVTRVQYEGDGSPCKIPFETMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS IGKALHQVFGAIYGAAFSGVSWTMKIL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQ AGGPGGIAL VPC AGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMTAS_V3_DV2_O 54 - EM30

[0998] 3 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHSALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIITGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGGIAL VPCCGMGI E TR TE T WMS S E G AWKHVQRI E TWILRHPGF TMMAAI LAYTIGTTHFQRALIFILLTAVT PSMT AS_V3_DV2_056- EM 30

[0999] 5 MKAILWLLYTFTTANAMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFEL IKTEAKQPATLRKYCIEAKLTNTTTESRCPEQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGR FGKGGIVTCAMFRCKKNMEGKWAPENLEYT IVIT PHSGEEHAVGNDTGKHGKE IKIT PQSS ITEAELTGYGTVTMECSPRTGLDFDEMVLLQMENKAWLVNRQWFLDLPLPWLPGADTQGSNW IQKETLVTFKNPHAKKQDVWLGSQEGAMHCALAGCTEIQMSSGNLLF TGHLKCRLRMDKLQ LKGMSYSMCTGKFKWKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVN PIVTEKDS PVNIEAEPPFGDS YIIIGVEPGQLKLNWFKKGSS IGQMFETTMRGAKRMAILGD TAWDFGSLGGVFTS I GKAL H QVF GA I YGAAFSGVSWTMK IL IGVIITWIGMNSRSTSLSVTL VL VG I VT L YL GVMVQCGGPGG VC L VPCCGMGI E TR TE T WMS S E G AWKHV...

Claims

1. Attorney Docket No. 45817-0191WO1 / MTX1505.20 What is claimed is:

1. A stabilized flavivirus heterotetramer comprising two variant flavivirus envelope (E) proteins and two variant flavivirus membrane (M) proteins, wherein: the two variant E proteins are identical to each other and each comprises amino acid substitutions at at least three positions relative to a corresponding wildtype flavivirus E protein, wherein the at least three positions correspond with positions 76, 106, and 107 of SEQ ID NO: 276; and3.the two variant M proteins are identical to each other and each comprises a N-terminus and a C-terminus, wherein the N-terminus comprises an N-terminal region comprising at least one amino acid substitution relative to a corresponding wild-type flavivirus M protein.

2. The stabilized flavivirus heterotetramer of claim 1, wherein the position in the variant E proteins corresponding with position 107 of SEQ ID NO:276 comprises a substitution with a charged bulky residue.

3. The stabilized flavivirus heterotetramer of claim 1 or 2, wherein the position in the variant E proteins corresponding with position 76 of SEQ ID NO:276 comprises a substitution with a charged bulky residue.

4. The stabilized flavivirus heterotetramer of claim 2 or 3, wherein the charged bulky residue is selected from the group consisting of aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q), lysine (K), tyrosine (Y), and arginine (R).

5. The stabilized flavivirus heterotetramer of any one of claims 1 to 4, wherein the position in the variant E proteins corresponding with position 106 of SEQ ID NO:276 comprises a substitution with serine (S), threonine (T), asparagine (N), or lysine (K).Attorney Docket No. 45817-0191WO1 / MTX1505.20 6. The stabilized flavivirus heterotetramer of any one of claims 1 to 4, wherein the position in the variant E proteins corresponding with position 106 of SEQ ID NO:276 comprises a substitution with serine (S).

7. The stabilized flavivirus heterotetramer of any one of claims 1-6, wherein the at least one substitution within the N-terminal region of the variant M proteins comprises at least one substitution selected from the following positions: 90, 91, 93, 94, 96, 97, 99, 101. 103, 104, and 105. wherein the positions correspond with positions 90, 91, 93, 94, 96, 97, 99, 101, 103, 104, and 105 of SEQ IDNO:275.

8. The stabilized flavivirus heterotetramer of claim 7. wherein the at least one substitution within the N-terminal region of the variant M proteins comprises at least one the following substitutions:10.(a) the amino acid substitution at position 90 is valine (V) or isoleucine (I);11.(b) the amino acid substitution at position 91 is isoleucine (I) or cysteine (C);12.(c) the amino acid substitution at position 93 is isoleucine (I), phenylalanine (F), tyrosine (Y), or tryptophan (W);13.(d) the amino acid substitution at position 94 is isoleucine (I), leucine (L), asparagine (N), or lysine (K);14.(e) the amino acid substitution at position 96 is cysteine (C); (f) the amino acid substitution at position 97 is isoleucine (I) or cysteine (C);15.(g) the amino acid substitution at position 99 is isoleucine (I) or leucine (L);16.(h) the amino acid substitution at position 101 is methionine (M), isoleucine (I), or phenylalanine (F)17.(i) the amino acid substitution at position 103 is glycine (G), alanine (A), serine (S). or cysteine (C);18.(j) the amino acid substitution at position 104 is serine (S); and (k) the amino acid substitution at position 105 is cysteine (C); Attorney Docket No. 45817-0191WO1 / MTX1505.20 wherein the positions correspond with positions 90, 91, 93, 94, 96, 97, 99, 101, 103, 104, and 105 of SEQ ID NO:275.

9. The stabilized flavivirus heterotetramer of any one of claims 1-8, wherein the variant E proteins further comprises at least one additional substitution relative to the corresponding wild-ty pe flavivirus E protein, wherein the at least one additional substitution is selected from the group consisting of the position in the variant E proteins corresponding with position 131 of SEQ ID NO:

276. the position in the variant E proteins corresponding with position 194 of SEQ ID NO:276, and the position in the variant E proteins corresponding with position 134 of SEQ ID NO:276.

10. The stabilized flavivirus heterotetramer of claim 9, wherein the at least one additional substitution is selected from the group consisting of:21.(a) the amino acid substitution at the position in the variant E proteins corresponding with position 131 of SEQ ID NO:276 is alanine (A), asparagine (N). or leucine (L);22.(b) the amino acid substitution at the position in the variant E proteins corresponding with position 194 of SEQ ID NO:276 is aspartic acid (D); and (c) the amino acid substitution at the position in the variant E proteins corresponding with position 134 of SEQ ID NO:276 is asparagine (N) or aspartic acid (D).

11. The stabilized flavivirus heterotetramer of any one of claims 1-10, wherein the variant E proteins further comprise an amino acid substitution at the position corresponding with position 495 of SEQ ID NO:

276. and / or the variant M proteins further comprise an amino acid substitution at the position corresponding with position 90 of SEQ ID NO:275.

12. The stabilized flavivirus heterotetramer of claim 11, wherein the amino acid substitution at the position in the variant E proteins corresponding with position 495 of SEQ ID NO:276 is a glycine (G), and / or the amino acid substitution at theAttorney Docket No. 45817-0191WO1 / MTX1505.20 position in the variant M proteins corresponding with position 90 of SEQ ID NO:275 is a glycine (G).

13. The stabilized flavi virus heterotetramer of any one of claims 1-12, further comprising a cavity created by:26.(a) amino acid substitutions relative to the corresponding wild-type flavivirus E protein at the positions in the variant E proteins corresponding with positions 262 and 265 of SEQ ID NO:276; and27.(b) an amino acid substitution relative to the corresponding wild-type flavivirus M protein at the position in the variant M proteins corresponding with position 97 of SEQ ID NO:275.

14. The stabilized flavivirus heterotetramer of claim 13, wherein the amino acid substitutions at the positions in the variant E proteins corresponding with positions 262 and 265 of SEQ ID NO:276 are each an alanine (A) or serine (S), and wherein the amino acid substitution at the position in the variant M proteins corresponding with position 97 of SEQ ID NO:275 is alanine (A).

15. The stabilized flavivirus heterotetramer of any one of claims 1-14, wherein the variant E proteins further comprises the following amino acid substitutions:30.a tyrosine (Y), glutamine (Q), or asparagine (N) at the position in the variant E proteins corresponding with position 267 of SEQ ID NO:276; and31.a lysine (K) or arginine (R) at the position in the variant E proteins corresponding with position 445 of SEQ ID NO:276.

16. The stabilized flavivirus heterotetramer of any one of claims 1-15, wherein the N-terminal region of the variant M proteins comprises at least one amino acid substitution of a non-cysteine amino acid with a cysteine amino acid, relative to the corresponding wild-type flavivirus M protein.Attorney Docket No. 45817-0191WO1 / MTX1505.20 17. The stabilized flavi virus heterotetramer of any one of claims 1-16, wherein the corresponding wild-type flavivirus E protein is SEQ ID NO:401 and the corresponding wild-type flavivirus M protein is SEQ ID NO:400.

18. The stabilized flavivirus heterotetramer of claim 17, wherein the variant E proteins are at least 90% identical to SEQ ID NO:414, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:415.

19. The stabilized flavivirus heterotetramer of claim 17, wherein the variant E proteins are at least 95% identical to SEQ ID NO:414, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:415.

20. The stabilized flavivirus heterotetramer of claim 17, wherein the variant E proteins are identical to SEQ ID NO:414, and wherein the variant M proteins are identical to SEQ ID NO:415.

21. The stabilized flavivirus heterotetramer of any one of claims 1-16. wherein the corresponding wild-type flavivirus E protein is SEQ ID NO:403 and the corresponding wild-type flavivirus M protein is SEQ ID NO:402.

22. The stabilized flavivirus heterotetramer of claim 21, wherein the variant E proteins are at least 90% identical to SEQ ID NO:418, and wherein the variant M proteins are at least 90% identical to SEQ ID NO: 419.

23. The stabilized flavivirus heterotetramer of claim 21, wherein the variant E proteins are at least 95% identical to SEQ ID NO:418, and wherein the variant M proteins are at least 95% identical to SEQ ID NO: 419.

24. The stabilized flavivirus heterotetramer of claim 21, wherein the variant E proteins are identical to SEQ ID NO:418, and wherein the variant M proteins are identical to SEQ ID NO:419.Attorney Docket No. 45817-0191WO1 / MTX1505.20 25. The stabilized flavi virus heterotetramer of any one of claims 1-16, wherein the corresponding wild-type flavivirus E protein is SEQ ID NO:404 and the corresponding wild-type flavivirus M protein is SEQ ID NO:277.

26. The stabilized flavivirus heterotetramer of claim 25, wherein the variant E proteins are at least 90% identical to SEQ ID NO:425, and wherein the variant M proteins are at least 90% identical to SEQ ID NO: 426.

27. The stabilized flavivirus heterotetramer of claim 25, wherein the variant E proteins are at least 95% identical to SEQ ID NO:425, and wherein the variant M proteins are at least 95% identical to SEQ ID NO: 426.

28. The stabilized flavivirus heterotetramer of claim 25, wherein the variant E proteins are identical to SEQ ID NO:425, and wherein the variant M proteins are identical to SEQ ID NO:426.

29. The stabilized flavivirus heterotetramer of any one of claims 1-16. wherein the corresponding wild-type flavivirus E protein is SEQ ID NO:280 and the corresponding wild-type flavivirus M protein is SEQ ID NO:279.

30. The stabilized flavivirus heterotetramer of claim 29, wherein the variant E proteins are at least 90% identical to SEQ ID NO: 428, and wherein the variant M proteins are at least 90% identical to SEQ ID NO: 429.

31. The stabilized flavivirus heterotetramer of claim 29, wherein the variant E proteins are at least 95% identical to SEQ ID NO:428, and wherein the variant M proteins are at least 95% identical to SEQ ID NO: 429.

32. The stabilized flavivirus heterotetramer of claim 29, wherein the variant E proteins are identical to SEQ ID NO:428, and wherein the variant M proteins are identical to SEQ ID NO:429.Attorney Docket No. 45817-0191WO1 / MTX1505.20 33. The stabilized flavivirus heterotetramer of any one of claims 1-32, comprising two fusion proteins wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins.

34. The stabilized flavivirus heterotetramer of claim 33, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant E protein and the variant M protein.

35. The stabilized flavivirus heterotetramer of claim 33, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant M protein and the variant E protein.

36. The stabilized flavivirus heterotetramer of claim 34, wherein each fusion protein comprises a linker between the variant E protein and the variant M protein.

37. The stabilized flavivirus heterotetramer of claim 36, wherein the linker comprises GGGG (SEQ ID NO:364).

38. The stabilized flavivirus heterotetramer of claim 36, wherein the linker comprises GGPG (SEQ ID NO:365).

39. The stabilized flavivirus heterotetramer of any one of claims 1-38, wherein the flavivirus is selected from the group consisting of Yellow Fever virus, Dengue virus, Zika virus, West Nile virus, Japanese Encephalitis virus, Tick-Bome Encephalitis virus, Kyasanur Forest virus, Alkhurma haemorrhagic fever virus, Omsk haemorrhagic fever virus, Powassan virus, Ilheus virus, Rocio virus, Karshi virus, Usutu virus, and Spondweni virus.

40. The stabilized flavivirus heterotetramer of claim 39, wherein the flavivirus is Dengue virus.Attorney Docket No. 45817-0191WO1 / MTX1505.2041. The stabilized flavivirus heterotetramer of claim 39, wherein the flavivirus is Zika virus.

42. The stabilized flavivirus heterotetramer of claim 39, wherein the Zika virus E protein further comprises an introduced glycosylation site.

43. The stabilized flavivirus heterotetramer of claim 42, wherein the introduced glycosylation site comprises an N-X-S motif in positions 67-69, wherein the positions correspond to positions 67-69 of SEQ ID NO: 282.

44. The stabilized flavivirus heterotetramer of claim 33, wherein each of the fusion proteins comprises:58.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;59.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417:60.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:424; or61.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

45. The stabilized flavivirus heterotetramer of claim 33, wherein each of the fusion proteins comprises:63.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413;64.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;65.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; or66.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

427. Attorney Docket No. 45817-0191WO1 / MTX1505.2046. The stabilized flavivirus heterotetramer of claim 33, wherein each of the fusion proteins comprises:68.the amino acid sequence set forth in SEQ ID NO:413;69.the amino acid sequence set forth in SEQ ID NO:417;70.the amino acid sequence set forth in SEQ ID NO:424; or71.the amino acid sequence set forth in SEQ ID NO:427.

47. The stabilized flavivirus heterotetramer of claim 33, wherein each of the fusion proteins comprises:73.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:43I:74.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431;75.the amino acid sequence set forth in SEQ ID NO:431;76.polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432;77.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432; or78.the amino acid sequence set forth in SEQ ID NO:432.

48. A vaccine composition comprising the stabilized flavivirus heterotetramer of any one of claims 1-47.

49. A vaccine composition comprising:81.a first stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:401 and the wild-type flavivirus M protein is SEQ ID NO:400;82.a second stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-ty pe flavivirus E protein is SEQ ID NO:403 and the wild-type flavivirus M protein is SEQ ID NO:402; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a third stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:404 and the wild-ty pe flavivirus M protein is SEQ ID NO:277; and83.a fourth stabilized flavivirus heterotetramer of any one of claims 1-16, wherein the wild-type flavivirus E protein is SEQ ID NO:280 and the wild-type flavivirus M protein is SEQ ID NO:279.

50. The vaccine composition of claim 49, further comprising:85.a fifth stabilized flavivirus heterotetramer of any one of claims 41-43, wherein the flavivirus is ZIKV.

51. The vaccine composition of claim 49 or 50, wherein:87.the variant E proteins of the first stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:414, and wherein the variant M proteins of the first stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:415; the variant E proteins of the second stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:418, and wherein the variant M proteins of the second stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:419;88.the variant E proteins of the third stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:425, and wherein the variant M proteins of the third stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:426; and89.the variant E proteins of the fourth stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:428, and wherein the variant M proteins of the fourth stabilized flavivirus heterotetramer are at least 90% identical to SEQ ID NO:429.

52. The vaccine composition of claim 49 or 50, wherein:91.the variant E proteins of the first stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:414, and wherein the variant M proteins of the first stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:415; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins of the second stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:418, and wherein the variant M proteins of the second stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:419;92.the variant E proteins of the third stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:425, and wherein the variant M proteins of the third stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:426; and93.the variant E proteins of the fourth stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:428, and wherein the variant M proteins of the fourth stabilized flavivirus heterotetramer are at least 95% identical to SEQ ID NO:429.

53. The vaccine composition of claim 49 or 50, wherein:95.each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:413;96.each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:417;97.each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and98.each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:427.

54. The vaccine composition of claim 49 or 50, wherein:100.each of the fusion proteins of the first stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431;101.each of the fusion proteins of the second stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;102.each of the fusion proteins of the third stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:424; and103.each of the fusion proteins of the fourth stabilized flavivirus heterotetramer comprises the amino acid sequence set forth in SEQ ID NO:

427. Attorney Docket No. 45817-0191WO1 / MTX1505.2055. A vaccine composition comprising one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 1-47.

56. A vaccine composition comprising one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 1-47.

57. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:107.a variant E protein at least 90% identical to SEQ ID NO:414 and a variant M protein at least 90% identical to SEQ ID NO:415;108.a variant E protein at least 90% identical to SEQ ID NO:418 and a variant M protein at least 90% identical to SEQ ID NO:419;109.a variant E protein at least 90% identical to SEQ ID NO:425 and a variant M protein at least 90% identical to SEQ ID NO:426; or110.a variant E protein at least 90% identical to SEQ ID NO:428 and a variant M protein at least 90% identical to SEQ ID NO:429.

58. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:112.a variant E protein at least 95% identical to SEQ ID NO: 414 and a variant M protein at least 95% identical to SEQ ID NO:415;113.a variant E protein at least 95% identical to SEQ ID NO:418 and a variant M protein at least 95% identical to SEQ ID NO:419;114.a variant E protein at least 95% identical to SEQ ID NO:425 and a variant M protein at least 95% identical to SEQ ID NO:426; or115.a variant E protein at least 95% identical to SEQ ID NO:428 and a variant M protein at least 95% identical to SEQ ID NO:

429. Attorney Docket No. 45817-0191WO1 / MTX1505.20 59. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:116.a variant E protein identical to SEQ ID NO:414 and a variant M protein identical to SEQ ID NO:415;117.a variant E protein identical to SEQ ID NO:418 and a variant M protein identical to SEQ ID NO:419;118.a variant E protein identical to SEQ ID NO:425 and a variant M protein identical to SEQ ID NO:426; or119.a variant E protein identical to SEQ ID NO:428 and a variant M protein identical to SEQ ID NO:429.

60. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:121.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;122.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417;123.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; or124.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

61. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:126.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413;127.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;128.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 424; or129.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:

427. Attorney Docket No. 45817-0191WO1 / MTX1505.2062. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:131.the amino acid sequence set forth in SEQ ID NO:413;132.the amino acid sequence set forth in SEQ ID NO:417;133.the amino acid sequence set forth in SEQ ID NO:424; or134.the amino acid sequence set forth in SEQ ID NO:427.

63. The vaccine composition of claim 56, comprising an mRNA encoding a fusion protein comprising:136.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:43I:137.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:431;138.the amino acid sequence set forth in SEQ ID NO:431;139.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:432;140.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:432; or141.the amino acid sequence set forth in SEQ ID NO:432.

64. The vaccine composition of claim 56, comprising:143.a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413;144.a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417;145.a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:

427. Attorney Docket No. 45817-0191WO1 / MTX1505.2065. The vaccine composition of claim 56, comprising:147.a first mRNA encoding a first fusion protein comprising a first polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431;148.a second mRNA encoding a second fusion protein comprising a second polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;149.a third mRNA encoding a third fusion protein comprising a third polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:427.

66. The vaccine composition of claim 56, comprising:151.a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413;152.a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417;153.a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

67. The vaccine composition of claim 56, comprising:155.a first mRNA encoding a first fusion protein comprising a first polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:431; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a second mRNA encoding a second fusion protein comprising a second polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;156.a third mRNA encoding a third fusion protein comprising a third polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:424; and a fourth mRNA encoding a fourth fusion protein comprising a fourth polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:427.

68. The vaccine composition of claim 56, comprising:158.a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO:413;159.a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO:417;160.a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and161.a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

69. The vaccine composition of claim 56, comprising:163.a first mRNA encoding a first fusion protein comprising the amino acid sequence set forth in SEQ ID NO:413 or SEQ ID NO:43E164.a second mRNA encoding a second fusion protein comprising the amino acid sequence set forth in SEQ ID NO:417 or SEQ ID NO:432;165.a third mRNA encoding a third fusion protein comprising the amino acid sequence set forth in SEQ ID NO: 424; and166.a fourth mRNA encoding a fourth fusion protein comprising the amino acid sequence set forth in SEQ ID NO:427.

70. The vaccine composition of any one of claims 48-69, further comprising a lipid nanoparticle.Attorney Docket No. 45817-0191WO1 / MTX1505.20 71. The vaccine composition of claim 70, wherein the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1.2 distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1-5 mol% PEG-modified lipid.

72. The vaccine composition of claim 70 or 71, wherein the lipid nanoparticle comprises 1-25:

170.

73. The vaccine composition of claim 70 or 71, wherein the lipid nanoparticle comprises A7:

174.

175. HO'176.(A7).

74. The vaccine composition of any one of claims 71-73, wherein the PEG-modified lipid is PEG2000-DMG.

75. The vaccine composition of any one of claims 56-74, wherein the one or more mRNAs are fully modified with 1-methyl-pseudouridine.

76. A method of inducing an immune response in a human subject, the method comprising administering to the human subject one or more doses of the stabilized flavivirus heterotetramer of any one of claims 1-47 or the vaccine composition of any one of claims 48-75 in an amount effective to produce, in the human subject, an immune response to a flavivirus viral infection.Attorney Docket No. 45817-0191WO1 / MTX1505.2077. A method of inducing an immune response in a human subject, the method comprising administering to the human subject the stabilized flavivirus heterotetramer of any one of claims 1-47 or the vaccine composition of any one of claims 48-75 in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring flavivirus.

78. The method of claim 76 or 77, wherein the stabilized flavivirus heterotetramer or the vaccine composition is administered intramuscularly.

79. The method of any one of claims 76-78, wherein the flavivirus is Yellow Fever virus, Dengue virus. Zika virus, West Nile virus, Japanese Encephalitis virus, Tick-Bome Encephalitis virus, Kyasanur Forest virus, Alkhurma haemorrhagic fever virus, Omsk haemorrhagic fever virus, Powassan virus, Ilheus vims, Rocio virus, Karshi virus, Usutu virus, Spondweni virus, or any combination thereof.

80. The method of claim 79, wherein the flavivirus is Dengue virus.

81. The method of claim 79, wherein the flavivirus is Zika virus.

82. The stabilized flavivirus heterotetramer of any one of claims 1-16. wherein the flavivirus is Zika virus, wherein the corresponding wild-type Zika virus E protein is SEQ ID NO:282 and the corresponding wild-type Zika virus M protein is SEQ ID NO:281.

83. The stabilized flavivirus heterotetramer of claim 82, wherein:187.the variant E proteins are at least 90% identical to SEQ ID NO:450, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:451;188.the variant E proteins are at least 90% identical to SEQ ID NO:452, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:453;189.the variant E proteins are at least 90% identical to SEQ ID NO:454, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:455; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are at least 90% identical to SEQ ID NO:456, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:457;190.the variant E proteins are at least 90% identical to SEQ ID NO:458, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:459;191.the variant E proteins are at least 90% identical to SEQ ID NO:460, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:461;192.the variant E proteins are at least 90% identical to SEQ ID NO:462, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:463;193.the variant E proteins are at least 90% identical to SEQ ID NO:464, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:465;194.the variant E proteins are at least 90% identical to SEQ ID NO:466, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:459;195.the variant E proteins are at least 90% identical to SEQ ID NO:467, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:468;196.the variant E proteins are at least 90% identical to SEQ ID NO:471, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:472; or the variant E proteins are at least 90% identical to SEQ ID NO:

473. and wherein the variant M proteins are at least 90% identical to SEQ ID NO:472.

84. The stabilized flavivirus heterotetramer of claim 82, wherein:198.the variant E proteins are at least 95% identical to SEQ ID NO:

450. and wherein the variant M proteins are at least 95% identical to SEQ ID NO:451;199.the variant E proteins are at least 95% identical to SEQ ID NO:452, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:453;200.the variant E proteins are at least 95% identical to SEQ ID NO:454, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:455;201.the variant E proteins are at least 95% identical to SEQ ID NO:456, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:457;202.the variant E proteins are at least 95% identical to SEQ ID NO:458, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:459;203.the variant E proteins are at least 95% identical to SEQ ID NO:460, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:461; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are at least 95% identical to SEQ ID NO:462, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:463;204.the variant E proteins are at least 95% identical to SEQ ID NO:464, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:465;205.the variant E proteins are at least 95% identical to SEQ ID NO:466, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:459;206.the variant E proteins are at least 95% identical to SEQ ID NO:467, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:468;207.the variant E proteins are at least 95% identical to SEQ ID NO:471, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:472; or the variant E proteins are at least 95% identical to SEQ ID NO:473, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:472.

85. The stabilized flavivirus heterotetramer of claim 82, wherein:209.the variant E proteins are identical to SEQ ID NO:450, and wherein the variant M proteins are identical to SEQ ID NO:451;210.the variant E proteins are identical to SEQ ID NO:452, and wherein the variant M proteins are identical to SEQ ID NO:453;211.the variant E proteins are identical to SEQ ID NO:454, and wherein the variant M proteins are identical to SEQ ID NO:455;212.the variant E proteins are at identical to SEQ ID NO:456, and wherein the variant M proteins are identical to SEQ ID NO:457;213.the variant E proteins are identical to SEQ ID NO:458, and wherein the variant M proteins are identical to SEQ ID NO:459;214.the variant E proteins are identical to SEQ ID NO:460, and wherein the variant M proteins are identical to SEQ ID NO:461;215.the variant E proteins are identical to SEQ ID NO:462, and wherein the variant M proteins are identical to SEQ ID NO:463;216.the variant E proteins are identical to SEQ ID NO:464, and wherein the variant M proteins are identical to SEQ ID NO:465;217.the variant E proteins are identical to SEQ ID NO:466, and wherein the variant M proteins are identical to SEQ ID NO:459; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the variant E proteins are identical to SEQ ID NO:467, and wherein the variant M proteins are identical to SEQ ID NO:468;218.the variant E proteins are identical to SEQ ID NO:471, and wherein the variant M proteins are identical to SEQ ID NO:472; or219.the variant E proteins are identical to SEQ ID NO:473, and wherein the variant M proteins are identical to SEQ ID NO:472.

86. The stabilized flavivirus heterotetramer of any one of claims 82-85, comprising two fusion proteins wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins.

87. The stabilized flavivirus heterotetramer of claim 86, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant E protein and the variant M protein.

88. The stabilized flavivirus heterotetramer of claim 86, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant M protein and the variant E protein.

89. The stabilized flavivirus heterotetramer of claim 87, wherein each fusion protein comprises a linker between the variant E protein and the variant M protein.

90. The stabilized flavivirus heterotetramer of claim 89, wherein the linker comprises GGGG (SEQ ID NO:364).

91. The stabilized flavivirus heterotetramer of claim 89, wherein the linker comprises GGPG (SEQ ID NO: 365).

92. The stabilized flavivirus heterotetramer of claim 86, wherein each of the fusion proteins comprises:Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:433;227.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:434;228.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:435;229.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:436;230.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:437;231.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:438;232.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:439;233.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:440;234.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:441;235.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 442;236.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:444;237.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 445; or238.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:446.

93. The stabilized flavivirus heterotetramer of claim 86, wherein each of the fusion proteins comprises:240.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:433; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:434;241.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:435;242.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:436;243.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:437;244.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:438;245.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:439;246.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:440;247.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:441;248.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:442;249.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 444;250.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 445; or251.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:446.

94. The stabilized flavivirus heterotetramer of claim 86, wherein each of the fusion proteins comprises:253.the amino acid sequence set forth in SEQ ID NO:433;254.the amino acid sequence set forth in SEQ ID NO:434;255.the amino acid sequence set forth in SEQ ID NO:435;256.the amino acid sequence set forth in SEQ ID NO:436;257.the amino acid sequence set forth in SEQ ID NO:437; Attorney Docket No. 45817-0191WO1 / MTX1505.20 the amino acid sequence set forth in SEQ ID NO:438;258.the amino acid sequence set forth in SEQ ID NO:439;259.the amino acid sequence set forth in SEQ ID NO:440;260.the amino acid sequence set forth in SEQ ID NO:441;261.the amino acid sequence set forth in SEQ ID NO:442;262.the amino acid sequence set forth in SEQ ID NO:444;263.the amino acid sequence set forth in SEQ ID NO:445; or264.the amino acid sequence set forth in SEQ ID NO:446.

95. A vaccine composition comprising the stabilized flavi virus heterotetramer of any one of claims 82-94.

96. A vaccine composition comprising one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 82-94.

97. A vaccine composition comprising one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 82-93.

98. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:269.a variant E protein at least 90% identical to SEQ ID NO:450 and a variant M protein at least 90% identical to SEQ ID NO:451;270.a variant E protein at least 90% identical to SEQ ID NO:452 and a variant M protein at least 90% identical to SEQ ID NO:453;271.a variant E protein at least 90% identical to SEQ ID NO:454 and a variant M protein at least 90% identical to SEQ ID NO:455;272.a variant E protein at least 90% identical to SEQ ID NO:456 and a variant M protein at least 90% identical to SEQ ID NO:457; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 90% identical to SEQ ID NO:458 and a variant M protein at least 90% identical to SEQ ID NO:459;273.a variant E protein at least 90% identical to SEQ ID NO:460 and a variant M protein at least 90% identical to SEQ ID NO:461;274.a variant E protein at least 90% identical to SEQ ID NO:462 and a variant M protein at least 90% identical to SEQ ID NO:463;275.a variant E protein at least 90% identical to SEQ ID NO:464 and a variant M protein at least 90% identical to SEQ ID NO:465;276.a variant E protein at least 90% identical to SEQ ID NO:466 and a variant M protein at least 90% identical to SEQ ID NO:459;277.a variant E protein at least 90% identical to SEQ ID NO:467 and a variant M protein at least 90% identical to SEQ ID NO:468;278.a variant E protein at least 90% identical to SEQ ID NO:471 and a variant M protein at least 90% identical to SEQ ID NO:472; or279.a variant E protein at least 90% identical to SEQ ID NO:473 and a variant M protein at least 90% identical to SEQ ID NO:472.

99. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:281.a variant E protein at least 95% identical to SEQ ID NO:450 and a variant M protein at least 95% identical to SEQ ID NO:451;282.a variant E protein at least 95% identical to SEQ ID NO:452 and a variant M protein at least 95% identical to SEQ ID NO:453;283.a variant E protein at least 95% identical to SEQ ID NO:454 and a variant M protein at least 95% identical to SEQ ID NO:455;284.a variant E protein at least 95% identical to SEQ ID NO:456 and a variant M protein at least 95% identical to SEQ ID NO:457;285.a variant E protein at least 95% identical to SEQ ID NO:458 and a variant M protein at least 95% identical to SEQ ID NO:459;286.a variant E protein at least 95% identical to SEQ ID NO:460 and a variant M protein at least 95% identical to SEQ ID NO:461; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 95% identical to SEQ ID NO:462 and a variant M protein at least 95% identical to SEQ ID NO:463;287.a variant E protein at least 95% identical to SEQ ID NO:464 and a variant M protein at least 95% identical to SEQ ID NO:465;288.a variant E protein at least 95% identical to SEQ ID NO:466 and a variant M protein at least 95% identical to SEQ ID NO:459;289.a variant E protein at least 95% identical to SEQ ID NO:467 and a variant M protein at least 95% identical to SEQ ID NO:468;290.a variant E protein at least 95% identical to SEQ ID NO:471 and a variant M protein at least 95% identical to SEQ ID NO:472; or291.a variant E protein at least 95% identical to SEQ ID NO:473 and a variant M protein at least 95% identical to SEQ ID NO:472.

100. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:293.a variant E protein identical to SEQ ID NO:450 and a variant M protein identical to SEQ ID NO:451;294.a variant E protein identical to SEQ ID NO:452 and a variant M protein identical to SEQ ID NO:453;295.a variant E protein identical to SEQ ID NO:454 and a variant M protein identical to SEQ ID NO:455;296.a variant E protein identical to SEQ ID NO:456 and a variant M protein identical to SEQ ID NO:457;297.a variant E protein identical to SEQ ID NO:458 and a variant M protein identical to SEQ ID NO:459;298.a variant E protein identical to SEQ ID NO:460 and a variant M protein identical to SEQ ID NO:461;299.a variant E protein identical to SEQ ID NO:462 and a variant M protein identical to SEQ ID NO:463;300.a variant E protein identical to SEQ ID NO:464 and a variant M protein identical to SEQ ID NO:465; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein identical to SEQ ID NO:466 and a variant M protein identical to SEQ ID NO:459;301.a variant E protein identical to SEQ ID NO:467 and a variant M protein identical to SEQ ID NO:468;302.a variant E protein identical to SEQ ID NO:471 and a variant M protein identical to SEQ ID NO:472; or303.a variant E protein identical to SEQ ID NO:473 and a variant M protein identical to SEQ ID NO: 472.

101. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:305.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:433;306.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:434;307.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:435;308.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:436;309.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:437;310.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:438;311.a poly peptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:439;312.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:440;313.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:441;314.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:442; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 444;315.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 445; or316.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:446.

102. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:318.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:433;319.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:434;320.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:435;321.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:436;322.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:437;323.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:438;324.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:439;325.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:440;326.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:441;327.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 442;328.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 444; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 445; or329.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:446.

103. The vaccine composition of claim 97, comprising an mRNA encoding a fusion protein comprising:331.the amino acid sequence set forth in SEQ ID NO:433;332.the amino acid sequence set forth in SEQ ID NO:434;333.the amino acid sequence set forth in SEQ ID NO:435;334.the amino acid sequence set forth in SEQ ID NO:436;335.the amino acid sequence set forth in SEQ ID NO:437;336.the amino acid sequence set forth in SEQ ID NO:438;337.the amino acid sequence set forth in SEQ ID NO:439;338.the amino acid sequence set forth in SEQ ID NO:440;339.the amino acid sequence set forth in SEQ ID NO:441;340.the amino acid sequence set forth in SEQ ID NO:442;341.the amino acid sequence set forth in SEQ ID NO:444;342.the amino acid sequence set forth in SEQ ID NO:445; or343.the amino acid sequence set forth in SEQ ID NO:446.

104. The vaccine composition of any one of claims 95-103, further comprising a lipid nanoparticle.

105. The vaccine composition of claim 104. wherein the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1,2 distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1-5 mol% PEG-modified lipid.

106. The vaccine composition of claim 104 or 105, wherein the lipid nanoparticle comprises 1-25:Attorney Docket No. 45817-0191WO1 / MTX1505.20348.

107. The vaccine composition of claim 104 or 105, wherein the lipid nanoparticle comprises A7:

352. 354.(A7).

108. The vaccine composition of any one of claims 105-107, wherein the PEG-modified lipid is PEG2000-DMG.

109. The vaccine composition of any one of claims 97-108, wherein the one or more mRNAs are fully modified with 1 -methyl-pseudouridine.

110. A method of inducing an immune response in a human subject, the method comprising administering to the human subject one or more doses of the stabilized flavivirus heterotetramer of any one of claims 82-94 or the vaccine composition of any one of claims 95-109 in an amount effective to produce, in the human subject, an immune response to a Zika virus infection.

111. A method of inducing an immune response in a human subject, the method comprising administering to the human subject the stabilized flavivirus heterotetramer of any one of claims 82-94 or the vaccine composition of any one of claims 95-109 in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring Zika virus.Attorney Docket No. 45817-0191WO1 / MTX1505.20 112. The method of claim 110 or 111, wherein the stabilized flavi virus heterotetramer or the vaccine composition is administered intramuscularly.

113. The stabilized flavi virus heterotetramer of any one of claims 1-16, wherein the flavivirus is yellow fever virus, wherein the corresponding wild-type yellow fever virus E protein is SEQ ID NO:283 and the corresponding wild-type yellow fever virus M protein is SEQ ID NO:284.

114. The stabilized flavivirus heterotetramer of claim 113, wherein: the variant E proteins are at least 90% identical to SEQ ID NO:476, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:477;361.the variant E proteins are at least 90% identical to SEQ ID NO:

478. and wherein the variant M proteins are at least 90% identical to SEQ ID NO:479; or the variant E proteins are at least 90% identical to SEQ ID NO:480, and wherein the variant M proteins are at least 90% identical to SEQ ID NO:481.

115. The stabilized flavivirus heterotetramer of claim 113, wherein: the variant E proteins are at least 95% identical to SEQ ID NO:476, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:477;363.the variant E proteins are at least 95% identical to SEQ ID NO:478, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:479; or the variant E proteins are at least 95% identical to SEQ ID NO:480, and wherein the variant M proteins are at least 95% identical to SEQ ID NO:481.

116. The stabilized flavivirus heterotetramer of claim 113, wherein: the variant E proteins are identical to SEQ ID NO:476, and wherein the variant M proteins are identical to SEQ ID NO:477;365.the variant E proteins are identical to SEQ ID NO:478, and wherein the variant M proteins are identical to SEQ ID NO:479; or366.the variant E proteins are identical to SEQ ID NO:480, and wherein the variant M proteins are identical to SEQ ID NO:

481. Attorney Docket No. 45817-0191WO1 / MTX1505.20 117. The stabilized flavivirus heterotetramer of any one of claims 113-116, comprising two fusion proteins wherein the fusion proteins are identical to each other and each fusion protein comprises one of the variant E proteins and one of the variant M proteins.

118. The stabilized flavivirus heterotetramer of claim 117, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant E protein and the variant M protein.

119. The stabilized flavivirus heterotetramer of claim 117, wherein each fusion protein comprises, from N-terminus to C-terminus, the variant M protein and the variant E protein.

120. The stabilized flavivirus heterotetramer of claim 118, wherein each fusion protein comprises a linker between the variant E protein and the variant M protein.

121. The stabilized flavivirus heterotetramer of claim 120, wherein the linker comprises GGGG (SEQ ID NO:364).

122. The stabilized flavivirus heterotetramer of claim 120, wherein the linker comprises GGPG (SEQ ID NO:365).

123. The stabilized flavivirus heterotetramer of claim 117, wherein each of the fusion proteins comprises:373.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:447;374.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:448; or375.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:

449. Attorney Docket No. 45817-0191WO1 / MTX1505.20 124. The stabilized flavivirus heterotetramer of claim 117, wherein each of the fusion proteins comprises:376.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:447;377.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:448; or378.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:449.

125. The stabilized flavivirus heterotetramer of claim 117, wherein each of the fusion proteins comprises:380.the amino acid sequence set forth in SEQ ID NO:447;381.the amino acid sequence set forth in SEQ ID NO:448; or382.the amino acid sequence set forth in SEQ ID NO:449.

126. A vaccine composition comprising the stabilized flavivirus heterotetramer of any one of claims 113-125.

127. A vaccine composition comprising one or more nucleic acids encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 113-125.

128. A vaccine composition comprising one or more messenger ribonucleic acids (mRNAs) encoding of one or more of the variant E proteins and one or more of the variant M proteins of one or more of the stabilized flavivirus heterotetramers of any one of claims 113-125.

129. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:387.a variant E protein at least 90% identical to SEQ ID NO:476 and a variant M protein at least 90% identical to SEQ ID NO:477; Attorney Docket No. 45817-0191WO1 / MTX1505.20 a variant E protein at least 90% identical to SEQ ID NO:478 and a variant M protein at least 90% identical to SEQ ID NO:479; or388.a variant E protein at least 90% identical to SEQ ID NO:480 and a variant M protein at least 90% identical to SEQ ID NO:481.

130. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:390.a variant E protein at least 95% identical to SEQ ID NO:476 and a variant M protein at least 95% identical to SEQ ID NO:477;391.a variant E protein at least 95% identical to SEQ ID NO:478 and a variant M protein at least 95% identical to SEQ ID NO:479; or392.a variant E protein at least 95% identical to SEQ ID NO:480 and a variant M protein at least 95% identical to SEQ ID NO:481.

131. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:394.a variant E protein at identical to SEQ ID NO:476 and a variant M protein identical to SEQ ID NO:477;395.a variant E protein identical to SEQ ID NO:478 and a variant M protein identical to SEQ ID NO:479; or396.a variant E protein identical to SEQ ID NO:480 and a variant M protein identical to SEQ ID NO:481.

132. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:398.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:447;399.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:448; or400.a polypeptide at least 90% identical to the amino acid sequence set forth in SEQ ID NO:

449. Attorney Docket No. 45817-0191WO1 / MTX1505.20 133. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:401.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:447;402.a polypeptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:448; or403.a poly peptide at least 95% identical to the amino acid sequence set forth in SEQ ID NO:449.

134. The vaccine composition of claim 128, comprising an mRNA encoding a fusion protein comprising:405.the amino acid sequence set forth in SEQ ID NO:447;406.the amino acid sequence set forth in SEQ ID NO:448; or407.the amino acid sequence set forth in SEQ ID NO:449.

135. The vaccine composition of any one of claims 126-134, further comprising a lipid nanoparticle.

136. The vaccine composition of claim 135, wherein the lipid nanoparticle comprises 40-55 mol% of a lipid of 1-25 or A7, 30-45 mol% cholesterol, 5-15 mol% 1.2 distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1-5 mol% PEG-modified lipid.

137. The vaccine composition of claim 135 or 136, wherein the lipid nanoparticle comprises 1-25:

412. 414.d-25).

138. The vaccine composition of claim 135 or 136, wherein the lipid nanoparticle comprises A7:Attorney Docket No. 45817-0191WO1 / MTX1505.20417. 419.(A7).

139. The vaccine composition of any one of claims 136-138, wherein the PEG-modified lipid is PEG2000-DMG.

140. The vaccine composition of any one of claims 128-139, wherein the one or more mRNAs are fully modified with 1 -methyl-pseudouridine.

141. A method of inducing an immune response in a human subject, the method comprising administering to the human subject one or more doses of the stabilized flavivirus heterotetramer of any one of claims 113-125 or the vaccine composition of any one of claims 126-140 in an amount effective to produce, in the human subject, an immune response to a yellow fever virus infection.

142. A method of inducing an immune response in a human subject, the method comprising administering to the human subject the stabilized flavivirus heterotetramer of any one of claims 113-125 or the vaccine composition of any one of claims 126-140 in an amount effective to induce, in the human subject, a population of neutralizing antibodies that cross reacts with a naturally occurring yellow fever virus.

143. The method of claim 141 or 142, wherein the stabilized flavivirus heterotetramer or the vaccine composition is administered intramuscularly.

Images